?2635430 Summary - Canadian Patents Database (2024)

Note: Descriptions are shown in the official language in which they were submitted.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
l'_tSL OF A PCV2 IILla1t, NOt3L:~NIC t:'OMT'OSI"! It7N-1 FOR LESSENING
t:'L:tNIC A:1.,
4Y MI'TUNIS I\ PIGS
SEQUENCE .t,lS'I'lNC
This applicatic?n contams a SLqricsaUc lastam~ in
paper fbriirat aaid ia1 coziapartcr readable
fos-aiiat tlic tcacliings <aiar3 c.oritezit oÃ'4N-laicla a:rz, laerw.by-
izicc3q)oruted hy referezam

k3At'Kt-iR(-3[.'=tiU (}F'T'NIn. TNV.1;:NTr[)I+3
Fieltl vfthe I-aveniion

':l'(ae prGscnt invention iclatcs to the tflse o:1'an inuacr7aicage;nic
c.onapnsiticaza conaprisin4~ ra
l~i.~rriale cfrri.~~virus ta,~: 2 (Ia'C4"'~) ~ta~ii~~;aa for Ãr~f~Ã~tae~xt
c.Yf sek~er<31 c~liiaict3l ~~ar,1airl~esta~Ã:i~.~ais
Ãc114eases3. Pr~lsr:tE?la;, tkic~sc cli.-aic.al aaaÃuaifistation4 ure
as5i,ci:tis:al w-ith a PCV2 inre4tion.
More parÃYCulrtaly, the present iacve;ntYon is concerned with an
i.zaumazaoIogical composition
Xectivc f(yr prok.iding ari iaiiiaittaie respcmase ÃIiat redtsces, i.~r
lesseias tlie severit}', of the

:'(1 s;.li.aieal svfliapt(ifliis <asscac.iawd avitli PCV:' iiil'eQtiota.
Prefi;rab1:y, t1w i. Lmologic:al.
c.omposit:icm comprises a reccstalbinaant.ls produc:ec.i antigen or I'Ct''.
'blcit-e preferably, the
I'C-V2 antigcn. is zi. rec.canibina Ãlv Iarc>cltkceci protcir~ cncoclcci bv
or~c of the oIaeaa nadin:
t'raitaes ÃORI"s3 i.tl tlw PCV2 gcnosnc. Still morc pr<l'ertably> t11e antigen
is PCV2 OR.F'-2
Iar~tcir~. ~Iost p.trti.culaa'Iy, tlac Iarescrit invention is c~.~nccmea~
~viCla a intarmnological.

'.; coaaapos:it:is>n ctlcctive f's>r treatment of c:lÃmcal sypnatonas
asseac:iatcel ix ttli PCV2 in-Pec#:ions faa
sw1!)G receiving lila; #:ill!)gl7FlCtll'1g80al t;<71t1pUsEtEt?Bl- ;1BlCj TN-
11L:rc111 the Gt?B11171?SatiUtl cCtBlltlrtSa;ti t11L

p:ro#:eÃn expressed by ORF2 of PCV2. :3.neathe:r ac~:.c.t: of tlic present
invention is tlic iacc: O:C
asly of the compositions provided laercwitli as arnefi:ic:amcaltr
Iarc:i:c..raEaly, as a acterinary.
arletlicart~ent, evcyg rtlore Pre:l-erably as a aac:cir1e, NI0rc.oi~~er, tiic
Iar=eseait InvLntion also relates

30 to tlic use d, <aias of tllc compositions siescrilxd herein, id3r the
prepaa=ation of :3 .medicamezat
1

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
for redlr~<irl ~~r lcssen:irl,: the Sc:vcr-its of cli.zlical syniptnnts
associated with PCV2 irlkcticrrl.
I'rG.forably. tlie; medicameflri is for the privintion tyl ti PCLF2, h*ctacrrL
OV011 flri~.~re pre:ferably

irr ssvitic. A furtlicr- a41x.cÃ of the pmrq imcntirara relates to a process
I'car- the production oÃ' a
m<tl:icamcntr c:osrrprisinr arl isrrnirmo'<flri+~ t:t~r~rp~~>:iti~srr. of
1'C~': for tlle treartrrtont of several.
L'lescripticrn of tho Prior Art

.1'orci:rrc circovirrrs tN'pc 2 (PCV2) is a srtiall. (1.7 -22 ram :irr.
diar:rrct:.r;, icras;ilr:cdr.tl,
arorg-crilelcspcrl lls'!~IA z:irr.rs. which contains a sral glL-strirgded
circular gcrrr?rrrc, l'C:V2 shares
1 tl aplaroxirrgatcl~y 84% scqrxcrgce irlcritit~ ~Nvitlr porcirgc circolietrs
t~:PC 1. (Pt:.V1). Hc~~~'Cs,Cr< in

contrast wrtla 17CV1, which is generally :rr~~a} ~i:rbrlea}t.. mv.irAC, ia}:fc
,c#:ed with PCV2 cAt:ibit: a
syrgriresarlc com.raronly rcfe.rxed to as 1'ost-wc.arriart; NlultisN.sir;:aruc
Wasting Syndrome
(PMWS). Pf4lWS is c.linica.lly characterized by wastgng, palvrles, of'thc
skir1, u.rrtl3:r.ifti:iress,
x,:,piratc?ry distress, dia:rrlACn, act.crr~,, ~ar7c1 j~r~rrASiice, l:rr some
affected smme. a conrhrtration of
all sympto:llr.s ~A ill k- xppr3reart wlxile trtiicr aftected swirac Nvill oai-
ly have orrc c?r- two of tlresc
,Vmptoms. During mcrc3psy, microscopic mzsi ziiac;rosccrpic iw.sicrzis also
:31~pcaa= c3ai rixr:rltiple
tissat<s <rrgd c3rhtrrrs. u-ith lymp.lrc?itl ocgaais beraig the most cum-
trr.trn site for lesic3rr.s. A c:m'ng
correlation has lrccrr observed between the airr:crtrrit tAt' PCV2 rr.uclcic
acid or antiger1 air.d tlrc
severity c?!'mic;rcrsc;c?pic liImphoisi lesions. Mortality rates for swizic
infected witli PCV2 can

ht~ rrpprotrcla St-%. .tac ar(Ãditiozi to t'\,,1WS. PCV2 lifas been associated
~.~itlx scvcra.l otltc-r.
intecÃY~.~ns itrcltidirYg pseudorabies, porciii~, rel.~rodcrs.trvs arYCl
re;spiraton' sytrtlroma (.l'RRS),
Glasser's discase, sd:repti.~ci.~ccnl meni-ag-it-is, salmoni.llosis,
pi.~stw4.atring, ri.~lil3t3:c:illosis,
dietetic lic:pÃatosas, arxid suppuratave brozichopzicr7.arlt?narr. 1-
ioai:cz:cr-, research thrxs far has :aicrt
corrÃirxm.cd 4N:-h,;t1YCr- zirax. of t1icsc clinical syn--~ptcrrr:rs arc in
#~act, the direct resul.t of t 1'CV'l
2

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
inkction. Moreover, it is ~iot Yet known avlreÃher aan'. of thesc: clinical
synclxoms can be
.f[ectivily r..tlucetl or cured by an trctrt-e agent directed against I'CVm.

Cxarr-etit aplaroacl:es t~.~ treat PCV2 irrfec.tions i clrkclc v.iccines,
stic:ll. as
those described i.tl Cl S. Patent No. 6,701,023. llowever, such vacc:ii.ws her-
ve been
> inefl'cctivc at c,onf'crring Protective irm-ntmity against.1'C'V" infecaio
~.~t- r.ecluci:ng. ].esse: ing

t1rc severitv of, or curing any dinical sviiilatottas wssraciatecl Ãknewitli,
klcareovcr, vac,ciraes
tl Qribed in ilrc: prior art were fc~ciflsed sololt> on the prevention of PCV2
infi;s;,ti.olas itr swill<,
but clici not cowsic.~er any ffirtlYer rtrccl:ic..tl tisc.

Accorrliygg1y, wliat is needed in tlle ci.rt is a.rl y.rarnLtmo{~emie:
cornlaosaticsa :tcsr tlle
tret]t9l1t;111. of Sa;S~a;Ial O#:illca.l I11aI11reSl;'1tiUI15. Fi8r111~:r.
wfiat 3.ti needed in llla; art is aIl
immunological composition INlIicla cottlers Paotcctive imnimity against PC V2
ia}Ã'e.ctioa} htcÃ
wlricli ca.ri also be used to tr=e..at es:istiygg cliygical s~ snlxonrs
associatLcl im>itfiPC:t"2 ini'e.ction.

.[)ISCl:f?SI '.17E [)Ft'HE.tNVENT.lON,

1i 'T'lic present i~iveaitioi1 c?vLrcomcs t.he prc?b1cnis inhemm isi the prior
art ijid prowicles i
distinct advance izi 11ze st:3te c?!, til~:. <rrt. 'Tbe presw.rzt: i:nvemican
provides a medicinal use(s) of
immurlohenic c;onllvsitiorl(c:) cc?mprising 1='CV' ar1t:igen.

1l1 gmeral 11c.~ adverse Lvents or injeation 5ite reactions were noted for ans
of ttic
l?(..VM aaiÃigesi isiirixtctiogeiric coziipositioiis as usesi liereirz. til~:.

h~t compositions rxsed Eaerein a.plxar to be salle ~Nlxn a.daii.nistcree( to
Yor7nb P:igs, lvcferably- to
pigs not olcler thaEt 15 weeks of age, ritore l)riferably ri~.~t older 11 t 6
weeks of age, ev iti
mi.~re preferably tiot oltÃe.r tlrwi 3 weeks, rtac.?st pre-f4n4ly jicyt older
tlwn 2 we.eks.
Altemafie Gly. it is prelerr~..:d tliat tlie adaniatistration of tlic of the
presctit invention occur ~vitlu:n at least 2 and lareforabiv> witlrin. at
least :t N~~cels o#'ext:~.~4ure to

2i virtkleait PCV. According to a furtlicr csubc>cli:merYt, the
irramxtsiogga;raic: c,ompasitioras used
3

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
be.rein for any medicinal use des~:~fiF?ed herein, is adaniatstc:rod to pigs
of 3 wecks of age or

older, prei'erabiv- of 2 i4 e,il;:s of mge or oldir, flii~.~st pre,ierabiy but
iiot vltler than 15 ds Get_r of
age.

Unexlaeetcdly, it found tha.t ilic therapeutic use oftlle iMI11t11l0gClus;:
comlat?>:iÃia~ns,
> descr.ikci bciow, is effective for lessening tl::e sever.ity ~.~f"w-vioa.4
031li.cal syttaptcattas in

ItI laarÃirular, it Nk.is ciiscoxerec.~ that Ã1ic therapeutic asc Of il:e inn
nt a~.~4Cnic e.cattalaosiÃion"s o'.
tN present invent:ion, asic.i sln..cifiea.lly eomlaositions cosnpe-isHm, PCV2
ORF2 anÃ:igen. is
;Ifectixc for reducing or ]csscning lyniphadenopwhy. lyrnpboici depletion
and!or
maltiygueleatedigiant histiocytes in s7m>irie isifee.ted witli .I'C'V2.
Moreover, tlie t1ierapeFitie use.

1 tl of ayg antf;;esii,~ coniposition, as provided liere.witli, aaid that
e.omprises, PC:V,21 asitig!Lnr
pt'e.Ã'embty ORF2 aatt:igen. mtiFaces tiie: overall circovirus loacl aiitl its
iaauAttmosuppr, "sive
FBl1[?at;t, thereby resulting in a higher lei=el t?f gt;11a;m~ [lEsa;;1Se
rt;sFSl;'191Ce ciI1d a reduced
ineidmce o:t'.l'C'4' associated dise.asc .sand sN a31ptaa3ls.

'1'.hus one aslxct of t11e Presew: ia}3,:ntioa} z,:.lates to the us+: of aa}
imanu.no<FeRiC
1i eompos:it:ic.~.Tt eompr.ising, PCV2 antigm. tneÃ'erably zeUombinant PCV2
asingem attd ittt?r-C
paef:w.rahli~ PCV2 ORF2 protem as provided berewith, l:m tlie preparutic3ai of
u~~iedicaaiierit for
the PrevLm:ion, lesseagii1g anc3./o.r reduction of 1d~mp11a.c1LnoptiÃ11y, lvy-
npiioid tleple,ticial aaitfr'or
z~I ultinucleatedihia.ilt .histioeztcs in swine. Prcferably, said
inccliealiicjit is e.tyeetive f'or ttle
pre:vesitic?n, lessenim, unctior reduction of lympiaadenopaths~, lvaiiplioir3
depletion wcVor

hist:incd~Ães associated with FICV2 :infc:Gtions in swine. Still more
priferably, said iiiedic<3iYieirt is c1TectYve for the prevemion. Iesssning,
and/or rstfYtction of
l~'mplintfenopathy, 1ymphc.~id deple.tion <3:nd./or associated
w-ith PCV2 ixifectaoxis in pa,gm when adaniatisterecf to pigs not t?ldc:r
i1iaxi 15 ~N:c:eks of ~~go.
rnc~tc lai-c#'er.alaly' rioÃ older t1::an ti ~,,-eel:s of'-qg-c, eveia more
preferab1y not ~.~lc.~er than 31 Nk~,;cl:s,

2i atict rtiosÃ preferably not olciec- tltzixa 2 w4eks. Mteriiati4.:ly, it is
pr4.tccs.:ci that t.1i4
4

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
adaninistratiozs of tltc :imaltmol;eatic cornpn;;itions nf the prescm
izrve:artion r?ccisr within at

least 23 and preferably ti.ithirL at letist r i4oel;:s of e\posarre to
virulerit l;'C'V,

Atiotliei- aspccÃ of Che preseraÃ i_ ver~ti~.~n rehacs to a 11t0thcad flor the
t'rc.at:mcni of
lymp11ade~~~~patht.]:4 n1p11oid deplctioii anc.~ror mtitltimicleatec.~rgian[
hiati~cytes is) swim;,
> cornprisi g Cli,: ac.~n.-n_ isYraticatl of '111 cca npcasikion as
provic.~ec.~ licrewi.tlt, to a

pig, saic.~ irnmurtc~gcnic e.cartifa~,~siÃion. ccym:pr.i.sink, a 1'f'\72
antigcn, pre.Ã:er-al.?Iv a rce.carnbiraanÃ
PCV2 tantiv<n.r and nlotepreferal<aly PCV2 ORF2 proteim ln vot another aspect,
th< present
invention la~ovicles arn6l::(A f(Yr the #:ma#:tlient of
1yrnlalYac.~er*patlYV>. Iymphoicl ci:.l):letion.
anCVor histiocytLs associated witli a f'CV2 y.riiib.ctioai i:n sw~ine,

lt~ comprisiygg the arimiygistr-it:ion of ati imymmoge..nic e.oytipositioai is
larm=irieri liLrewitli, to a
pig. said iat7rt}Fano~ez~ic ~:c~at7p~~sitic~~~ cr~~Atl~cisi~~~* a .t'C"I
a~~Ãigea}., l~rc:'er~l~ly a :recs>r7i1~:i~A~~~Ã
.l'CV2 antl;,~en aairl yticsre pr=eferrAbly PCV2 ()RF21 protein. l'refi:rabh .
saitt tre.atment results in
the .les,eaing_ avÃlrr;;tioxt, prevexitioii, and'or cu.re ot tl3e
lymp13aÃlmopathy. tya31p.hoirl
clel?le:#:ion antlfo:r rtaultirtFac.leateti:'giaati l;:istiocyte:s in smia}e:
receiving said gsnanu.nogeniu

1i compos:it:ic.~.1t. Arcordi~ig to a f'rirtiics' aspcrt, said snethorls.t-t?r
treatiitent ffirtlxer comprise tiic
ahnimstr:3tion of suicl i:mriimiogenic corixpc3sitiozi tca pigs itot oicler
tlaaii 15 wewl:s of a.;e.
mo.n;- pre1Lralaly aiot older tliaai 6 weeks of age.. Lven iigoce preferably
iic?t cilclLr t11ar1 3 vvei'}:s,
and most preferably trot: olcler t:l~a-a 2 ~~:ceks. Alternativcly, it is
pre:Ã'erred that tlic
a(lrixiziastratioii of the uzmiuitot,
~eziac comIX)siYimz s of tlic prc~~.iit inae,ntimz occur %vallzm aÃ
htt terast ?andprefirably ivathiac at least 3 avceks of exposure tova:r lem
1'C,V

lt w-m~ lirrllmr clisc~.~verstl that the ther<31mr6c Ytse of an inYmunogenic
coml~..~sitiori
coml.~rising PCV2 t3:iiÃ:igiii, preferably a re.cortaiiis3irt: PC4"'
siixt:i~,eri. -iritÃ t~xi.~st pre.f~:re~33~1~~
I'C'Vw ORF2 protei.zs. as provicled laereai.:itla. caxi reduce or leswac l~-
mphraelenopa:thy in
c~-~r~tl.ii~taÃis~-~~~. with c~ra~. or a tratkiti~~le c~:F Cl~~. f's~-
~lls~~l~ta~-~~~:~s in af~~~i~cl s4si: c: (1)

2:? 3t3.#Lrstfltfla.l pt1E:$]:[ilomsE i'4'1#11 fl3lti:i'1obAE1sEr edLr(1+1,
(2) C:utax14(3;k5 pallor or 1Cterl3s. (3) rtlUttlE:d

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
atmplric Ix~,ers, (4) Ã~a.stric ulccrs. (5) sacplaritis and (f~l
rcp:rvelmÃx~,c (lasordoi:s, abor~ion,
stilibirtlm mummie;s, ctc.

"l'li s onc asfxct ol' Ã1ic present ii:Rcntion rcl:it:;4 t~.~ thc tisc o:r ari
irm-ntnlc~ge: i.c
s;.omposition cmnprisi.ng PCV2 an:tigen, prel<rably a recombinant PC'V:
anÃ:igen iiittl itiarc
preÃ',:ra1>Ãy, 1'CV'2 ORF2 pt-caÃci as provided for the pr~pmaÃion ca#' a
ttaecli.canxnt

for Ã1re preveraÃion. .nci:ar rcdciciia ol' 1yrnlahadcncypathv> in
cornbiraation ~~itla a c
or a iiit.xltipl< of t11e followin~> a~'~~~ptt~~~~s is~ 1~i~>s: {1
i~~at~:rst:it:i~~l p~~c~.ts~~~~?~li~~ ~~.~itli i.~ltcrlc~b~ale~r
cci::nia, (') cuta cms pallor or :ictcra.s. (?) ttaoalcd atrolahic lilers. (4)
gastric alc.cr,-;. (>)
9)L[?Ilrltlti alld (6) r'G;prUClI.EC:~BZ''G; Cll,~ rC)Iclers, G'.&
~315C)r~BCtB), s~Bl.ll}irtl)S. B)1i.i!)gB)11LS. Ltc.. E1g l?ES-'_,s.

'I I~ ha;.tL:r;11?li. SaBd lllGd:ti a!)gellt BS C1:reC:~BZ't; for ~:llc
I1r<'.i<'.91t#C?l1, la;titiCI1Bl1g al1[Yi?r rCdlJct1C)11 of
ly3Alpl1ad4'13d3patln' in cl?mbil.latio)l with (7:[3e (7:r a 1.11F8:1t1.1).It:
of t114' fio11d3wi:[3g Symptoms

asqocyatcri wztl] t'C4''~ iasl.c.ctioas ias pigs: (1) iygterStitial
pnGirmc)rlia 'B~l) iBiterlohula:r eriema,
(2) cglt"mc:olls Patlor ar ictcrus, (33 i mottled atropl c livexs.. 441
gastric. u.lcc:rs,(3 i xi+:pliritis
at7cl (6) rel.?rccliictive siisa?rclem e. ;. also:rti+.?ii, sti.IllairtlAs.
mtnmt7:ics, etc. Accord:ing to a

1i f'ar~.hcr aspcct, saiki sneclicunc.1it is cffective fot the pr<vLntion,
Iess.e:ai1ig ancl/o:r azrlrictio:a of
IympJzacleasop.3tlly. irl cc3alihi:tlutic3lz Wit:li ozie oa= a multiple
czÃ'tlle: toliou-im, se"tllptoms irl pitg~s:
(1) :iiitc:rstatitil palLm-nc3alia witb arlteriobtil<rr eclcma., (2) c:ut:a-
m<ar2 s pallor or ictea=tiis-, (3) aiiottlecl
atrc.~pbiU liv~e:rs, (4) gastric ulc<rs .(5) neplixitis and (fa)
ml3rarttacti~~c rlisc?rtlCrs, e.g. abor~:ic.isi,
stilibirtlw iria:tsiirixres, w.~c.. isi pigs, w-ben aclmiziasÃe:red to pigs
iiot olclcr t:liati 15 wewl:s o1'age.

htl :anore prct'erabh, :aiot nldGr ffiall 6 wecks of agc. Oe Gac tnare
prcii;rable: not oldor- tliissl 3 woc:l;:s,
a#td ritosl prefinil.~lv riot older tlitiiY i w-ceks. Alt:entanseIy, it: is
preTsrrstl that the
ablimstratio-a of thi immzinog4nic compc.~sitions or tli4 prcsc-at i-avesrtion
mcttr Nvitliin at
least h and preferalils> ai: itbi.n at Jc zrst 3 , weel;:s of cxposure; to
virulcist t'C'LF..

Moreover, thc prcsent irae,critiora also rclaÃcs to a tractlic>ci for the
treatnterat of
2:? IymplYadortop:iil~ti iai cartibisiatiorY ckitlfl ora4 or a raiisltiplo
ol'tii4 followi:n~ svsiiptcYsiis iai pigs.
6

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
(1) intGrstitia:l ~~ictflzi:cn:aii~i ~N:.itla ime:rlobibr ~..:doinis, (2)
ctitziaccor7s pallor or ictertis. (3) mottled
atr~.~pli-ic livers. (+) gamic akers . (5) iiipliritis aiid (tr)
ropr(Auctiv~.. disorders, e.& aborÃi~.~n,
stillbiril::s, i.urnra~im etc.., said ntcthod c.caniprising the
aclttai:nistratiori ~.~f an iml-nultc~ge: ic
s;.alilpositiotl conlprisis~~ PCV2 anÃigcn, prcfi;ralal:4 a recombinant: PCV2
anliYTe~~. and itiar~:

> preÃ',;ra1>ly PCV2 C3RF:2 jxcatcira as ly.rovidccl :li,.rewiÃ1i.
Prc#'cralal:y. the larescrit itivention also
relates to ani,.t1YC>cl for the trcatntcm oÃ' lyn:iph.;tdenolaathy in
c.canibiraation with one or a
multiple of the follom-,ia~T sz t~1l~l~st~ls a~.s~:cc:i;~t~.rl with PCV2
infection in pi~>;:: (1) iflit;~rstiti;~l
Pncattlarli.a Nvitla itite:rlot}ul;tr edema, (2) c:a:taracotes pallor or
ictera.s. i:>} niottlcd ati-ralahic
liver-, (4) gastric ulcLrs. (5) ncphritis aaid (6# reproductive disordcrs,
e.g, abortion, stillt3irths,

1 tl mFamnfies. etc., saitl ancthod cosit1yfising the acimilristration o.Ã'
a:ti iniligamcs;;enic cc~a~lpositioyr
coaaip.r.islmg PCV2 mitggea}. prcl'eaeah13 recombinant 1?C';V2 an#:i<Fc:n and
niorc Paef-"vrahl3
.l'CV2 ORF2 protLiyg, as prov-irlcd hcrewith, to a pig, Prefcr=ably, said
t:reatmcnt results in t:tiL
lessening or r,:ciictioai of thc , tya31pha.cienopathy, aiicl oaie ar multiple
of the fi-A.lowing
symptoms assoc:iatcel with 17CV2 ia}Ã'ection in p:i<Fs: (1) ia}t,:t'stitial
prt, Fall+.?lAia ivitii

1i iziterlol3tilar ede.Tna.. (2) cmaneou5 pal.lo:r or irterris, (3)
:Tnottt.lecl atrolaliic livers, (4) V-ast:ric
ulcw.rs .#;5j sicpliritis utlcl (6) reproductive clisc3rders, e.g. abrartion,
stilibirths~ mummics., ctc;.
According to a f'uctlier ac:pect, said iiietlgoils for trLtitiiiciit further
comprise administration of
tile immmlog.1lic cc?mposition comprising PCV2 a1itiger1, paefcrxWy
recorTibi.raalit PCV2
xztigen and silorc Prw.lerubis~ 1'(:-V2 {3R.F2 protcnz, as prc3vicled berein,>
to pigs sic?t older t:liuti

ht~ 15 ai eeks ni' aAc:, more preferably ziot older tllim 6 wecks of age.
c:vc:n xiaor~:. pro-fera:bls ~im
older th<3n-3, -,vse;ks, and iiiost prk,fLr-aEalg~ n~.~t vltlsr than 2 wia.ks.
AIternatively, it: is prefirrid
that tlre administration of the imamioge-aic c=o nipositio-as of tlic pmscrit
iriv criti0-a rsc;c tir
w-ithin at least wfuicl pmkual?:ly dviih:in at loast 3~~~eck:. ot'extx,sure to
vira.flent PCV.

Tt ~~~~~s also exfsccteciiv> #'amtd. that the tlacrapctitic use of a

2i composition cocrYIx-isirag PCV a#itigora, preferably recombinant 1'C.V2
a#itigon zirad iiicys.:
7

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
pre4'eraF?li, PCV2 O:ltiÃ?2 protoan as prov:ieled 1)or~.:-,viffi, caxi falso
reducc: or lessen k'ia li.l;:e
lesions, nor))1ally l:li~.~Nv)Y t~.~ ~.~e associated ~Nith L<3Avsonia
iiitracGlltflliaris hzi'cctio))s (Il..itis).

"1'licis onc asfxct ol' Ã1);: present ii:Rention rcl:it:;4 t~.~ the cisc o:f
ar~ imi-nunc~ge: i.c
s;.on)positic)n c:omprisinYT l~'V" e~~~ti~>c~~. preferably ~~<ca~~)iE~i~r~~tt
PCV2 ~~~~t:iY.~-e~). ;~i)~Ã t)iur~:
preÃ',;mil>h PCV2 ORF2 protein as provided herewitli, for Clic preparation of
a medic..uncra for

the Preventia , lesscrai:ng, tl)e ,sea"critv> ~.~I'andor reduction cA' }'ia
like lesi~.~rrs. ~~~.~umalk" known
to Ik:: associated isi.tll Lawsonia int:raceilul.taris iniectioa;: in swisie.
Acs;.orc.iin,y to a. lurlN;r
a4pccÃ, said mec.~licarTm)t is c('I'ecÃive fior the lar-ce"etttiora,
.lessening of the sea"critv> of and,or
rerllictzc)ai of 1'ia lyke leszc)rls, nomally l.aown to be assocBatecl 'Btl)
l.awsonia iyrtracellrllaris

'I I~ Ffl:tLcllo!)S. )dIG!) administered to pigs 1gUt oWer 1llaI1 1..~
Si~Gck,~ r of a,,,!Lõ 1)lt?r<'. [?Iel'<'.B'i7}l!~ Bll?t

older tl)aa) 6 ts>,;ek-s oÃ' nge. evea) more pret;::rab.ly iAot older than 3
we:eks.. and niost paef-"vrahl3
aiot older thayg 2vvecks, Alternat:ia"ely, it i-s prefirxLcl that the
administration of t:tle
inumn1o-gez1ic compositions s?t the present inveation ocegar witl):iii at
least 2 ai)c-1 paefcrahlz-
witliin at least 3we:eks oÃ'e,,,posia:re #:o vi:riale:iAÃ1'C'V.

1i moreoy-er, t.he present ia~ve.1rtion also t"clat.e5 to airretJioki fZar
tJie treattixeait ot'Pia like
lesioz)s.> normally known to be associute d witii i'_.aNv:sor):ia
int)=<rcellularis infectic)ns, said
aiiLtli<acl cc?mprising, the ailixiit)ic:iTatiorl of an
iri)ammohe.t)iccoaiiÃa(isiti<ajg cc?mprisit)g, PCV2
, -s)tigent preferably recombi1)-ant PC!r? a)rta~}cs) a1)cl s)~c~:re
t~re.tc.rat~lz" PCV2 [?.IZF2 prc~tcas) as
i
provided 1)ereM." to a pig. Pa=el:wrahli., s.3ic1 treatment results in tiic~
lesswrziz)g or resiuctic3rz of
htt tllc Pia l:ike tesinns, nn:rn)al:ly known to be assnoaatc:d witl)
Laai:sc)ms i.z)tracel:lr)taris
intccÃYoms. rlecordins
g t(i ti fii.rtlrer aspea, tl)c i)ietl)ocls for trea:tt)Yem ricscril:wcl above
t'iirtlisr
c~.~m~.~risc tlie~ s3dminisd:ration of tl)e immullc)gciric c~.~m~.~ositic)ir
c~.~m~.~rising PCV2 s3ntigen,
prel'erably- rc;con)biant PCV2 am)t,:en. fu)cl more pre.l'crabty PCV2 ORF2
protein as provided
licrei_ , to Ãai.gs rioÃ ~.~icler than 15 ts"ce:ks of'age, more preferably
ra~.~t oicl:ei- than 6 4N:c-cl;s ot'agc,

2:? :.v::i1 rtlcaro pre&rab14' not older diat) .3) 4N'ca;ks, and Irl~.~st
profa;s"abIy rl~.-~t cTicla;r Ã1),n 2 weeks.
8

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Attcm.atavety, it is prefc:rrc:d thaÃ i1ic acbui.n:istTaÃxon ol'i1i~:.
cc~lupnsitions of tlie

prisont invGaYtioli mt;atr withiii at least. ? anti. preferably i.yithin ~q
least 3 wv..ks tyl ixpost7ri t~.~
virsilem, }?CV.

> The irrwmmcager6c. c:ornp~.~sition.

7"hc in m rtc~gcnic composition as tsscd bucin is effective I'car i_ cla.ci_ ~
~i-ia imrna:tic
response against PCV2 and preventi.ng, reducing and/or lessening the
aez~:rit~' t~f'tll~. s:1i.~li~;;~l
sytulatc~rr~s associaÃed with .l'C"V2 infection. The c:onilxasi.tiora
g,.n;;rally c.carnprisc4 at Ic.ist. on:;
f?C:4''? a:titi ge.ti.

1 t~ I.,rZleqs defined otherwise, all te.cli.riical asitl -scienti:fic terms
used he.rcin have tlie sarne
aneania}gs as commonly understood by one o:Co:rdimn.t~- -,kill in ffie "Irt to
wlaicli tJiis Ãnx-cntgo:a
he.1yngs. The term 'imymmogenic comlositioll" as usetl berein r66-s to am
phartamc.cutical
caa31pos:ii:ion canta:illing aPC;V2 ant4lcu.: whicli coa31pos:ii:ion can be
used to prcx-cjlt or treat a
l'('V' it~~~uta~a asse~~:iateel cliscacc or condition in a stifaje:ct. A
prefi?:ravd imanu.no - ciu
composition catt iiiduce, gt:imulatc os' e:aJiaiiec tltc isiia~.~tu:ttc
response aVaiztst 1.'C;V1 The tenit
tliu.s encompu,~ws both sttbt~iiit irzmiuitc~tgeziic, coi~posrtions, as
described b,;::lmv.. as well us,
compositions contain-ing whole }:i.lled, or attenuated and/or inactivated
.l't;V2.

The tenit "subuilit :immualt~gel1iU Umtlpt?sitiol1" aas usetl .ltemi~l mt'ias
to a compc.~sition
c.ontahling at least one immurzcage nic polypeptide or <rntigen, brit iiot all
<rntigerts, tiw.rive d
ht~ .l'romc or bomolt~gous to an antil;exl t':i=c~~~l PC'Vw. Sa.ioli 's
Gozupt,s:it:inn is substantially of

int<3ct t''CV2. Tlitxs, a 'subzttiit immufliogenic coritpositioti ' is
prepirstl froin at least partially
pzirified i.~r trt3c.t-ii.~natctl (preferably sifll_istatitinlly purif'ie4)
immunogenic pi.,l}'pcptidcs fro-al
PCVw. or rL'i:CM1mbi3'1E33'lt a.RfiflCtigS thercCht'. A SEIb13:Rilt
]#t3.Rilu:#logLt3E~.~ composition cali t:CM1t31l}t':lSe

the subunit antigson or anEig,;ns of iiaterest substantially fr= oÃ' othcr
antigens or lxalypepticics
9

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
from PCV2. or in fractionated t':i=ont A prc:t'irred irnarluiiogera:ic
scrbr7rait cnarlposataon
c.crriiprises tlic l:,'C V2 C3RI2 protiili as described bi>lo-,k=.
. . .
An 1~i3Elrl~.l: ~lt.a,'#0.,1l or #rtlr"CIAErIC I~.t~,l<pr~s0' to a
O.C}r"Clfr~?sltr~lll. C~#' l~',lcclr"l0 Es the

~l~ ~;~lc~~r~l<flrt iflr the llcrst or a cellular andt or antibody-mediated
inlmxrne responst; to tllc
> corrtpos:it:if-m or vaccir:rc c?Ã' iraÃcrest. LisAtalla,ar:r "irm.-ntartc
reslorase" irrclAtdes btat i.4 r:rr.~t
lirtrit:;ci to cmic or i-ncar-c ol'the following c#Tec.ts: the prc>cltrcÃiorr
or activation r.~l'aratil.~c>cli.es, B
c;clJs. lr<ipor T cells, sttpprossor Tcell;:, and'or ct>-totox:ir; T cells
and/or yd Tcell;:. tlirr;t:tod
spa;cifically to ara arr:tig,.rr or arrtig,;rrs included in the
cor:srpr.~siticart r.~r vaccine Of irttenst...
1'rcfcrahly, tlic host will display LitJrer a t:Ererapetrtyc or protcctii-c
rrar:rrLtra~~?lcs~i~;rl rLsporgsc..

1 tf slfclr that resistance to aicw infection iz>i11 be criJrarrccd arrd/or=
the c:liaiical sLzLriti- ol' t:Jre
d.is,:a5e r,:cltccc ,tl, Srrrr..Jr pr-rDtc;;tirDat will h,: demonstrated by
ertlac:r- a rcelr.ac#:iozr in attcrnbc:r or
se1 erih" cri; or lack. of orge or rtrore of the sy arlptr?arls rassoci;rterl
im> itfi PC'V21 inl~ctiorgs as
described abnv+:.

The tcrrAls "i:rrArmmogea}ic' protein s>r PO.lo peptrcl, Or' arxtig
'ezr'" as Fasecl l;erci:rr rctvr to
1i m xarr:irr.tr acid sequence which elicits xar ilrr.rriu-nolc?gical
:reslxarlse as clescrit3cd a-love, An
"immurlc3.;ealic:" protein crr polvpeptide, as used herein, iziclr:rclcs tlie
l:ull-iw.rzgth Sw.cluerr:ce of
,my: PCV2 p:rt3icirls, analogs tliLreof:; or irrl-trr.rtalcireeal-ic
fiatj:trr.crgts tlic:reol', The terr-n
".irrrmualtrgcariU fr~~incrrt" refers to a f3-agrr:rent of a protela~ Nvlxiclr
izrcltrclcs c?rie or rr1orc
wprtopc s arr:cl tlrtrs a:ircits tlie i:trr.mmioic?gical response described
above. StrcliÃ'ragrzrcrits c-utr

htJ l~. identified using ariA~ rivznbcr cYl' Opitope 111rappi.rag
tcchra:iqcres, 3~ cll t;:.arcr3s-ra in tlre art_ See,
~.g., 1 laitope Mapping I'rotot;ols irt klithoci.s in Molecular Bi~.~logy,
Vol. 66 (Glitiflr E.
Morris, Ed., 11~96) I-ltr:mza-rza Press, Ti.~iowa, New Jersey, Fe.~r example,
linear ~.pit~~~.,es may N
dote;rrninecl bil c_l;_, cnracarreritly sY:artlacsizing large Xm.mbc:rs of
popt:iele;s on solid sr7pporm
tJ:c lx.pticlcs c.car-rcslacmic.~lirlg. to lxar-tif-ms 0:F the Prr.~t:.irt
rtrcrlmtk, arr:cl mac.ti:ng the pt;latidcs Nk~:itfa

2i atrtib(xJics while dr4 Jnptid~s uc still aÃtac:licd to tlYo srrppcysls.
Such ÃccliiYiclucs strc luloma iri

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
tltcar-Ã and described in U.S. Patent No. 4.708,871; Goysen ~..t fal, (1984)
Proc. Nail.

Acad, Sci. USA 81, 3995-4002; t;soysen it trl. (1986) -Niole;c, IituiiuYiol.
213,709-715,
4iniilark'< conform.ati~.~n.il claitcypcs atc rc.tclily idctiii(wcl ba
cletcrminiag spatial cora#cyn:n.tiio:
of tami.no acids such as bs. c.a > :~-vav cryalallor.~-rapl~~ ~~~id 21-
dimenaional iiti.cl<<ir magm tis;:.
> res~.~nancc. See, e.g.. Fpit~.~pc Mapping }?roÃocols, 4ulara...

SvatltcÃic antipcras are also iricltaded witl:ira ilw dc#'h:mion, for
c~aniplc> po14'clyitcalacs,
flanking cpitop+s. and other recombinant or syniheticallt derized
tatitiYT<flrs, 5~~,
Bcrgmann. ct al. (199.33) l; ur, J. finmano1 23Y27: f~217Kt: Bergrnarm ot al.

l.nLmmicsl, 157.334?-;ry49. SuIis hier, A. (1 ~Y)7), 13mmaygol. a.rid Cell
Biol. 75;402-408:
1 tl Giartlacr ct aI., (1998) 12th World AIDS Con.l'Lrencc> Ciesie1a.
Switzerland. .lusic 28-1txli~ . <
1998. In a prefcrrcd embodiment of tlle preqcylt invcntion. ayI ccsanposiÃ:ion
that
inÃi.uccs ati i.i:iiiiixie re,poasc axiÃi.. more p:retembty, confers
Protect:ivc i.l:tillixlity. qmixist the
clinical sigats ol PCV2 inl'c:cti+.?n. i,-, providcÃ3.. The composition niwt
p.refembly comprises

1i t11e polypcptide, or a fi=16s7iel1t fficr<c.~Ã':, expressed by ORF2 of
PCV2, as tiic witihwiic
component of 11ze compc?sitimz. PCV2 ORF2 O\A <riir3 proÃe iii, tised herein
fd3r ttic
preparation c?f the cotilpc3sitiorls ~~id within tlgc processes provided
iiea=eiii is a highh~
conserved clc~iira.iii N01iii1 PCV2 isolates ijid thcrcby, xnzPCV2 C}RF"
~.z.c?uld k- clfcctivc as
ilze source of the PCV t:.?RFM DNA :3nd,'Or poh-pcpticle as uwd herei:n, A
prelerrecl PCV2

htt ORf?2 protein is i1iat of SEQ I1-? NO. 11, A p:refirrcd 1ICV ORl?2
polypeptide is provided
licreiti as SEQ lU NNO. Y, but it is understcaocl by those of skill in the art
that this saquenck,
c~.~ ld vary ~.~ly as iiittc~1i <3.s t?-t(t".<i in sec7ticsire hom*ology and
still retain the antipiric
claaractcristics 11iat render it a.Ãsel:r7t in innnisllmpnac wnlpnsitions. The
ant.iA;~cnic
c1Yaract:.rist:ics of .ul int11tanological composition cara be, for
exartipl.e; csti:maÃed l;av the

2i cliallcrit;e exp4siarYent as provici4cl by, Example 4. Morc~.-~t<cr, the
aritit;caric oharac:terisÃic of a
11

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
modi:liod antigell is still reÃai~iod, ai:hen i1ic il~t-A:if~'iecl aaci.igen
c.ont'ers at least 70%, p:refcrably.

80%, itror.; preferabiy 90 },o of th.; protet;tie c inimutrivy iis compared to
Ã1i.; PCV2 OIU' 2
protcii:~, cncoclcci b4 the poly nuc. lcoticle scrlmnce of SEQ ID NN'():33 or
SEQ ID NOA. Nrl
"immifltrogoni.c Qotrlposition" iis tit*cd lrerei.ar i1reasis a PCV2 ORF2
protein ",l1ic11 elicits an

> "imrnatlolcagical rc~~onsC i_ the host of a cel:la.lat .tncl/or antib(xly-
rnecliatctl inn:ntne
r.espowsc to PC-V2 L?RF2 protcin.. 1?tef~r.ab1:4', tlti. cs-)n-q>o,,-,ition is
capable of
elii:ii.itr;T or errhancing an amalxsm, TOaf.n,flise aga:irrst laCV- Ãllct-
eb;v iortfering proteci.iv"e
intrna:nity aga:in.4t PC.V" infection and zi. r.eclucÃion in the inciclerwc
of, sexetity of, or
prevention oI"oriL or smyre, aaid pre.fe:rably all oi'the clisiical signs
associated therewith.

1 t~ In s(y.mc i'brins. imm nogLnic portioris of PC~ '~?. ORF2 protein are
aserl as i:tic
a~~tg~e~Ai~ comp+mcnt in tlAC compocitioa}, 'T'lie i:elaat '"iaawttctto
geni;, tortgon", as used l;erci:n
ra l~nti to 'Erl7Flc;ltt'.d al1dti?r substituted fC7rBl1S, U:r frag11)<'.Blts
C7f.PCV21 OR.~2 pr[?ta;lll a11cl,/Ctr

golz-xtu.cle:oticle., respe:ctive.ly, Pretera.t3ly_ such mi;;ate:d a:neltear ,-
bsiitutcd t'orms, or
t'ragm, ntc will compris, at l.east 6 csitttiÃ;u.r,us aminr, acitls -fro.m
tlic, tia.tl-:lengtJi f?.17F2
1i }xal~ype-ptirlc, More prefirably, tlle trtnicat.ed c.~.r substiftrtcc!
k'~rms, o:r fi=agmer1t5 will ha~~c at

iw.ust 10, ziic3re pa ef:w.rabli- at least 15, aiid still morc~ pre firabh~ at
iwwa 19 contiguous asmalo
acids f'r<ai-n tlie f'trll Jenhth ORF2 pc31~pepiide. 'N.o preferred
;ecluLiicLS in this respect are
provided 1~crei1t i_s SEQ ID .'~{)s, 9 aiid .lt?, It is ffirtlxer-
t~iidcr5tood tJiit such sequc.Ttc<s may
be a part of larger fi=a~inealts car intsicatezi l:~~ra~xs=

h~f A l:r7:rtller prel:errecl PCV2 ORF2 poly-fx;pi.idc: prov:ieleel herein is
caccoeleel by tlre
nu:cle~.~tirt~, seqticiices of SEQ ID NNO: 3 or SEQ iD NiO: Ã. However, it
i~,, understood by
tlic"se of Aill ilx the art that Ã:fris ~scclzfl4nce c-ortld Nsu~ l.iy iss
much as 6 ?M in sequmc,e
bolxrolt?gy and still main tltc alitigeacic cltaracte:rist:ics that re~ider it
useful in ilxrarla~logc:zric.
compositif-als.. I1). 5cmix fonws, a truncated ot= substituted filrrn. or
f't.igmeat of this 1?VC1

2:? ORF2 po1yp.:pticia; is used as the arYait;cs-& camponcart irt tlYo
ccampc,siÃi~.-~n, pr4kxstl.?ly, sa:c:li
12

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
truncaÃcd or substamted foraim or fra.gments will comprise faÃ lc:zist 18
cc?ntiguous nuclcoi.idc:s

froiiL the iull.lcmgt1L C3RF2 iitic;leoticle seqaence, e.g. of SEQ ID NO: 3 or
SEQ ID NO: 4.
More prc.feral.~ly, the truncated or s bstitutcd or Ãi-agnic: ts, will :liavc
at least .' 30. 31101-e
preferably ziÃ least 45, ~~~id still i1iore preft;ral<aly ziÃ least ; 7
contiguous ntitc1.cotiti of the ftiill-
1,.ngtfi ORF2 e..g SEQ TD N-'O: -" or SEQ ID NO: 4.

"Sequence Ideatity,> as it is l;nosvr~ in the zirÃ r6er4 t~.~ a relaEionsltip
Ix.tiveen. t4vo or
fl~iere pol;vlaQpt:ide seeliwnc er two or snore lolvsawlcotitl<
st;clt.xences. namely a n;ferenc:e
s~.qxaence .uicl agw,;n sequence to bc c,ornpareci witli the rcferer~~;~:
scqAwiae.c. Secluenoc
i(leaititi- is clLterm:iaerl by coan1~aring the given qe(itxciice to the
refcrer1cL seqt~ence after the

lt~ seqFictices 1iave heeri optimally aligaie.tl tcs pr=oeltic:e the liigliest
degree of sequence sim:ilariÃy<
as de#:ea~~Ai~~ecl hy the match between strings of such seqFa,:nce:s. l_,~poa}
such a#m~~~~lent,
seqFictice ide.m:iÃy is ascertai~~ed csai aposmon-by-lxssition baqis~ e.g.>
the sequences are
::icie.ntical" at a pai-ticula:r position if at that positioi1, the
nu.ckoticle.s or aiTiiaio acid residues
are idea}tical. 'T'11e total number of sFach position idea}titie.s is tiie:ii
divided by tiie: total ritcmbe:r

1i of nuckoticles or zcsidues iii the refcrettce seclricaiUe to giy-e %
seÃfuemc :identity. SLqricsiUe
identity can be re.3di1y calc.tihkter3 by knou-n i~milzcads, inclur3ing; btiÃ
riot l:imited tca, tlic3se
described in t;-ac~~putational Molecular Biolcigy_ .t,<sl;:, A. N., etl..,
Oaf:ortl UMiversiti 1'ces;;,
~cw York (1988). Biocomput:inh: Trafo:rariaiics a1ic1 Ciejioraic Projccts..
Ssnith.. t7.W., ed,
Ac.ademic Press, New York #;1993.y t;"oiiiptiter Anals~sis of Scclticricw.
Duta. Part T. (:iriffinz.

hta A \I.. and Gri13im. .F-t, G.. eels.. E-1uniana T'rc,ss. Ncw Jersey (1994);
Sequence Analy-sas in
blolccular Biolotye,v ori lisirigi, Ci., r'lc ademic Press (198 i~.
Seyzflciic:e Analysis PrinYcr,
Gril.~sl;ok., M. and I3ea.er4zflx, J., eds., M. Stockton T'ress, N4w. York
(1991). and Carillo, 11.,
and L:ip.mau, l? . SIAM J. Applied :,\1mh., 48: 1073 (1988). the teachings of
which zire
incorlxarated krein 1>y, teierc: c.c. Pi-cferred xÃhcsd4 to cletcnninc the
seclaericc iden.ti.tv are

2i do it~~.:ci to give tlto lasga;st match betw.:cri di4 sa:clueiYc4s tested.
Methods to dotermisi.:
13

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
sequence ident:cty are cod:ifiecl in publicly available co:anpister prmgraans
w-lr:ich cleten-ni.zre
sequence i.deirmg bmve,cn igiven s..cluences. Extiniples of stic.li
progriatrls hic;leido. but are fliot

limited to, the GC'~'i jxogran:~ laac.kagc (T4eacreu . J.. ot al., N cloic.
Acids Research,
l { 1):.387 (1984)), BLASTP. BLASTN and FASTA {Al.tscllrtl. S. F. + tal.. J,
Molec, Blol.,
? 15:4f)j"s-=l l f} 0990). 'IIYe RIsAS'l."X lmogr.un is publicly available
#irorn NN"f':131 ar~d ~.~tlter

sources (BLAST lllanxaa:l, Altsc.laal, S. et al., NCVl ~T.hl NTH Betl::e,.cla.
N1C.3 20894,
Altsclrnl> S, F. et: tal.. J, Molw. Biol.> 2 15 .403-41 ti (1990}, t1w
waclrinr.~-s of which are
incorp~,~r.it::cl Itere:in. bN~ nferetice). Tb,;4e pt-ca~,;r~~~~:~s
cypti~:~~:tliv ali.g~~ seclact~c,e. using c~.c(~~t~lÃ
g:1p wt;Fglaq in orCla;I to proffllce the 11# l]t SE It ~'t l C7fSeqIJL:[lcG
EdG1gtit>' between i:lla; given ;1B1d

1t~ reference seqlwriccs. As asi illustration, by a po1~ynacleoticlL lialiaig
anlfc.lecstide secluerlc:e
having at least. to:r emmts#e. 85%., pr, ferablo, 90E'40. eves7 nio:re
pre.l'erablN9;':e; "se:ques7ue
identit~," to a re.i'erencG aitFcleotirie seqlfe.nce, it is intended t:liat
the aitFcleotirie sequence csf t:t~e
given pealz-xtu.cle:oticle is :iÃi:e.atica.l to tlle avfcrexice sequence
except that the given
l.?ola a}Facl, ot:ide sequence may iatc:ltatle up to :l'?, pavf-erahly tip to
I i3. even iitoi-c p:rel'eaibta up

1i tc? 5 point :aiutatiosis per eacii 100 :aueleoticlcs of the refercnec
jiuUlcotide qeÃIrtcrlcc. ln otlier
%vorcls, in a pralynacleotide buvim' a Izueleotide seqttciice having at least
85'No, preferably
90"i,, even aii<arL preferably 95% identity rL.la.tive tc? Ã11e relerLnce
tiiiclecitiele seytrencet up to
15".. ps'cfer-a.b1y l t)%, ev<~ii rttt?rc p:rcfi.n l.sli ?"~a of the
niteleotides in tiie mÃ'caencc setluertcc
rixav he deleted or substituted wit:li z~iiotliea= izuc-leotide , or a nrimlx-
r o.Ã'nuclec?tide:s up to 15%,

htt prel:ct-al?li l tt%. even niorc pre.ferabtN of tlic total acuclc:otictes
in the :rcfironoe seq1~enc.c:
may be itisertsci into tlic refire.ric;e secluciYce. 'ilaase iYiYtÃiatioflis
of tlaa refe.rancc sequence nwN
cccrtr at Ãlie 5' c.yr 3' terminal positions r?r t1i~~ raer4.nce n cle.c.~tide
seqti:eiice or a#ivwliere
b m:c:eac those torminal positions. iactc:rspersed catlicr individually
aanonz;: xmole:ntacles iac ilic
rcfcrer~cc wclxac: cc or in one or. : nore c:orrm"laows groAtp4 witllir~ the
reference seelAterwc.

2:? -AdIalo-gotrsly, b1 a polypeptici.: lYavirag agiva;ra amino stoid
sa:cluerYo.: lYavirag at l4stst, for
14

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Ex~IiT'll'Sle, mckral'?l4' 9Mv, Ul'C3't 111i?#"L 1?ri fet-al?lt' c}?v'rr
sequence :lClt:wlty to a i'i fere#lcL

aitiiii~.~ aci(i se4lucnw. it is iiLtciYele;el that the giv.;ii amino acid
sequence cyl the potypa;ptide is
iclcnt:ic.ll to the nl'ermce scqxae: cc cxupt that the given polylacptidc
sccluct?cc rwav> iriclladc
:ltp to 15- prei'<rably tip to 10, ey-ei1 ~~iore t?rel'erably tip to 5 asnino
acid alterations per ea:ch.

100 amino acicls o#'tl::e r,.l'ereace .ltnino acic.~ sequence. 1n r?tlicr
~vor.d4, Ão obtaiti a givera
p~,,llt'pept3(le sequence having at IC:.E$st i;5t1j+;. 1)m1%.mb.li' 90ta(z,
even 3TiCIrC preferably 915%

scqu:enco itlen:tity with a. rei'<renco amino acid sequens;,e, ttp t(i
15'':i,r preferably tip to 10%.
even traote pmf'et.lblv rkl? Ãr? 5"i, of the a-mino acid ~-esiclucs irt the i-
e#crerac.c scqwncc titav be
[i<'.1GtLCl or substituted lS'1(ll another iilills)C7 ;1C:ld~ or a f3i8lllt7er
of ;1B111I1o acids up t#~l .l 5%,

1 t~ laref:c..raE?l~y Fap to 10%. even niore larc.ii=t?li tip to of the total
numE?L:r of amino 1cid
etrsicluo:s in ilh: reference sequence may lae inserted into tlic reference
sz:cliwEl+~,e. These
al~cra~BCSBis of tlle re:lerence S~ellfeaice may occrlr at the iytlzs)o or the
ca.rboa>' t~s-miygal
positions of tl3e rete:rc:ncc aa3li-tirs acid ,c:quc.ncc or ~~ivwlic:rc lae-
hvec.ii those tcrjiii:tial
positions. iWe:r,pe:rsed c:iffie:r individually aanong :rc:siclu.cs in tiAC:
reference 5equence or ia} the
o :; or :~i~?re c~?l1t~~lac~us ~~-oups w:it.his) ttic refuenUe seclilejice.
.E'refe:rab.lN .residrxe positions
%N,lzicli are tzot iclemic;al siilfea= hy cc?l~sc~~uti~e asnWca acid
substitutic?rzs. F-T<?Nve1~er.
cc3nsea=z;atiz~e substitutions are not iilc.lutled as aiiititc.li Vv.lrcn
det.cnn:iniygtj seclueacc aclLaititv.

<.Scqueaice .t1c?1110l0gN.,', as used hereiai, re.t'e:rs to a aiietliocl of'
deterlnirli.rag ttic
rel.3taless of mw Sw.cluences, 'T"o de ter#zfirie sequence bomolc?gy, mvo or
rixc?re sequences aa=e
ht~ optuma.lh aligned, and gaps are, antrodr7cocl if ne:cessan~. x-1ow~.:v,;r.
iia coutTasÃ to 4'seq1ietic.c

itlsatitN'", c~.?nsmatis>e <3iititio aeid slibstilxstioiis are c~.?luit:ed ias
a m<3teli w-lien tlstemining
seqli:elic4 liiiric~le~~a;. In i?tlier words, to obtain a l?c.~lypepticle or
pt?la,nls0coÃ:ide having 95"N~~
Si,que3'lcL' liCM1t3l[?lCti~~~ dvitl3 a #'e.rLrf:ilt:o sLql1e#icL, 85%,
1}:rLfE:ral'?l4' 9Mv, even lili?re preferably
9~% or the amino acid 1'Cs1.(ltli.:s E?T' t3tlcli:Clt#dCs in the rGfi.:reTIcC
sequence i13lEst 3"Ciatc.li or

2:? Comprisc a ocniscrx stiix-c Su1<istitutiorY wit1~i another araririo acid
as rYlic:leoticlc., or a number ~.-~I'.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
amino facids or nuclet?ticles a.ip to 1 Y' v, ~re4:erawy t7p to evezi rtiorc;
preleraF?:ld~ up to

cii' tlie total amino acid resitlYscs or nucl.;otidm fliot hicluding t;on_rirv-
mive substiiutiolYs, m
the i-c#'ererac.c seq c~icc iz4 ~ic irasc~iecl itito the r,.l'ercme
setluer~c~.. Preferabiv> th,. Itcm ioiog
seelifloiat:e comprises ziÃ letasÃ a stretch of 50, ci.~;n more preferably at
least 100, eaea iti(Yre
> preÃ',;mal>h' at least '250. and cvcri rnore prefcrably w, least '?t}Et
nucleotides.

A "c~.~nscrvati.vc substitution" re f'et:s to the substitution of zira amino
acid n5icluc or
niflck ot.ide wi.t11 anothu ai1iiit(i as;:ic.i residiflc or nucleoti.de
havinr.~- ;:inulae' c11arac:terist.ics or
pi-olaerti,.s irw:lucling s:in, hyclrop]::obiciEy, ctc., such thm, the oxcrall
functicm Wity dms ricaÃ
c1~angG

1 t~ "Isolated" aneasis altered "by tlre liaad of ytiasi" from its natural
qtatL, i.~ ., if it occurs
in nature, it has lvn ClA~~~ged s>t= rc~~iovcd ti:ona its original
environment, o:r lotly. For
CaMgPlC~ a lAynacleoticle or polype.ptide naturally present isi a 1i-vi:ng
or~anisn1 is aiot
::isn.lateel,< biit the saxnc: polvaigacte.eatide or polytepticle se.pa:ratecl
txoa31 the coesist:ing
matecia:ls of its untu.ra# ctate is ''aso.lateel"Y. as the tem7 is employed
herein.

fllu5, tl1e i.r1iiti-nogcaiic composition -as used herein -also refers to a
cc?iiipo5itiosi that
comprises PCV2 ORF2 prote iii, wliereizi said PCV2 ORF2 protein is wymc~ o:t'
those.
described above. i'ceÃ'eaably, said PCV2 {)R_F2 proteiai is

i) a po.l~~pcpticle comprising tlic sLqucsicc tAt' SEQ l.D NN[?: 5, SEQ ID NO:
t~"a,
SEQ ID NO, 9, SEQ ID NO: 10 oa= SEQ1D NO: ] :t:

htt iat any polypeptide, that is at least 8(3% laomologoiss to the po1ypoptide
of i),
iii) any portiori of the polypepticles (?i i) and/or ii)

h-;1 tlic inimmii.~geriic l~i.~~ion (.yt iii), comprisirig t3:t least 10
coliti-tious W11i110
acids included in t8ic seq1~~~iccs of SEQ ID 3dt7; Y. SEQ ID NO: Ã4. SEQ ID
NO: 9. SF()1 C3 liO: 1 () or SEQ ID NO: ]. I,

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
v) apnlvpc:ptaclc that is encodod F?y- a DNA cnarlprasiXig tllc sccla.rearce
of SEQ

ID 310; 3 cir SEQ ID NO: 4,

l i) any laoh.gx.gmicle tlmt is er:rcc3ded 1>y a palyrrAtclesmide that is at
least '80'a:i,
hom*ologous i(i the polymtcleofitl< of v),

> vii) arry imamrrcagertic. la(yriicrir. of the gxalylaolaticies crr.cr.?cicd
by, tlle
txah,na.c:lcc,ticlc c,Ã' V) aacli'or vi)

viiia tlr< isrr.rlirasror.~enir; Pcrr-t:iosr of 'vii), wl.wroin
polysrr.teleotitl< ccrc.iin~> for stiricl
irnmxrrtc~ge:rric pcrrtiolr cr.~mgxises at ]cast :itt contigmcaus nucleoticics
indAtded
isi the scqticrice.s of SEQ ID NO: 3, ar SEQ li? NO: 4,

1 t~ l'ra;I-Gr;rl?lti ;rrly of ttlosa; islgrl1E3:[1ctge11i0 PortiClygs llave
t11G ilwalli#ZUg!L:[1Fc characteristics

of PCV2 ORF2 protein #.hnt Is encoded by the seqr:rericc ol' SEQ ID NO: 3 or
SEE? It) NO: 4.
According tr? ;r ftrrtheraslect,1't;.:V'2. ti)]:.l~'~ pr-oteiyg is provided
isi t.trL irnmranologica1
crsr31pos:it:iarr at axi aritiger7 inclrrs:iarr level effective for
iriclucirig tlic desired ir3umme respon,c:,
11a117eh, r=edFrcim, the incidence of, le.sseni_tr-V tiAe: scx-crity of. or
p:re~~er7till~ c-rir.c or mart:
cl.illici1 signs restrltirtg from PCV2 :irr.fictiorr.. I'zel-cr'al3ly, t.lte
PCV2 ORF2 protein .irrdiaslort
lovw.l is at least tl.'k jig aiiÃigeri :' 111l of tlle final
imr.mrrr:c3g"ealic cmz~positiorl snore
preferably from abotit 0.2 tc? abotit 400 Itg.'Ml, still more pre.Fe.r~trb.ly
:fro:rn trl)(airt 03 to trl)c?irt
200 trg.'arrl, mn r-nore ptcfirably ftorr:r about 0.35 to abotit ]tat#
trg,"arrl, still morc preÃ'er'al3ly
f'rc?m abom 0.4 to abotit 50 lag.iml, still siiore preteralaie, from :rlxnrt
0.45 to abotit 30 htt still arlore prderabtN from alom 0.6 to about l-i ~qg
/rxll. even :arlore pro:ler-ab:ly ftcrmr about

0.75 to a:botr:t S p.r~(rYil, eviti riis~rs prcf~ir<rl~le~~ frc?iti r~l.icaYrl
1,C? to tibotri 6 ~tg/i~tl, still 111c?re
prete.raE.~l}' from aEaout 1.:. to about 3.0 tr~r'rril, e.ve.ii m~.~re
prderaE.~la, from about 1.4- ti.~ t3:botr:t
15 p,rg/nrl, even more prct'errrbh, !'rorxi abotit I.5 to aF?oa.rt 2.0 Ãz4~
arll. and n:cnst pie!'oraWs>
al;rotsÃ :Ã .6 ~t,:nl.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
kcGordi.zig to a li7:rtlle;r a.spect. i1i~:. ORF2 aniigpi inclusion level is
zit least 0
.2 ug'
PCV2 ORF2 proteiiY as described abov~~~ per clos~.. of the final aiitigoiYic
composition
tfLg/doscD. : i.rare larcfi;r.at}ly fi-otti about t3.2 t~.~ abraAti 400
ftg!ct~.~4c, still niorc preferably ('totta
abot.xt (1.3 to about 200 Ãt.;T: tlose. evea~ ~~iorc preferably fresii. about
035 t(i abot.xt 1 00 pg/dost;,

> still rnc~re 1yn1'crably Frcani about 0.4 to about 30 l.tg.'clc~se. still
rnc~re 1yn1'crably frcatta about
0.43 to about 3~() 1r4::'dow, still itiore prok:r.ibly ('icstta about 0.6 to
.tbotkt 15 u,g/cto',sc; excii.
fliiere Prefi;rably from about 0.75 to ziboist 8 lt.g:'tlosc. eaesi. iiiorc
prei'<rably frotti abc~Llt 1.#) i:o
about 6 still more lai-cf'cral;aly' ('icatta about 1. i to about 3.0 eveia
mor,;
prLt-erabli. from about 1.=1 to abosit 2.5 il g/dose. L1esi rnore
prGfc..rahhÃresan about 1.5 tcs ab~~ut
1 t~ 2 i3 fa*g/clcssc:.< a.rid niost lytefGrably~ about l.fi ggi'dosL=

'T'lic .t'('V? [).171~ 2 po1ylsels#:iÃ3:e used in the im:aauns~genic
composition in accoadanuc
witli tiic prLscylt invention cas) be derived isi asiy fashion i~iclttcliygg
isolaticssi asitl lnfrification
of .l'C'V" (?RF?, standard protcirl wtithc .sas. and :recaa3lbinant
mei.hadologa'. .E'refc .xx,;cl
mei11ocls for obtaining PC'V' (3RF2 poh-pcpÃisie are 1.?ro3iclcsi in t"S.
Patent Application

1i Scrial No. l.t U34,797, tiie teae1141gs a1iki cc.~.nterlt c.if Whic.h arc
hereby i1icozpotat.ed by
r~ FirG~icw.. l~ri~t7s <susc>eptible colls are i:ntecicrl N~-iffi :3
rec.ombuzxzt viral vector coniaimaig
F+tr"V2 O.t2T?2 DNA cc?diygtj s.c;clucagces, 1'CV'-) ORF'2 pt31ypcptide is
expressed by tlgc
recanibinaait vints, and tiic expressed PCV2 ORF2 polypepticlc is mcc.~vcrcd
f:rom ttic
supc.mate by filtratiozi aaldinactiuatecl by any convealticanal me Yhoci,
pael:erahli. usim" hisiary
htt c,tlayleni.nAle, which is tboal aielflirataze(t to stol) tlle
allact:iz:ation proGcss.

7'lic inYinuliov"crlic cOflIil.~QsiÃY~.~i1 ti:s zflsk;d lie;rciii also re;fcrs
i:o ti coritpositioti that
comprises i) any of tii~:. PCV2 ORF2 protein ttesca=il=aecl above,
prel:wrabli. isi cozicintrawris
clescrit3cd alxay-c, aiicl ii;l at least a~ortim tAÃ' the viral vecto:r
cxpress:inh said PCV2 (3RF 2
Pa=otein. Pre:Fer:3bly. of a recoml=aiziaw huculovims, \wioa=cover, tlle
itiisiititlogc~llic c:oaiipositioii
ca:~l CoMprase i) a:ny o.t' the PCV2 ORF2 prowi:ns described abovz:.,
prelGrably in
18

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
cnnconÃraticans describGd ttF?cavo, u) at leasi: a portion of tlic: viral
vector ex~ress:inA;-said FCVh

ORF2 pxoÃtiri, preferably ot' a recoizibinaiit haculovirus, aiid iii) a
portic?ii of t1ie ctll culttirc
supenmte.

'T'lic iita.a7iu-nogcaiic ccaztlpcasitioai as usetl i>ca'<i.~t 'a.lsc.~ rcfirs
to a Ccampcas:iF:ic.~n that
;,omprises i) ano of the E'('V? O:&t.F? protciiis elvs; ribcd a1~ove.
prete:mb.ly in concentrations
described aisove. .Il) at least a potÃion ol' ffi,: N.-ira:l vector
,:xpavssingsaicl PCV2 C3R F? protein,
preferably or a. recombinant baculovirus. and iiil a PorÃion (il'tll< cell
etitltu.re; ",11ereila about
90% :ca;:
:~ c?l E te c~.~ttilxaatcnts have a san 4nta 1,.r t::arl I ktrn,

Tlae immuaao-genic eomposit:iesa as iflsed 11eroin also refers to a
composition ihzit
e.omlxrist;s i) any (ii'the PCV2 ORF2 pr(iteitis de>:eritnud al<aov<,
preferably in

described above, ii) at least a portion of the virnl vecÃor eapr4ssin4r said
PCV2 ORF2 proÃ:eHi,
iii) a pnrticali of tlie cGll culture, iv) and :inactivati~~g aA;~ent to
inaGtivato Ãhe recoilibinatit viral
vector preferably 13E:1, wherein <3bcatt 90%, of (li~, umnpo-aenis i.) t~.~
iii) have t3. size siiis311er
tli<3ai 1}tm, Preferfa~.ily, E3E1 is Prese-at i-a cont;ewrat-icmis e11cctivc
to imat;tivs3ti ilae
1.4i 1xiculovanfls. E13Gctave conoontratio:ars are clesor-ibecl above.

The imm ni~.~ntaic composition as ti.sed liert:iai <31si.~ refers to a
cotax~.~osit-ii.~n that
coniprises i) any of t1ie PC'Vw ORF':'. proÃcixis clescribed ttbnva,
preferably in concentrations
described aboy-ct i.i) at least i portion tal'tlxe vir-al vectcarexpressiilV
sa:id PCV2 t)Rk'2 protciai,
iii) a portion ol'tlae C,:.ll culturc, i~~~ an i~~ac tivating agent to
araactgva#:e tlic avec-amfsanant viral

~~ecÃcsr prefeaahl~y BET. atad v) asa aLGuÃaa.lintioaa agent to stop the
imictaiatioal ataeri.iate-d by t:tae
, . . . .,, .
a;1~~,,Ãavat. ~rag agv;1t. es lvr~;~,a about 90% of t~~l;:
~.~~,~af~s~~za~:zaÃc . ~) to ,.u) have a ~~zc sma"I . e:r Ã ha;1 1.
liai7. l?avf"vrnh13.. it' the hmcta3 ntirag agent: is .131'I., Said
coaaipositgon comprises sosiiirra}
thlClsulfi]_ta; Bll Gql1lViAl"a';Ilt t]ll)C7t1BltS to B.F.7

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
'1'lie; poJi~peptide is incorl)oratecl into a composition that cziac be
achuin:isterod to axi

aiiiiii<3l srtsc.eptiblc to PCV2 inil.;ctioli. lflI prefirred forilLs, tlic
eomposi.Ãi~.~n may also iiiclacic
additional compon:cats known to those oÃ' tkill in the art tscc also
:Rcrningtora's
P11arma:cmfltical Sciences. (1990). 1 gih ec.i. Mack t'iflbl.. Laston3.
.lclc.iitionalls. the

> cornpos:it:io include one oi, ttaore vetcrinary-accelaÃable cat-ricrs. As
used laenin, "a
vctcriraaty-ar,ccpCal>le carric:r" includes a: 4 and all solvcnts,
ctispc:rs:ion media, co.ttings,
ac.ijuvtants, stabiliring agwnt,, tliliflent;:, prmrvatii:~,sr antibacterial
aiad anti.i'iflt~~,'al a
gents,
isotonic agcn.Ãs, acts~.~rpÃion.dcl.;iy itig agcnts, a c.~ the l.il~c. t_ a
pref'err.ecl emt}csdinmit, the
gLnic coytipositiori compriscs PCV2 C3h..l~'2 protcm as provided hc.rew~ith,
preferably
ammu1o,

1 tl in concentrations dcscfibcd abos=L, which is mixed with a.ri ariisÃva:nt.
prc.1~.rabl~y C:arb(Ylxsl<
and p.hN siOlOgica:l Sa.ti:ne.

Those of sk-ill in the art iz>ill undersmaci tliat iliL comlxssition used
liereiii mai
incorloratc kamn injc.ctiible> p13ysio.logica.tlz- a:ccc.ptahlc: stc.ralc
solaitioiis. For prcparing, a
r,:ady -#:o-u.sc soli.cÃio:a for parea}terat inJc.ctioa} Ot' inticsion,
aqueous is+.?tnnic ,olutic?ns, such as

1i C.g. sa.lme or corresponding lalasma proteisi solut:ic.~ns, aa-c :rcadi.ly
available. In adcl*tic?n, tl1c
immusic?gewc wzd vacciac~ cc31z~positions o:t' tllc presem inventimz c;as)
hicluclw. diluents,
isc?torlic agents, stabilizers, or ailjuvams. Diluents cati include watea=,
srI.tiarc. dextrose,
ctlla.rlc.~l, gJvccro.l, atid the lil~c. Tsototiic a6jerlts caii include
socliu:iii Uhloridc, dextrose,
rixaa~iiitc31, sorbitcal,> aticl lacÃose, asnozig, offie:rs, Stabilizers
isiciticie albumizi wzd alkali sialt:s of
htJ e;tJIvlendif azm ntci.-amic acid. aanonA;: t?the;rs.

.ldju-vanls" a~s used hers:in, can iflis:ludi aluminum li4'dr~.~xitle and
aluminum
pliospht3te, ss3pc.~tli-as e.;.~.. (Fuil A, Q'S-21 (Caiiibridge Biot.et;li
hic., 1=_amle~ridgc MA), GPI-
0100 tGa.lenaca. Pharmaceuticals. Jnc.. kfi~~~i.z~,:haan. Al.;t. water--an-oil
c:zrmlsioxt oil-in-wme:r
enutlsi~.~n. crna.lsi.on. TJ:c c: i.ulsican car~ be b.iscct ir~ p.u-tica.lat
on light

2i liquid paraffin oil (EaTcapcari f'lmrinacapca tyN}; isoprcrYoid ciil sracli
as sqtealarta; as sq al4si.:

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
oil restfllting frozn tJt~..:oligc?nac:rixation of atkwces. in pargictilzir of
isobutene or clec.e110; 0-sto-rs

cif acids or of alc;oliols corit<3inirL;~ a liaear alkyl gr~.~Ysls, more
partica.ltrrly plant orls, e'thyl
oleate. propylene g1ycol di-(caprylate,caprate), glyceryl tri ~c,alazti l~~t~
i'ca~~rat~ } or propylclie
glycol. diolcatc: esters of 1<aranchod i'atty acids or al.wllols. in
partis;:til~ir isostearic acid Qators-

The oil.. is used in cottabii.xatiot~ ~v:itla ~ra~~~isifie~s to for.rtl the
cttaulsion.. The e~t~Atls~#i~r~ are
pi-c#.'er.al;aly' nonionic scrrfact.nts, in particular esEen oF ,-wr.bitan, of
rn.;tn: i.cic (e.g,
anlrlvc.ironlansntol oleate), of gls col, of pols Tlycorol, of propylene
~'lvcol asic.i of Oeic:,
isostearic.~ ricirtole:ic or liv>clrcixvstear.ic aicicl, Nk~laic:li. are
calaticy. all-v 61::c,xyhoaccl.. arid

ccspobmer bloc;~-s, y.rl pasiycaila.r the 1'lttroalyc products,
1 tJ especially. 1,1':1. 'seL HsKtiter= et al,. The The(x-v arici R.ractacal
Application of Aciju-vants
{EdStewart-"1'id1. .l)..1=::.S.}. _lolyriWil,:y and Sons, NY. l~p-51-94 0995)
aa}cl 'T'oÃ3:c1 ,:t al,,
Vaccine 15:36=1-570 (1997),

For examp.le, it is prsssilalc t(-i ir,e: the SPT etiiti.lsioji rlescrihe.rl
on pap, :147 of
"Vacc:ine t)esigai, '1'lic Subunit and AÃ3.#tcvaa}t :3.p1.?roac11' edited by
:k1, .l'e~ive.ll and M
1i Newman, .E'lcliri-ni .l'rcss, 19951, ajid the crnulsic.~.n MF59
rlcsc:r.ibed oji page 18 3) of tliis 5~~~le
btac3k

A :fitrtlicr .iastance of an actluvatit is a c;on1pc?unil clioseai li'oall the
poly.tners of trcq lic
or Inaita.c:rv-l:ic icirl artrl tttc copolysuers of rnalcic a.r1lwclricle arid
ilk-csrvi derivatite.
:kr3vaaitagocaris acljuvwzt c.orixpotiiir3s are t:lic pc34~mea=s of acrs fic
or nwtla<rcnjic; acid wliicli aa=e

ht~ crt,ss-link-od, espoc.ia.lly- with pol-va.l.l;:enyl ctliers of srigars or
pol-va.lcollols. "I"hesc: compounds
are kno~s,ti by t:lik~ t:ei-iti cfirboiner (Phanieurcapa Vcal. 8, No. ',
,TciiYk, 199(~). Pir~c?iis skilled iri
the <3rt: can also refer tc.~ U. S, Ps3t4=nt: No. 2,909,462 vvliicli
descri}t:s such s3rn-lic pi.~l}'awrs
cross-linked vi itEa a poly Eay-dro:,.,Oat~..:d oonipotflncl having at least 3
laydroxyl,trnum
preÃ',;r-al>I~. r*t rlicyr; than 8, thc bvdrca~~~en aton:~s of at least tl~ice
ha droxti ls bcint; replauA by,

2i xtslsaturatod allpllatlc: radicals havÃsiv at la;,lst'' car1:~(x1 aÃorns.
The pre&rrod radicals are those
21

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
cnniaini.z~4~ f'rorn 2 to 4 carbon fai-oilis. c.& vinvls, ally-ls and oilicr-
ctlivlc:nicalli, unsaturated

grotflps. "I"1i.. titLCiitxtrtitcd radicals may t1Lenlse.lz.es wmaln other
sabstittietLts, sucli as meÃ:lYyl.
The larociAtcts solci under Ã1i:; name Carbcal.-,0l; (R-F Oooclric:h. Ohio,
USA) .ire particularly
appropriate. T'1iev aire cross-lisi1:ed w it1i an. allz 1 sucrose or w ith
a1lyl lx:tilacry ihriÃc~l.. Among

t1Yern. there rnaa b,: rnc.nticaned Carbopol 9741', 934l? ancl. 9711?. klcasÃ
pi-efor.recl is tl:e a.se o:f
C'arlop~.~l, in fhirtie.talar the a.se of Carbopol 9711?. pr,.l'c.r-al>ly in
.tir~~.~unt~ of al.ioAti 51)0 ug to
~~b(yisÃ 5m g pe e' dose, ~;wn itiorc pe-eft:rre~.i in aia amount of alaot.xt
7i 0 p l; i(i alaot.xt '.~ sm> per
closc .uicl raiost laicfer.rec.~l in an amount oi'abcaai l. : ng pc.r dow.

1"13.t'tlle[' S(111;'ll?lt; a4#13:ti3:[1tS Illi;ll3.d~õ bIJt Eir'G; llot
l.EltlllLd tC). il]e 1'ZIBl aclli91'a111 S>'Ste1t1

l t~ (Ribi lac.), Block co-polynicr (Cyt.Rx. Atlanta GA). SAF-X-1 (C'hirori,
Fsneryllile CA)<
anonophosplyoryt lipid A. Avridine lipÃcl-anfia}e asi.ju:vant, tyeat-.lahi.le
enterotoxi:n ftoiii E. coli
{recombi.narit or otlier asL'). e.liolLra toxiai, Tli!tS 1314, or mFaramyl
dipeptide among anaaly
otlie:rs.

l'r+ Perably, ffi,: asi.ju:vant ig added in an aniount ot' ahout 100 lig to
a.hou.Ã .10 mg per
1i tlosc. Evei1 :aiorc p:refiralsly, t11c a4juvanÃ is acltled in an aTiiotajit
o.t'alsotat 100 Ixh to about 10
m~ per clca:~w., l:.a~~w.iz z~~:c~re pl:wrahli., the z~~ija.~~~.3r~t is
aclci~:.~zi i~~. uti aaii<~tirit of about 500 1~;..; to
about 5 mg, per dose. Even y-nt3a=e pre.Fe.r=t~b.ly, the ael,juvanr is
aclileil in a-ti aaiiottait of'a:bout 750
lag tc.i about 2.5 sug per clc.~se. .N.-1ost p:rcferalsis, t11e a.clluvant is
added in an a1iiotajit ot'abotit 1
riig per dow.

ht~ ~-Viditionalty, the oomposii.ion oan include one or rnore

cfirriers. As used laercin, "a pl~t~r~i~aekY~li~~~l ~~c~ spt<3l~ls cfirrier"
includes any and all scalvents,
dispersion media, coaÃin4rs. stssbiliri~ii
g ag,,ent.s. dil; ents, prcsertaE-ives, a-atibacÃ:erial and
antifunl;a.l aAe~a.ts, isotonic ~agc:z~rs, a.(isc~rptic~il ~IGl~~N~ix~~ a
c:a~i~, and il~c lil~~ .'~Ãc~si lsrct'ir~~bl~,
il::e c:ca npcasi.iion larovicleci lacrc:~viCk, c~.~ntains }?CV21 ORF2
proteiri t-ccoa-cred #'rorn tlle

2i sxtln-mstte ci#:' i;.r vitro c,ulÃtir4cl cells, svl:te.r4iri said cells 4N
cro irtfccta;cl ckitli a s.:c,oarYl.?inant t iral
22

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
vector comai.n:in,: T'C Vw ORFh DNA aixtel exT,ress:in,: T'C Vw ORF-h protein,
and wherein gtid

ciil ctiltxtre tva5 trcat,.tl ~NithaboYst 2 to ab<.~Yst 8mN.-1 T-3E1,
prcfer<3bly with about 5 iiYM BT::T to
i~~acti.v.tt:: the Viral vectrar, and an ecluivalcm. concentration of a
raoutr.tlimEi.011 agcnt,
preferabl4 sodiiflm thio;:ulfate solution to a final c:oncentratiotr of about
2 to al~out: 8 111M,

> preÃ'mal>Ã~. of about 5 The present inve tion. also nlate~ to a iran
nu~~~.~4cnic c.cattalaosition that cottalarise~ i)

ans ol' tlic PCV2 Cti%<.Fw proteins described aloz.c, pre.ferablN~ in
concentrations (Ãcscribed
above, ii) at least a T.~ortioii of tlic viral vecÃor cxpressMg si3id T-'C_V'
ORF2 protein, iif) t3.
Pc-~rtion c?f the cell cultu-m h) azl imctivating, -aVcait to imactiy.ate tile
recombil1am viral vector

pmt'erablv R.1~:.t, a-ad v) ~ii mutraliratio~~ ~~~iit to sÃol) tiic
mactivatic?n aiietliateki t3y tiie
gnactivatim ; ngeilt. prctcralaly socliFani tliiosu.llntc in ,;cltciva:lcn#:
amounts to T:~E.l: "Ind vT) .1
sarit-We acl#ws~ant. pmÃ-eraWi C:arboixsl 971. in ayticstum c1Lscrihed abovL;
vitiercin al3oFat 90%,,
of'tlye conll.?onents :i) to iii) baven si:zesana.ller t.Eann 1 gan. According
to a fFart-he:r aspect, t.hic
immFa~~og
,enic Composition tFar#.Ea,::r uomprr,c:s a acceptahle sa.lt:, prcÃ'emblN a
Plxosphate salt i.ra physiologically acceptable cc?ncentratTons. Ã'rcferablz ,
the l).H o.t" said
immutzogenic. compc3sitiozi is acitustcsi to a pliN sic?lc3.;ica1 pT-1,
meaning be twecsi about 6.:5 and
7.5.

. The iitis7lu-nogcalic coatlpositioli ag rxsetl iicr<i.~t a.lsc.~ rcfirs to a
compos:it:ic.~n that
comprises per osic 111l i) at least l.Ea lag of PCV2 ORF2 protein sie:scrilxd
ubovc, ii1 at least a
portion of baculos=is-us cxpres:sing siicl PCV2 t;?R.l~'2 protein iii} a
lort:ion of the cell clflture,

ia )a~l-xmt 2 to 8 in.M T=?l':T. -v} sodimn tl3io~tilf'htc in ccluivaliari
amounts to l:;El: ai l -vi} al-xmt :1
rnt; Carbopol 97.Ã . an:cl phosphate salt i_ a pl:ysiolcagically acc.cptablc
cm ccn.tration;
wllcrcan about 90% of tlle coat1ponc:zits i) to iii) have a size sniatlcr than
1~..an and the p.F-t of
said irnrn unc~ge: ic c:cx nposi.ti.rar~ is aicti cistecl to al;a~.~tit 6.5 to
7.5.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
':C(ic atmuntlogcnic Goncpc?s:it.intls caxi l:t7rtllcr ialcta.idc: one or more
otlici-.
<3gcnts sticll as, i.g.. intcrleask-i11s. isiterl.;rons, or otliQr cytokines.
"I"lic

irn altanc~getlic c(Yillpositions can zi:ls~.~ itlOudc Ck;i-st:in.-sicin and
~1ta;rthiolzrtc. 'W7:i:10 the
aiiioiflitts and concentrations of. acljiflvants and additives as<(ul in tho
context of the present
irsaviti.ors cars r.eadil.-v bz c.~ctcrn.-sineci by thc Nkilled atlis.ui. the
laresc t inventi~.~n coaternplaÃes

C0111po51tICltt4 c(33T3pt'1s:13]g, Irot31 about 50 ~E'gg to about 2004)
uw,..':.~ E?l ai-titEt'attt s'#3]:(1 13ra l.ti:J'.1blt'

~~b(yisÃ 2i#) kf~;/ ral doso of'the vaccine compiosition, T'litit*, the
munlxfllogcnic: c:01~~POsiti011 as
~at~i~al.
Atseci kreirs also r6crs t~.~ a c.camf~,~4iÃion. that c~.~rnlyfiscs frcanl
about 1 ughn1 to a1.?oAtt 60

of antit3iotycs, aad siiore preficrablylcss tliaai abolFt:i0 p l;fMl of
asitibiotim

1 tf The iytummogcnic ccsanposit:ion ws FisLcl herein also rciib.rs to a
composition tltat
cornjx:est;s i} .ttiv ~.~f the t?f'V21 ORF2 pr~.~teitis ci:;4crilaecl above,
prefczably in conccrsCt~ati.(MIs
desc:ribcc.i above, 0 at least a l.n-)rti.on of the viral vector exprossi~~~,'
said PCV2 f_RF:' proÃei
iii} fs l.~ortioil of tlle cc-11 c-ttltttre, iv} an inactivatifla zayem t:o
ms3rtivate tlie reGoml.iini3nt: viral
vector preferably Bl:.l, aiir3 A) aiz zicu tr.3li:rutic3rs agent to stop llze
uzacÃivatiozi snw.cliatccl by (liw.

mantivatiztg ahwtt, preferably sodium thlt?suffiate izt Lquiz-alcsit -
aa~.~tc.iriztt5 to BEL si) a suitil.slc
ad~~~~-mit. p:rz:'embly Carbopol 971 in amounts dcsc:rgbc:d alsove; vii) a

acceptable Gonccntra:tian of a salirac l;sul1cr, preferably of a phosplaa:te
salt. and viii) ~~~ anti-
microbiological as;.ti.v< agent:: w11croin. ~~b(yisÃ 90% oi' t11c c:omposicnts
i) to iii) have a. size
sI:n.tllcr than. :Ã utt1.

It llil,~ r been surprisingly rC711B)d, lllilt the immunogenic
cC?ll)pi?Sitiolg c<7)I1prBsF91~; the
.P(-'.V2ORF2 prcYEeE13 ovas 13Ag:11lT' stable over a period of 24
131d?:[3t13s, 1'E ltafi also been fd?t)].td I:13e
iattattFaltog enic -apocitioa}c arc N-cry c.fl'ective it) zeditcittg #:he
clinical symptoms "I,souiated
wItl1 .1~CV7 1I1itct1C)lls. It was iAkCt d#sct?'lt'.rG'd, that t11L
1!)gB)1E]:[1ogG1gB0 cCl)Tip#~159~9Ct11C

coaail~tisi.ng the rccomlsi-nant laacaa.lov:irus expressed PC V2 ORF2 protein
as described alaove>
are surprisingly .tno:rc effective thalg an i-til:tilualcagclr.ic composition
c,c3mpr.ising, til~. Ve-holc
24

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
PCV2 z:irrxs in an inaotivzitcd form. or ast?lzitod viral PCV2 ORF2 anti,ten.

N>cn sm-prisingl}' lowid, that th~. rec;ombinont baculovirus cxpressid PCV2
OIt1-2 proteiii is
eiycc.tive in ve:rv .lciNk conceMrations, which rn,.,-ins in conccr~tratior~s
tala to () 2.5 p g/cicase . This
une3pect.ed high irmnanovenic pot:en:titid o1't11c l'CtV" ORF2 pratoin is
increased bz Carbopol.
Emmlal;;s 1Ão ? disclose ir~ cictail. thc production oÃ 1'tvN:2 OR.1~'2 cc~n.-
~prisi g i3T11-nurtc~ge: ic
~=~~: ~ ~ ~s~"~5 it i catt4.

The immunogenic ,omln-)sition as txseci herein a1s(i refers ta- In~,T<1~~e~c
:~ C ir~;c~l+'L.1'X','s,
(I3o,.hr.i:~~ger 1I:~c1h6tta VcUncdic..t, St 1oselalY, N'iL?, USN), 0rcci'v'~~
X' {\,lerW S.As',
i.ion, krance)~ Cis co4'Ltit 4'lntet-ve.t lnc:- Millsboro. DE, US:1)< csr
Slfaaxyti l:'C:\'-2 Oyge
1 t~ Dcsse',?

Adm:inistra-fiaTt ol'the immuslt?genic ct?mposition
Tlae rc.~iiiposiiioix s3rwrcliiig to tli4~ in;ention may 13e. <3pplied
inÃrndermfdla,,
1~ ifl~tratr~iell~ a~.11~', or intraval;inally. The c:oia~posi[ioii preferably
nniv be applicd
inÃlaniaac:ular1:y or in.tranasally, itiost prel'ertably intranumnlarlly. In
an iiiiiiilal bcclv, it cas~
~~~~ove acla mitagcoxas t~.~ aiplaly the lalu-mi-mceutical c:onilxasi.ti.Oras -
~s clescribccl above vi'-I 'In'
inÃiavenot.x;: or by direct iiljecti(ifli iiat:o tat'got tiss-ise>:. Fm
ststcmic aipplica[ion> t11e

:in.Eravascular, :iatrarntasc lzr, i: t~~munsal, intax-irterial, imrtlxcrita
mil. or.al, or
irqraithm-d routes ire preii;rzecl. A raiore local q~plic:ation cari bt;
c('Ã:ccÃcd 4tiln: umeowslv,
intrtadernufflc, intmQuUm:emssly, in:tras;.artlia:lly, inÃralobtalls.
inlramedullarls. inlrapt.xlnlot~~iri1ti>
or direct.lyin or nezir tiic tgssi.cc to lx: trcatecl (coa}:nect.ive-, boale-,
mFasct,:-, n,:me-, epitlle.lial
ussFae;), Depending oti the clesi.rLcl duration atitl effectiveness of tfic
t:t-cattiicyitr t:tic

iccortli.rig to tlie inz~Ltition amy be idaninistLt-eri oaice or se.-ve.ral
tia~ies. 1lso

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
a:aistancc on ai. daili, basis for :.evera:l da.-vs. dvec..ks or months ziacd
in clift'e:rczrt

d~.~sagc s.

Prcferab1-y, at l,.asÃ on:e dose of Ãlrc. :inltraAtn:ogoilic:
c:omlxasi.ti.rlils as dese.ri.bc.d alnil<c is
iflltramtit*4~ ifllarlv ac.imisli;:lc.v<tl to tlrc sub_jes;:t in ~ieerl Ãllc:t-
eol Ac:e~ordifllt; to a. ftitrtller aspec:t,
the 1'CV-21 atltigc.n or the ittummrlgeraic: c~.~ntpositiora conlprisi gany
such PCla-ILI a tigell as

clescril.~ec.~ abox e is formu.lated ancl .td:tii in ister.ecl in ~.~ric. (1)
at1, p,;t- dosc;. Thus. accordia4 to a
(iirther asile.a. the present inventiosl also r<lates to a 1 slll
isli.muslor.~enic s;:olalf.n)s iticlll.
crlrnprisiag PC'Vr2 araÃigen as descril.xcd lrc.rcn. (ilr rec.~ucirag- or
lcsserai:ng lyttalall.adc1lrlpat11:4.
1ympl licl clcpleticsn aaid:'csr multinlxcleatedigyant histiocyte.s i11 pigs
inl"ee:ted Az-ytli PCV2.

1 t~ Accordislg to a. fiirtlicr aspect, ace:clrding tcs a iirrtlier aspcct,
the prescslt ins=Ltlticsn also
relates to a]. m1 ianmtcllelgellic comp+?sition, celmprisialg f?C-'V-2 antigen
as desuribe:d :h, :reill,
for reducing or lesseyring 1yytlpl~adenopatliy, iin e:clytlbiaiatioyg with
or1L ar a ailFaltiple Oi' ttlc
follrlwn1<F svil.~llatoms Ãn pig,: (1) 6i.tc.rstÃtial lmic.umelnia witli
interlohula:r ec-leiila, (")
;,utanec-lus pal..lor or ie#:erus, (.33) 13,10ttlecl atxc-lptlic liver,. (4)
<Fastric u.lcers. (5) neplaritis a:ncl (6)
1i aeproductive clisord<r-s, L, g. abortiorl, stillbirtlls, :Tlirizllalies.

Accordi:tl; to a fi.lrthcr aspcct, at least c3aie lktlier adznimstration of at
lea,st clii~:. dose
of tlle i-tll-tlirtalogeai-ic c;ompc?sitiorl as tlcscribLil abc've is given to
a subjLet in tlceci tllerc<al:,
'w~11oreial tile secolid clr ~~ly f'arttlc;r adrTlinistratio:a is given it
.least 14 days bc:vclaid the illitia.l
or z~ity Ã'clnner .3dtlrirzistl=atictis, Prct'erably, tiic
isliriil:ctlc?geiiic c;clmposition rs adtlrrrzistere d

htt ~~.:it1~ aac iltimuno stinub.m_ T'refcrabh~, gtid iltimune stialrfllant is
givexl at leasÃ hviGc.
I'reterab1v. at leasÃ 3 tl~rvs, flli~.~rs preleraEaly fat: lea.st 5 days, cven
illc?re praterab1v at lca:st 7

dit4's fErU lIl }?etwef'Il tlle I~II'St and tllc si;=Cattd or iUly fuI'tllUl'
c3C11111I1fl5trcltii.~tt of tli~~ flililllZLile

stialrfllf urt_ Prc:l'crabh~, tllc inummo stiluxllaurt is z;ivczr at :1east 10
days, Prcferable .l-i da.-vs.
even i:ncare preÃ'c.r-al>ly 20, ,.vc.ri nt~.~re prei~r.ab1:v at lcast 22 days
be,v~.~ricl the itiitial
2i adrllltlflStrsft1E?Sl of #h0 ImSi1~IrECIC?i:illt; l (3rI1po5itiCttl
provided lit.:ri:fl31. A prt..ti:ind It13f31$]:[li:
26

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
stamu:lant is. for cmlxlaprc, keyhole 1.61.1pGt bcrnoc~~anan (..K1,r1).
prct'crab1y czrmtsxf:c~..:d with
iflicoiiLplete IircmicFs a(lj~vant (KL.I-VICl A). Hc~~~~cvcr, it is hcre~vith
Ynid:erstoml. that any

other iran nurae ,stiniu:lara known to a lacrsati sltiil:lccl in the art can
also 1;ic tsscci. The tcr.tta
"innnifltic atisnulant" as used hercbr momis any al;ent: tH c~~Enposilima
tlhat can tHgggr Me
> hmumnc resiX)rase, larcforaibiv> without initiat:ing or incre.tsirag.; a
slacciSc irnnit~~ic response, for.

,.xmnple the iramiune response against a ~peci:Ãic laaÃ1icagcn. li is
fisr.tli,.t- instru:cied t~.~
ac.imini.>:ter t1w imiiiittic: atisnulant in a. suitable dose.

14~.~rtav,.c it rams also l.iccra st~tprisitigh founc.~ that tlic
iramum~.~gemc laawratim af me
Ill)11)1911U!?L:[1FC: cCl1t1p#~1sWCt9)s EBsGd 1]'G;r!c;lll. [?['ete['~31}7!'
tl.loSc tllat t;l'P1t1p['EsL rLCi?!)gr?llliilgl

ltl hxdovir s expressed PCV2 ORF2 protcin~ cicyr more 1~re:t'L:rabl, ili
combinati~~~ Nvith
C-;arl~~pol, c.111 be IFar#.Ea,::r confirmed by t11e aclminis#:ration of the
IngelVac PRRS ..\:ÃIsV
-acci:ne ~sec 1.~amp1c P. 1't:12 clhical si~;ygs and cliscasc
m~.~~ifest;~iior~s are {~rL, t:ly
a31agii.i#:ied wlicti t'13.1t:4 iaifectioll is Present. Howc.v'en the
imj~iniogenic compn,itions aaicl
Vacci:llati0il s#:rategics as provided :h,::remit:ti lc:ss+:necl this ell-cet
greit:ty, and nio:re than

15 expected. In c.itiier ~v~orcls, a1i tiziexpect.ed synerpstic e.fÃ'ect: was
observed Nvlieji ani~~ials,
paol:w.rahly piglits %ve:rZ trwuted watli mV oÃ'Mc PCV2 CRl?2 irixmusic?goilic
compc?sitic3als, as
pcmidecl 11cmz~iÃ11, ancl Ã:11c rngclvac..PRRS MLV vaccine tBocllrirltjea=
lngellgcim3.

20 k3R1.1-vrt DLSC.'R ll'TlON OF 7-i rlv DRAW:lNGS

Fimflrc l is a ss.hsm<3iic fow- diagram of a pratk,rr-k;d c~.~mstruction of
PCV2 ORF2
recoi31~.'ki]1i311t: b*}cI.ElC1viT1ts: and

Fa,:s, 2zi fazicl 2b arc cac(i schematic llow cla~~gmms of llmm to pmelnc cmc
of to
cornpos:itio s used ir~ accordance with the proscn:t hnvnicati.

2.?

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
DETAILED DESCRIPTION OF THE PREFERRED .E:NN1k1ODily 3aTS

"I"1i., f~'ollo~N,ilizy cxitiiiplc:s set iortli pmfs.rred m~tori<31s <3~id
procodatres in rtccor-el;tnc~:..
wiÃli the present iraventicm. Although any, methods and materials sinfil.r or
cqttiv.tl,;m to
those described hereiti can be used in Ã11< practice or 1e;:ti.tll; of tlio
prosen:t invention, the

preÃ,.rr,;ci inctluxis. del ic.cs, aticl amteriais are tirasv described. lt is
to be unclcrstcxad,
l::c~~vc1<er, that tlacse e~~rniales are iarcivicl.ed b4 ~vati of
illAts#:r.tticxi ~.~tilti .and raotl::irag. tl::er.e:in.
shmtld bo tieop<ti a lisniÃtat.iotl ttp(itl the ovora.ll st;opc oftll<
itlvorat.ion,

EXAMPLE 1.

1 t~ This Laample compares the rLlatys=L yields of ORF2 ttsy.rig ytiLtliecls
of the present
imvmtn mtla raae:Modc tliit arc k-a}e~ivti in t11e lsrior arÃ. Four
10001,11.1., cpia}ne:r t'lask-s were
each seeded ivitli approximately 1.00476 Sil cdls:'ynl in a?t}%T.. of insect
scruni ii=e.e merih
Exce.ll 420 ORH Biosciences, T-tic., T...enexa. KS). The master cell culture
is identified as S.l ~--
~ti}?far:fc~/r~~tr:t 1~r.:<st~~~t<:i<~} 'Mas#:er Cell Stock, passage 19,
.Lot#N1.1? 095G4a. 'T'lic c,:lJs tc5ecl to

gcaierit< le SF+ Nb.st<r C'.elJ SmUk we:rc obtained f:rom lrroteisi Sciences
Corpc?ration, T-ac,,
:trterarlea. C"E *l 1ie SF+ ccll lizie: ltr this e usuple w.as c.onfined.
b,;:,mvew.rz pus'sagw.s 19 and 59.
C?Mer passag<s aall work for lmrlxaws of Me larLSmt iiiv~s;:citic3ai, but in
order to scale tlge
process tap for larVc gc-alc p:roduction.. -at least 19 passages ~zil.l
p:rc?balsly be nccessa. xaid
1mss~tges N;:yozicl 59 Rms 1mve an eD:w.cÃ c3iz eNpressican, a.llliouglz this
was aicaÃ iiivestigated, In

:tnme detail, tlic initial SF+ coll Gitl.tr7rc:s f:rom l:iqu:id. nitrogen
storage were z;rrm~-.n in 1xcel1
420 iiieciift in suspension in sterils spiflink,r flasks wiili constant
agitation. Tlis cti.1lYsres were
p~.~wn in 100 iiiL. to 250iril., spiimer flasks witli 25 to 150 iiil_, i.~l'
Eac4l1 420
s4.rrt~i~ t-r~e
nieciia. Wlic:ti i1i~:. cells ha.(l multiptaed to a cell domi, oi- 1.Et - K1}
x .lf)" cells/mL. they w-ere
split to ne{~. vesscis ~vitll a Pl.tnting density of 15 - 1 5 x 1#~'
SAtl.~seclucat cxlaansiora
28

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
cLllttireS d4'ere grU1S13 ]#1 spinner flaS.~.s up tf'~ -16 lEterS in size or
in stainless SlL'i'l bioreactors of

up tor(tt} liters for a period of 2-7 days at "? Y 29'C;.

Arter se&ing. thc. flasks 4vere i_ c 1õsated at 27.f' for forar hours,
SAtl.~4eclueat1y, ,;ac.h
flask wws s ;c.i~;d'u>ith a recombinant bat:islo-virzfls containing the PCV"
ORF2 ;T<n< .CQ 1D
NO: 4:D, 7'1::e rc.c~.~mbinani l;sacti:lovirus coraÃai im4 the }?CV21 OR.1~'2
gene was grreratcd. as

foll.raws: thc. PC'V2 ORF2 gene frorn a Zlor.tli N ncrican stmain of'1?CV2 was
Pt;:R an.-~plifiecl to
c.,_,i3ta:ia a 5' Koral4's seqtic:tlc:e (SEQ ID NO I at1d a 3' 1vt:oRl site
(S'EQ ID NO: '}, and
; fond. into tl::e pGEWT-l~:asy e,ce.tor (1'rcm n.cga, Macliscy. , Wl:}. Then,
it sva4 4u1=_asetlAterah'
ete:iqerl aygd sFabe:loaie.d i.rrto the transi.er vector I)VT_.1 3i}2 (BD
Bioscictices l'lim-minge.n. Sati

1 t~ C3icgo. C:A). The sFabe.loaied Iort:io:n is repr=e.seaite.tl lierei.ri as
SEQ ID NO: 7. TIiL pVX.l 391
p.lasmid ;,ontalming tlic PCV2 [)RF2 gene was sicsignite.Ã3. N47-064Y and then
co-transteutecl
witli BaculoCrcsW. (.Bl? Biosciences l'harnfint;Ln) bacarlo1 irus DNA i.rrto
Sf;- iaiseci. c01s
(Prote:irt Scie:aces, .k.fc.riden. CT) to gc.nc.rate. tl3e :recomb:imint
baculeavirtis co:t7tai:ning the
1'('V21 [)R1~=2 gene. I'.lie new con,trnct is provided 17erela} as SEQ Il) NO:
8. The

1i azct?rnl.siztaatt taaeulov.irus containing the PCV2 OR.F'? Ã;Liie was
lalaqric-13urified ~iid XÃa5tez
S licezi \
rims t\-1SV.} %vus prc~~atgatecl mz tiic~ &F- cell lnzw.> a.licla:totied,
aticl stored at -7(Y"C. The
MSV was positiz,viv iderltifictl as PCV2 ORF2 liactaloviru_s by 1?+tr".12 -
RF.t,i' atc;ir1g baert.lov~iru_s
specific primc;rs 1liqect c<l.ls itil'eUtctl ~.z-lth PCV2 Ã3.It1?2' barulc?-
viraxs to gmeratc MSV or
Worl:izig Seed Vira:ts express PCV2 ORF2 .3ntitgcn as clet"te:d bs
pcalye.lom.l sw.ra:ttii or

htt mono;loatal a:titibndies in an indirect .l7uoresceut ant:ilxAv assav.
Adclataonal1-v. Ãhe, ident:it-v of
the PCV2 ORF2 l.iacYtlcavirits -,vas confirmed bg ;ti-tsriliinttl tilYiiti(i
acid sk,tlt7ent;ing. 'I'lik,
PCV2 ORF2 bncrtlok.irus MSV was <31sc.~ teste(l for puriq- in accordance -
,vitli 9 C.F.R. ~11,+.27

t;G), 1 1:i.28. furcl 113.55_ Each reconiban.ant baGitlovira.Ãs secdcd into
i1i~:. spinner flasks had
l.uying 3t1Atltilalictties of in#'ectirar~ {\0()1s}. Flask 1 4vas secdcd ~vith
0Ã' .t~'("li ~l(}I
2i s..cd: #:lask 2 was so.:cic.d with 1.01sitL of 036Mt'r)I seed: (lack 3 ckas
sc4c14c1 xvitli 1.~rrtl, tii'.
29

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
0.1SMOt sce&, and flask 4was seeclecl with tt.7iualv ol'0.09N-Ã01. secd. A
schernrti.ic !'IoAv
diag-ram illustrating Ã1i..basic steps used t~.~ construct a PCV2 ORF2
recombinant bact7loviras

is pr.ol idcd liereiri as 1~ igtir,; :Ã .

After boino scedcd,u>iÃ1i th;~ bas:ulavifzfls, the flasks wero Ãllctl
isis;:tibated at 27 ~ ?"C
for 7 cla-vs ancl. were also agitated at l.ttt)rptu during tliat ti_ i.e. Tlac
f1xsks uscd evitilatecl caps
to allow fcyr air (1~.~w, Sattalalcs f'ram. each flask iver.e tak-cri every
214 hours tbr tJ::c ricxt 7 cla-vs..
:VRer extraction, <<it:li saiaiple wzis c<ntrifi.xvetlr and both the pellet
and tlio supernatant were
s~.p.tratctl ar~d tlaen ni.ir.:tofiitued. tlarotagli a t}. Ã5-1.#1 Wn fx~~-c
srz.e n:wrnbram.

'FJle resulting qamfales tlie.ai had the arnousit of GRF2 present w~itbyn
ilmni cluarlt:ifiLci
ltf -via aai li'lal:'4A amy. Tbe ELISA ass~y was coyiciFictecl with capttirL
antibody Swine ar1t:i-
1?CV2 .l'a.h TgCt l'rot. G pFarÃfie,Ã3. (dilutcd 1:250 in PBS) diltitecl to
1:6000 i:n tftl5:~~f C'arbomate
huffLr (l)l-l 9,6.), 100 ltl, ol'the am:ibotl~, ivas tbLn placed isi f.1ic
wells ot'the anictrotitLr plate..
sva.t+;cl.. and incubated overjught ai 37"C, 'I:be plate was tli,:ti wasl3c,d
three tixiies with a wasb
soJutioa} ixliicla ;,omprl,e,Ã3. (?.anff: otTwven 21) (Sigai7a, S#:. Louis. %-
10).. li~f:t.raaf.< of .l(lX 1:?-

1i PBS ('Gilacra 1.nvitrogcn, t'~atislsarl, CA) a1iki 899.5ml, of'clistil.lecl
water. ~~xt3scq~~eratl~, 250
la.t. of a blocl:iaig solatior~ (~- Curaiatic?ii Nosi-l:at dry milk ('Nwstle,
t;ilusia1e, t;..A) in llim.l'_.of
D-i'I3S Q~ to 1.00mL with distilled water) was added to eac:li ol'thL wells.
The next stel) was
to wa_sh tiic t<st plate ai1c1 then acJcl pre-cliluted antihcn. 7.'iic prc-rl-
flut<.d atitigc~i was lnoduccrl
by aclduzg 200 IA.I. ofrliluem soiritic~ii (t1.5m1n, 1.vv~een 20 nz 999.5m1_.
D" PI3S) to eacli of tli~:.

htt ~~:cll~ oii a dilution plate. "Flx saniplo ~N:ras tllc~i di1mecl at a.
1:24t.f rrttxo and a 1:480 .rrtÃxt?. a:al(Ã
100 .l:. of each of tlacse diluted samples wti.s t1iciY added to orte of tlie
top tN,-ells oti the
tlilzfltiotl plate (i:e. oixe to~., well received 1(0 gL of tlie~ 1:240
(lilzfltioti <3ird Ã:lic other received
1 f)(l ~iL. of the 1:480 dilution). Sc:riat dilist:inras w cre tlacri dc~~ic
for the remainder of i1le plate
bv rernovir~~~: 100 gil-: fcvin cach suc.cess:ive wel.l atict trans:f'err.i_ g
it to Ã1ic nc"I well on. the

2i pJ;it.:. Each well was mixed prior to dcyisig tlto cicxt transfu. Tli4 test
plate washing iiicslxtded

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
~N:asllblz;: tlac plate tlar~..:e tinies with tlie; wasli bul:l:er. 'l'lac:
plfate was t,lien scalecl and anctibated

for tin hour at r 7"tV' bc.ior.. N;ing washed tbr..i mor~.. tinics wiili tlic
v~-ash l.~Yffer. "I"1i..
clet:;cti~.~r~ ~i-taÃifxc>c1y seci was i~~~.~ncaO~.~n.il ar6bocty to PCV
ORF2, l:t was clilxaÃed to 1:300 in
dilo:etit s(ilttt:iot1, and 100 uL ol'the tlilxsted detect:iotl asitibocly
",tas tfflesi aeldec.i to t11e wt;lls.

> Thc plate was Ãlicri sealed and incubated i'cit- an la~.~tir at -' )7"C
faeÃ'orc tcing washed tlinc ti_111.cs
wit1Y the wasfa 1>~ frer. Cor~jug.aÃc dil.tmit ~vas tl:on prepared by adding
r~cx-lnal rabbit 4eratil.
4Jackson Minionorescarcl1. West Ge'ova, PA) to t11e clilw;nt stiltitlioia i(i
1% concentration.
C'cy jt~gate antibody C~.~at an.ti.rtnoAtse (H-d:D-:1-11'Lf? t7.icl:s~.~n lnn.-
nxnorcsearcli) was clilut:;ci :in.
tl~e coliju;;aic tliluer1t to :l :1 O<4Ttatt. 100 lil, of t:liL tlilatetl
ccsai-jugat~ antibody iz>as tltcyg a(itlLci

1t~ to each oi'tlic iz>~lls. The falate was tlieri sLaled ci.~id incubated for
45 minutes at 37'C bei'bre
lx:Ãatg tva,l~c ,tl three #:int, , with the Iva,:h hufl'er. :l (l[1 li.l:: of
sui)strate t':l':%-m Peroxitla-sv
Substrate, Kirkgaard a.~id PLn-% Laboratories (K.l'lat< Gaitbersberg. M.C3).
ytliaed ~Nvitli Iyg equal
Nol- xiie ot Peroxicla,c Sub,ta-atc 13 (KPT-:) tivas added to ca;,13 of the
tivcl.ls. The plat~. tivas
ia}clahat, cl at z~~~111 tvnil.?oxattcre :Por 15 att.invtvs. .100 ttT-: of lN
N.CL solFatioa} wa, then added

1i to all of'thc wells toStofa tiie :reaction. 'T'11e plate vv~as tiicsi rai1
tli-tc?txgl~ an ELISA rcader. 'T'lic
results of this :3ssav :3r~:. Provir3ed rtz Table I bol<n-v:

;C.
Table

C3aY .l~las1;. ORF2 in lx:llet (txg) ti-)1:.1~'~ isi mpLmatant {p.b}
----------------------------- -------------
------------------------------------------------------------------- -----------
------------------------------------------------------------------
~ l 4-7,53 12

7.46 ------------------------------- ---------------------------
~ 3 14
4

---+' -- --------- --------- --------- -------- --------- --------- --------- -
-------- ---------
4 3 70.:iti 32
619% 24
4 4
-----------------------------
:? 1 3 .1.74 1.N

............................... +................ -------------~---------------
---............ --............................... -----------------------------
------------------------------------------------
2 A9~ 142

5 3 47.84 90
5 4 5?..14 86
6 1 117 158
6 2 1 & 1.3 182
.
----------------------------- -------------------------------------------------
-------------------------------------------------------------------------------
-----------------
6 3 34.78 140

--------------------- --------- ----- --------- --------- --------- --------- -
-------- --------- --------- --------- ---------
f; 4 36,88 146
--------- ---+ -- --------- --------- --------- -------- --------- --------- --
------- --------- ---------
7 1 c'>. 54 176
7 2 12.{N 190
7 :t 15A 158
----------- ---------

7 4 1119 152 These resFalts iaidicaie that wlieai ttiL incubation tane is
e~teaided. ~xprLwcsa csf'OR>~'2

imca Ae swcm.3im Oftbe c~w.1ztral'uggw.ci c>w.lls aiid mediais greaÃe r iliati
~xpre:,~ron in !lzo pellet
of Ae c:oniriÃ'~gecl cells ancl mecli.3- Ac<cordiiigly, allownzg tlic ORF2
expression to pa=oc~w.e cl
32

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
for at teast 5 davs a:aid recover:im; it an Ãh
e su.~en-late t-aiher 111,111 atlowang expression to
proceod for less thtin Y cfay s and recovering OIU,2 froiii thG eollc,
pr~.~vicles ~gretit iiLcrease in
OR.l~21 vi,.lc.~s, and ittaprovernCrIt Oe-cr prior ttaethocls.

> EXAMT?T-:E1
This example Taravi.cics dam as to the effiicacy of t1ic inventia clainieci
hereir~. A,
1000mL, spinncr fltasl: was soeded zvitli. approximately l.O31O' Sf=;-
cell>:/nll in 300nIl. of
Excell 420 media. The :f7.asl, was then irieut}ateci m. 27"C atid api.tateci m
10t3rp3n..
St1bsLeflfe.ni.ly, illc :t7.is1. was seeded iviill 10 m.1., of PCV2 ORF2/Bac p-
;-6 (illc rLcombislnt

ltl baculovirus comaining, the. PCV2 ORF2 gene I ssaged 6 additional tisiges
isi the SfR) insect
cetlc# viru, seed with a [1.1 .N.401 after 24 hours of incubation.

The i:la,k is tlieyg incubated at 27,C (csr a. toial o:('6 days. After
ineuhatioyg- the flasl;~
tivas then centriftageel aairl three saniples of the resulting stipe:raiataiit
were ha.rz:-esteel aairl
inactivated. 'T'he sia,~ .matam: wis i~~acti~~ate.d by hriaving fÃs
tempe:rawre to 37 ~ 2 C'. To the
firsF 5amplc, a t3.4M solutior1 o.t' '?-kt?moetttyleneambie txyi-
lrobrc.~suicie ~v~.Ãtieh had I.su.Tt
c.s c>]and to tt.?.NM billare eYlihIenimine: (&3E1.) isi 03N traOI-14vas
acirled to i;lic supea=si.3tasit to

ve a final concentration cif .E3I:I of 5mA4. To the ,ec<ai1d Samp.lLõ 1 EtmgM
t31..1 vvas added to
the supennauant. 'T'o the tlxird ,uraplc, jio T3E.1 was -acldccl to the
supernatant. '-l'lie 5aaiip1c,
werw. Y1101z stiiTecl conmzuc3usiv for 48 hrs, A1.0 M sc?ciitiiii thiosull:ate
sc3lutioiz to give:3 final

htf alinimmu GonceXitTaÃYoXl cYl'5 iliM was fadclecl to neu:tral:ir:e ttny
rcsiclual :kTEl_ ~.-I'lae ctuamYÃy of
t;.>Ur in each sample was tliiti tlu<3niified usiiig tlie saEtie ELISA assay
prmetizflre as
tlesc;ribe.cl in E:ss3iiiple I. Tlie, resttlts o1 tlus m<3;y be se-eii in
Tablc 2 E.~clodv:

TaIxlc: 2
------------------------------------------------------- -----------------------
-------------------------------------------------------------------------------
--------------------------------------------------
'~~~zlple~ C~i~k~2 in ~~i~~a~z~t<~i~t {~~j

'1"bis ematulai,; clem.ranstr.it:;4 that noxatn.ilizatio~~ ~viCll I3FT cl(.?cs
not rerm-w,; or ciqraci:;
sigtiific:iiiit amounts of the recombinant PCV2 ORF2 pirotein proclt.xCÃ. This
is evidenced biv
the fi3ct that il-wre is no :lar.gp loss of ORF2 in the supernatani I'ron.-~
the BEI ~.~r cl.evaWd

iemp<rat: rea. Tl-iotc (il' skill ii:t ilic art isill. rcci>t~~ize tliat: tlie
roc.asesecl ORF2 is a. tta:ble
protein lyroduct,

11XA.li?tPI..I ~

Thifi cxaytaple cle;noastratefi that ilic presem invention is scalable l:ro;n
sslgall ;Ca.le
1(l production s>f rcconihima:nt .l'('V' ORF2 to la~-ge scale production of
recombinant PC;V2
C}R.F'2. 5.0 x lW cclls:'Ml o.t'SF- cellsriui i.ra 700fiiiiL o.t'ExCcl14kf~
iiiedia ilas plantcd i.ra a
20000siit... Applikmz I3iorc.3ctm 7'1i~:. suecli.3 and ce ll~ %ve:re tlic~ii
isic~uhated at 27't;" aaisi
a.gita.ted at 10t1I:.PN-1 for t11e: aem 68 h<aurs. At the 68', " 11otrr,
41.3mL of PCV2 (3I:.i 2
Baculovirus XISV-3 ~vas adclcd to 7000rTi.t: of ExCell 42E1.1ncdimw The
resultmit mixture

was then aticiw.cl to the bioreactor. For tiic~ mxt sevezi tiays. die mimrire
w.as iiicti1x-3ted at 27"C
and agitated at l t)O.1ZPM. :~iitplcs from tJie l3ic.~rca.ctor ~vc.rc
extracted cve.n~ 24 btauas
g.cl. The supkmatanÃ oi' the
beginning at day 4, post-itrfecti~~n. atrci eaclr sample 3~~~~s c.;ntriffig

samples w.crc prcs~;",ed and ilre nmotint: i.~t ORF2 was tlien qrtantifictÃ
Lusing SDS-PAGE
dcnsito:anct:r4~= "T1i~:, rm7lts of iliis can be see;il in'I'ablc 3 bc-lc~-'v;

Table 3
34

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
C<tw I 0:0i;784T
..............................................................
P mattest: 3wel?s h (S~~leat)
...............................
Ua---------- -------------------------------------------- ---------------------
-------------------------------------------------------------------------------
---------------------------------------------
.~~ after i~~.ie:~:~tic~~l: Ã~l~it~? i~~ supernatant
t,lz~ a~1L~~ _
29,=i:+
4
Y <l 1.,.9.'
F> 3 1..~ a
7 6tl.fi?

EXANNIP1,E 4

"T"lia~ example tests ili~:. officacy. of se;z:e;ll PCV2 candidate vraGcincs
and flartlicr ele;f~'iaces
? efficacy parameters follmNi-ar 4s~5twe to a vinflle-at strsiiri of
Pt.r:'4"2. Ch~rc hundred <3iid eight
(108) cc:samm elerivecl cnlosimm clopr-ivccl f(;0CD) pa;,:lcts, 9.14 days nf
a1;c. were randonils>
tli; ided iirt:o 9 groups c.yf cclzfls3l siz4.. '1't3.ble 4s4 ts fi.~rth tlae
Gemcral St tia Msi~,~r fi~r tl~is
.F xample..

Tablc 4. CpencrtiE Sl:uf1v Design

Grou~.~ '~V Of Treatment Dzav of KLI-lr=ICF Clrallem
p t~ Ncmpsy
.l':igs '.-I'matniGut A oii Da.-v dv. it(1 on Drtv 49
21tlrld VirEllt;liÃ

Day 217 PCV2 2 on

Dav
'1 12 PCV2 Vact;if3i3 No. + . ~
I - (vORF2 lt'i tig1

-, -?-
~ 12 PCV2 VaCOfei<': N o. {1 +

:-~ - {YORF? =1 fa

4 12 PCV2 Vaccine No. 0 + . -:
4 - (rORF2 16 [;)

~CV' Vacc ir:rt< ZIt3.. +-
- (rOR.l~' .1 8 fa~)

,
6 12 PC'V.? Vacc~ia~e Nc3. t,l +

6 - (rO~F2 4 u4r)
7 12 PCV2 iTact;iflr<No. 0 7 (Killed whole

cell vir=as)

8 l? NCtxe - tn'll<31lerlai;= NIA -# ,-
~:~Ilti'i?~S

9 12 Nor1G'' - Sfr')ct N/.r'jL 'f-

NI t~gaigVe Control

vt3RIF2 3s'c6Ecdv3m:E ()Rl ",' i[9Ã'Ã2)-= tcctrinb.ir3<3xat
t?<3Qetlcni.rzt.,~xpri.ssecl t)Rl'"? l,elleti stlitrle ccEl
virus -}'CVy virus grovvmt in stritable. cell cr..tlt:ur+r

Scveai of t11c hroulas (Groups l. -7) :reuivcrl rlos<g of PCV2 ORF2 polz
pcptrde, oaic of
~ ilze grorrps acted as a c>lialleage coriixol and received nc3 PC'V.k t?RF2,
rrrid rrric?tlre:r group
36

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
acted as th~:. strict ne,:atave Goiltrnt group and also roccivecl Xin PCV2
ORF?. 011 T3aN~ tj,

Gr~.~Yslss I tlrorigh 7~N:ere; Ãreated with tissigiied vacc;ines. I'i;~le;ts
iti Grorip 7~Nvrc giv..ii a
la<a~.~st:;#' treafttm]t on DaN> 1.4. Piglets 4s'erc oIaseneCl f~.~#'
adv,.#'se events ar~a~ ir~jcCtlon. site
roaetions followm1T; vaccituation aiad otr Day 19, piglets zvuc moved to the
sec(ittcl study siu;.

At the sec:cm ct study' site. Gr.~.~tiTas :Ã-t?. ~vcre group housed ir~ or~e
btiilcti_ g while C{rOxala') was
l::oused in a. scp.triac bAti:lding. Al.l pigs nceivea~ keyIYoIe l.iniTst;t
henioc:4..n_in.
41~L1T tlinQotrlplete Fn;rta&s ac.ijivanl (1CFA) on Days ' l and 27 iiiitl on
Dziv 24. Groups 1 -8
wen cl::allcr~geci Nvitla a virulent I'C.V"...

Pre- a:titl post-cliallciige, blotirÃ samples were collcctetl foe PCV2
szcrology. 1'ost:-
1 tf challeyg;;e, boclN. weiglit clata Ã'or determarlaticsm of a:vL:ragc
chil\, iz.eiglit gain (.'ADWtrT), aalrÃ
cliniual saaaiptoms, as wel:l tac nasat swab samples to dctcnaume m-sa.l
s:hedelin<F ol' PCV2, were
collected. 011 Day 49. all sus ii-ving pigs overe necropsied, lungs were
scoretl :tcsr lesiotis, atld
selected tissues were paes,::rz:-cc-1 iaI fonnalin for Ã1.E-1C" i tc .sting,
at a later
date.

:trtaterials aaisi Nktlic?ds

'T7gis was apactaally bliiiitetl zac~irlatic3~~ ~l~al.t~r1~~< fea.sihil:itv
stucly conducted in
( DC.I) p:igs, ) to 14 days of'age oji Day 0. 'I'o bc iaieltadecl in tiie
staxdy.. PCV2 T.l t3 titcrs of
sows Nvere -' l:ltliptl. Aciditic3mlly., the sca=ologic, st:3ws czÃ'sms werc,
ftom a l;:siowrl NRIaS-

htj net,:itÃYve Eaercl. 'I'3!i-e;nÃy-ei,tht (28) sodvs 3!ivre tostod for PCV2
scrological sta.tr7s. TtotirÃceXi
(14) sc~~ys ha.d ia PCV2 titer of 1000 aml tNue ir~insfemcl t:o tlii first
stu.dy sits. Olic
lizflixtlred teri {.l 103 pi-lcts -werc tÃcliveretl 1.~;y c.4sares3n sectioix
sur(gerics and were available for
this studd n:ai Day -4. 011 Dziv -3, 108 CDCD pigs zit the t~~i-st study site
iverc dvoighccl.
1C1L]Ft#j'3ti.d w].Eh CaI b1Cii:kd',Cl by lti,.#~,.':.bt and ra#1Clo#tilv
asslt''#1cd t[? 1. ~.ll 9 groups. as sti:t

2i fonli .il.?ovo isi table 4. I(":uiv test a#iiaiYal mc4tisig, tlYo
isicltksicari c:ritcri.i was cru-oll.:ci in tji.:
37

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
sft~dv and Ava.s httcr excta.tdc:d for any tGast?ri. ttic I.z~~~stxA~ttc~r and
:,\1onitor consultecl ixl order

to tl..tormini tlic asi cif d.tta collected lioflii Ã1i.. animal in th~,
fnLiti analysis. 'I'1Le date ~~f
which eraroll:ca~ ~iglcts svc~-c exc.lacicd and the :rc.ason for mlusican was
cioc.xttnented.
Initia,lliv, tlo sows wen <xcl*tdec.i. A total of 1t#8 of aia as=ailablo ].1t)
piYTc were t-ant~onlls

> assigned to one of 9 groups ~.~ti .C.3ay, -3 The tw~.~ miallest pigs tNcas.
17 .ur(i 19.) iver.e rt~.~t
assigm.cd. to a ggroxtp .uicl 4Ncre available as extras, if riccclect. During
the cours,; ca#'th.c 4iudy,
sci ~;ra1 anitna1s wei-e r+ movW. Pi v 132 (Cit-aitp 9) on. i_1ziv - 1. I'ir.~-
1~~:~. 5t~ (Groitl~r 6) on L'~tas ~T,
I'ig Ni.~. 53 {~'it-cattp 9} on. Day 4. Pig No. 218 {Grottp oii. Day S. 1'ig
N~.~. 69 (Group 8) Otl
Day 7, aygd Pig
No. 93 (Group 4) oti 13ay 9, were each f6mid tle.ad lsti(yr to chaJle.nge.
Tlieqe.
1 t~ six pigs iverL rioi i.nclrded. in the fiygal swriy re.srilts. Pig tio 17
(t?~ic of ilic Catr-,I pip) was
asslg:aecl to(_ir0FaPc:t. 'T'lie:remainia}g extra pI No. I;~, ~~as e~cl~~Ã3cd
ti~a~7 tl~e st~~Ã33 .

The f'armt.tlaÃit?ns given to each of the groups wLt-c as fblloivs: Urcstal)
Ivias clesigaed.
to arljiiiiiister Im.l of viral ()Rl~'2 (s'CYRF?) containing 16 p&Y
OR.1;'2dm1. T'l3.is was rloaie bz-
att:ixing M24 ml of viral ORF2 (256 ug,125 f.fgtml =].[1.24 .ml 0.-ORFI)
ts=itli 3.2 ml of O.R"%

1i Carbopol aaicl 2.56 ml of phosphate buÃ'Ã'c.red saline at a pH of 7.4. This
produced 16 ml of
Ic~s-liiulatrorl l:or group I. Group 2 was desigaed to aclmiziisÃe:r :lm.l of
vO11.Ij2 comaining 8 l.tg
zORT?''/tul. This was dorle by .tniria~g -5.12 y-nl of vORF2 (128 g~,''2.5
~tjitnl = 5.12 .tni
vORF2) with 3.' ml of 0.5''tr~arbopoI aaid 7.68 ml of phosphate lstit'lcred
&Mizre at a.pY-T of
74. This produced 16 ml o.1'l:amialaÃican l:or group 2. (:irc3up 3 was
desigmw.cl to admirzister

htt latil of vORF? Gozita:i.ziitiz;-4~tgvORF?,'tai.l, 'll~is d~~~s ~c~ace F?~
ta~i.~it~~ ?.Yt> a~~:l c~f ~t~I~F'? {Ã4~
~tzs.:i? as;/nYl = 2,56 ml vt:>Ii:.Fr). Nvitli 3.22 nil of 0.5"1r~ Carbopol
and 10.24 ml ~f phosphate
bzaered ~,niiae at a pI-I ~.~r 7.4-. Tlii~s prrsii:ticed 16 ml i.~t foi--
airtlatioji f~.~rgrortl., 3. [aroup 4wza$
dosiA;necl to aclrtii.ta:isÃcr I ml of .reomichinant ORF2 (r(-)RF2) containing
16 uz; rOM/nI1. "l~his
was cicatic by mixing 2.2.3 ) ml of'rtl.RF2 (312 fLg,210 ktg:atl . 2.23 nil
r~)RF2) wit1i. 6.4 nl.l of

2:? 0.5% Carbopol and 23.37 arYl of phosphate bttllcrcd s.iliaic at a pH of
:;A This produced e>?
38

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
ml oF:l'ormu:lation for gTor7p 4. Cror7p 5 ai:as clesigmd to administer lrtil
of rORF-h coxitannug

Sug rO1U m;-ml. 'I'liis was tloiic by mixin;~ 1.11 ml of rORl 2 t256
ltgr'2~:.~C) }tg/itil W 1,11 nYl
r0Rl;2i xvith.6.4 i.l o:F t).;?';i, f'arla~.~ixal. ancl 24.49 ral
oi'pl::osphate-buffier,;ci sziliiae at a p.H o:f
7.4. Tliis pe'oc.iucW 121 ni1 of formulation for group 5. Group 6 was
ck;air.~ned to aelmmust<e'

> :lml of t-ORF' ccantainir: 8 kt6) rC}RF2 Ml. This wxs c.~cm c by ttai.x:ing
() '?ti ml of ~OR:l~21 (l'8
tacv''~:it~ ktg: ml ~ 0.36 rtll ttl:RF?) witli ti. Ã ttal. of'0,'?% Carbopol
and 23.04 rtll of phosph.tt:;
biflfTerec.i sali#1< a.t a p1-1 of 7.4. This produced 32 ml of iorsnt.xlati.on
foe' gi-oup 6. Group 7 " tas
designed to admir6ster 2n:d of 1'C-V'2 whole kill.ed cell vaccine tl?f V~ KV;
containing the
MAX f?t_.4'2 KV. .:t'lris ~N-as clcsaic by mixing 56 ml of i'CV2 KV witli 14
ml of 0.5~~,

1 tl C'ar-bolaol, This prt?ciFaced 70 ml of fonnlflat:ion for group 7. Finally
group 8 desigaiecl to
adaau_isie:r KLH aÃ tl.5 ug,rml or:l.ii lfgrml per 2 m1Ã3.ose. '-1'hi, was
done by mixing 40.71. znl
hl,l:-1 17.t) gg proteiri:'Ml at 0.5 fa;;innl - 570 ml (7.0 (t) 5)(5747 244.29
yti1
phosphate biitl.crerl ,al:iae at a p-E-1 o#..i.4, ajid, 28-i ml .l"regand,
adjgavani. Table ~ describes the
tiai7e frunec to:r tlic :1tey activities of this Example.

'1':ible :?. S#ticly As.tivities
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
----------
Sttxriy Study Activity

Day
-4, 0 ti.~ 49 GQjiert3.t obserk.zatiotrs ror overall licflltli t3ild
cliilict3.t symptoms
} WGyghed; Tc~:~~~l~~~ia::c~l tcs grc~~~ps; Collected ~l~?ocl sas~~l~lcs
ti=oatt all pip,
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - -
f) Health oxam:inafinn: ~-Waii.n:iste;rod 1V1? Nos. 1-7 to Groups 1-
7, re-spcct-ive1y

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
----- --- ------------- -- -- -- - ------ --- -- -- -- - --- --- ------ ---
ta-7 0 bserve d p ig s for a:a~j c ~.iao u sitc ic act:inn s

14 Boostered (izotip 7 ivltii t'('V? Vamm,: No. 7; Blood sanil.?les
Ã'roaat all pigs
-------------------------- ----------------------------------------------------
-------------------------------------------------------------------------------
---------
14-M t Observed (xa otip 7 for inlectia~Y s~tc rc~:ciions

1 Fi- t9 7'reatccl all witli antibiotics (data snissinb)

19 Pigs transported fic?iAi i1ic first test site to a stcosYd tcst satt
21 'C'rczitecl Gri-y ps 1-9 with Kl:l-1i:ÃCFA

2=1 Collected blood and nasal mvab saiaip1es i:rom all pi;;s;
'44eiglzw.cl all pigs:. Cliullciigcrl Groups 1,8 withl'C'V2 c;ha.llengc
rnatenal
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
----------
2~, 27, Collected n.asal ssvab 4aniplc.s f'rcym. zill pit;,,-;,

'?9. 31.
3'.3 35,
41. 4-1,
4347
-------------------------- ----------------------------------------------------
-------------------------------------------------------------------------------
---------
27 '-l'rcated GrÃaups 1-9 ~+a111 hl,I-I:IC'FA
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
----------
~ 1 Collected blood samples from all pivT.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
-------------------------- ----------------------------------------------------
-------------------------------------------------------------------------------
---------
4s1 Cn11ected blood and nasal swab mtaiptes from ttl:l pigs;
1L4it glied t31l pi,s. -et;r~.~ps)y all 13igs': Gross lesiotas riot:ed w-it11
emplinsis placed c.~ii ictcrxts zt-ad ~zasÃric; t~l~.e~~s; Ltttigs i~N-
<31;tl~tt~:~l
for lesions, Fresh aiid fnranal:un laxed fissue sanlplGs savecl< I11-
lite plinse vftlie stu:cÃa, cojiiplet:ed
-------------------------- ----------------------------------------------------
-------------------------------------------------------------------------------
---------

Follow-ix~g oompletion of tlie; M-l:ifo pliftse of i1ic stt~dy. .l'=ot-
zua.lix~ fixed tissltes were
exanained bv l~i~-a~~t~ic~l~isti~clae~x~i~tra; (1liC) for dctertic.~n of PCV2
witigeii f.~~v t3. m3:tlioli.~gist,
blood samples wei'< eva1uw<tl i'or PCV2 sevolo&t'. tiiisal swa.b samples "ere
evaltitaÃe~.1 for

? .1'CV2 ~t~,;cicli_ng, and avcr.tgc daily ~vcigltt gain (ADWC~) was
cleterttai:nccl Ã'rorn I3av 24 t~.~
DaN~ l-'3..

Aninlals ~;<e'e hoatsed at the first stxtd4' site in incli.y-itlxta.l .ar.~es
i.tl .Cv: rooms frasii.
birtlt to approxitraatch' 1.1 ciays of age (alypr~.~xin-mtcly Day t) ca#'thc
stxtcty).Fad:: roon:t Was
itl<titical in la.-vi+ut ard c:orasistect (sf stacked individual stai.tiless
steel cag heatocl artd

filtcrLcl ii:r supplied szcpatatcl~y tcs eacli ist?latioai unit. Ji'acli
rooaii l~ad se1mratL licat aaid
ventila#:iozl.. ffi+:rc:by preventing crosc-coutuainatio:t1 of air between
:r~ionis. :3.i71aaia:ls w,:m
liousetl isi two dii:fct=ent t3lfildiyg;;s, at i.lic secoaid swdy site, Group
9 (Tlic Sttict iiegitive
control group) was bouscd separately i~i a ctanve;ted ti:ngsl3er 13ui.ldiygg,
atici Ciroup; 1-13 ev;:re
lae~~t5vcl i~~ u~at~crt~d ~~~~xs~~~ l~~~ilditt<F, Each groupixas l.toused i:tl
a 5e1.?a:rat+ pcnf.;l:l-12 Pigs

l.">. per pxnt a.rid eac1i pen provided ippt=oxi:mitGly 3,0 sqtxir=e 1~ct 1~~~-
pig. l::acli pen im>;ts oai Iyg
wlevatesi deck %villz plastac> slatted t'lc3oa=s. A pit b-clc?w llze peiis
wrvesi as a holdin- t:3d- for
ex(~rcmcnt aiici ~~-mtc:. Each 1=Su:iltliilg had its ou-tg separate lgcatit~g
and vcntalation svstea-nsõ
with little lik-cJ:ilxoc;dtAt ol'air betwun t3uildijiffs.

At ttie first suicly- site, prg,lcts were fed a spcciaW tornuilated inilk
rutimz frozii birdi to
41

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
rrpprox:imat~..li 3 ~voc:l;:s of ar.ge. All piglets dv-ere consuming solid.
qcxia] rnix~..:d rziticrrl by-

Day- 19 (<31Sproxim~rEeiv 4";z ~Nv..1's Lii a
gi). At ÃlYe, seeoflr(l study site, trll Isiglit_r i4.;re letl a
crrstcarn nran-meclic:ated cr.~rrurc.iai rrtix ration appro-pr-i.;itc for
theil ag, arr:cl {reiglaÃ. l:d
Ia1?zzrzrrr, kk'atcv at botlr stirc.it> si[os ",tas alacr available a.Fc.i
ztil?itfarr.

All. test l~it ~N~~cre tre.tt:.ci witli Vitart~:ir:r E cm Day -:?, -mi.tlt
iron i:rrjectior:rs (Yri Day rl.
and wi.tlt NANCf Fl ::~ (Ã.i) n:rl, IM, irr alternating 1'.ar':rs) orr. Days
16. 17. l fi ar~d Ã9.. I1r.
zic.itliti(irl, Pig No. ?: {Cir-otitp 9) " tas irca:tocl '~viÃh an iron
inJecticrri on Day 3 Pig 4? (~;r~st.xp 6)
wa3.s t:rcaÃcd witli an iron. it~jectit3rt cart C.3ay, 11, Pig Nca. 69 (Ci-.r-
ratap 8) was C[,;ated witli
\N?:C'El, *; oar Day fi, Pig Ncr, 74 (Group 3) ~N-;rs treated ~N-itlr
dexamethazonc irLri penicillin

1 t~ ori Day 14. aricl Pig No. :?t (Urotxl) t) im>;rs treated with
tlexarrietlrraxor~e ci.rr?;l pe.nicilliri r?rr Day
:13 aa}cl ix itli NAXC El.::ti: on Day 1.4 tor vaa=iorr, health z+:ass?r7s

Whrle at tm.lr study srtes, pigs were under a"eterarlari' cim Ar).rma.l
IrLaltli
ctarTrial'It:iozrs wc:r'c cozrelu:cted, ozr Day 0 ar1d were recor'cied o:r7
tlr:c: .1-tealtlr. Ftam:inat:iorr Record
Form. All arAinmls ixere in good licaltty and mitrationa:l staws lae:fc-rrc
vauci.rrat1011 as

1i dctcrminecl by observation t?ri Day O. All test a-ai1tr.ils were
olrscr'v~ed Ec.i be .in good lxealt.lt -aaid
aittÃritiolial StaÃus larior to challenge. Carcasses <rrir3 tissues wea=w.
clisposw.cl of by rcuclerirr.&
Fai1a.l clislaosrtic?rr. cif'studd aiZiairals was records oi1 the Arr.iiirtrl
D.isptrs.it.io.tr Rccar&

011 Day 0, pigs assigned to (ixc?irp5 1-6 :rceeived l.t) r~a.t, of PCV2
VaUcin" l-t~"a,
r~s}~e.ctilcl~', l.:trt rrz tllc letl nw.ck region a:rsiaig a sterilw. 3.11
riiL I...trw.r-lc?c;k syri:tr.;e mzsi a stea=il~:.
htt ?dV xt:z" nudte, Pigs assigned to Gror7p 7 reccaveÃi ?.tt Xia.l,. of
lIt"..V2 Vacoaare No. 7 lNNÃ in

ttrs left iiec,k region usirisz a sterile -:t) iiiL Lr.wr-ltrc!' syringe and
ti sterile 2()g x ncstlle.
011 Day 14, pigs assigned to Cirort~., 7 receivcrl 2.0 itaL, of PCV2
Vt3:ccrure '~cr. 7 TM in tlie
right :areck regiorl a.Ãsiacg a ste~:ilc d1 rnl, Luer-lock syrirtge rrrld a
ster-ale 20g x ';=w" nc:~..:dlc:.

On C.3ay, 211 all t:.st pigs r-ecciveci 21.0 rrtl, of lil.l'T11Cl A :1M in the
r-igltt. ]:arn region
2i xtsisrg a sÃcrile :1,0 iri], Luer-lock s;'ring aircl a sÃcrilo "flg xi"
rica;cllc. Ori Dav'17 all test piY;ns
42

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
received 1-0 xiaL of KLl-i;lCl?A in the lc:tl li.a:ail reggaon issang ra
sterate 3.0 ilil.." Luor-lock

syrimp and a sterilc 20g -, x I ' m.;tllc.

On Day, 24. pa~s assig-ncd to G:roups 1-5 t-eceie,ec.~l :Ã,4) n.i_: ~.~f PCV2
1SLllaD1,
challenue
sntat:eria.l (;.l ] lamn,, TCiO;;:rnlU IM in the loft iaoc:l4 roI;ioii using a
st:erile ;30 ntl-> ~i-tad .i stefilc 20g x 1" tieecl]e. An acldiÃiona1 l.tt
i.i_: of't1Ye ,a-iaie : naterial
was aclttainistucd l~ to eaicll. pig. (0.5 3t1ts per nostril) using a stcrile
' ).t} ml_. LMr-loclti syrin.g;:
iiiitl nasal t ti~suila.

Test pigs Nkcre c,bscrv,;cl claily #cx oe-crall ]::calÃh .uicl adverse cxetit*
oii. Day -4 artd
from Day 0 to Day 19. t;?b,erlatioris ~N-ere.recorclLcl oai the Cliygical
C3bserlatiori Record. All
i tl test pigs im-erc observed l:rom Day t} to Day 7, aaicl Urotxl) 7~N-as
lurthe..r observed from Day 14

to ? ]... :for inje:ction s:i#:e at nutirDats. Average da:ily weigItt gain was
Ã3:e:#:ermiatecl bs tve.:i<Fhia}g
eicli pig on a calihr-ated scale oyg.Day s:1, 24 and 49~ csr esai tIiL day
that a pig vvis Ã'ounci dead
a#ler c.ha.llea~ge. Pt-idv tiveig17t:, tvere recrsrcie.d on tlic Body Weiglit
Forjii. Day -3, Earsdz-
weigltts werc, atilircel to hloc.k pi-'s prror to :ranclonAira#:is>m 1:)ay24
and Day 49 ixe.iglat tiata

1i wa_s lxtiliz.eki to determine tilc avL~~~~ge diilv weOit giiTi (Ai?W6) fo:r
e-acl1 pig during tiicsc
tirm poiuts. For pigs tliat rliecl afier challuge ancl hetoa=eOas~ 49..11ze
A.DWC; vv~as u4#msted tca
rep.resLm t11L AD1%s'C from Day 24 to t11L day of cletrth.

III order to rlcteraiii.rae PCV2 sero.logy, Y-cnous wlxo.le lsloc.icl Nva5
collected from caeh
piglet Ã'rom tiic orbital veiiou.s siaitis oai .Uays -3 <rnd14. For eacii
piglet. blood was c.oliw.ctecl
ht~ .lrozr:c Ãhe nrliatat vc:nous sixms be rnseriinz;: a stGrile capilian,
tiflbe iacto tlre, lueclial callihrxs of

orie of tlie Lyes aiYCI draining approximately 3.() fliiL of whole bls~.~~tt
irrto a 4.0 mL Sireiiii
ScIlar<3tc.~r Tube tSSTI. On ]_)zays 24, ;+], and 49, v4no s sohole blood
fri.~m et3:cli pig was
cC3lli;ct'Ld fr(?#t3 tl3e FImLtl[?t' 4'ini3 c~Il%FI using a sLs#71e l8g x I
~trr" Vacd3.Ll3:liler needle (BE ct[?tl
Dickinson .ui(i Ccattalaarw. Franklin 1_:al~es. IreN~ Je:rscv}. a
\,'acuta:incr raocd1o lio:lder .uicl a l:t

2i rtit SST. Blood ccilloctioras stt eac:li t;isita; poi:tit w4s.: rocorded on
the Sartiple Collection
43

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Roco:rd. Blood in cach SS"f ~N as allowed to clot, cach SST was then spun
c1o3s-a fuicl tlie

s.;nsm hamested, flar4ostod ss.ratm tvas tramf;.rrod to a stirile siiiip tube
and stored at -70.-2,'-
:l0" C until testect at a hacr datc. Sera:rii. sartiples wcre ÃcsÃcd for the
prescmc of PCV2
antibodies bz BTVI-R&D pcrs(iiliao1.

Pigs wer,; obsmccl once daily I'rorn Dav 20 to Da~~ 49 for cli:nicaÃ svt-
lalatot-las .uicl
clinical observations 4x:cre rccorci:;d ora the C'l:inic..tl ()bsuvation
Record.

To test foi' PCV2 nasal slicddsrig, on Days 24. '2i. aad 11wn every other odd
niflmbt;roc1
stciclv day tkp to .uicl irac.laciing I)aa 49, a steril,; ciaici-ora s{va1õ~
~vas inseried inir.a rms:tllv> irito
either tiie left csr right nosttil of eacli pig (osic mvab pes- pig) as
aseptically as possiT3le.

1 t~ swiqliccl aro nd f'or a few seconds a.rid tfiLn rLnio-ve.tl. l;:acli mab
was tliesi placed into a
5iatgle ste.i-Ã:te c~7al~~.al~ ttihe. containing :1.(1 ml, s~t'
1~:l~rl.l~.l~r'1. atted:ia ti~~itli ?" e; IFBS. 5i30 la:niÃs;'iait.,
of I?erlicilliygõ ~tt#) ~g/nI11 of StrLptom~ycin a:ti(l 2.5 gg~/snX, of
Flfyggif,on. TIiL sizah was
b:rak-e:a off in the tuhe. micl the siial) ttila,: was sa-i.teel and
appropriately labeled witli munial
aiu:mber% studo, number, date of collection, study day aa}d "nasal swab."
Sealed smap tialaec

1i were storcd at -40 -+ 10a C itsitil transportcd ovc:mi0ii on:icc tofflL?I
St. Joseph. Nasal mva13
collections were recorded on Tlzw. Nasal SNvah Sample Collection Tjc3ri.n.
BtVl-R&D
cc3aicTr2 cted quantata.tivL v~ii-ti_s isolatiorl (VT) testing fiar PCV2 on
iiasa.t m~-,a:b samp.tes. 'T'lge
results were e~presscd isi 1ogE ;valu<<s. A v~alitc o.t' 1. ') logs or less
~v~as considered nmtibe
mzd aizy value greater tlian 13 logs was considered posrtrve.

2 t1 PEgS t13F1t died (Nos. 28, ih, 56. 69. 52, and 9' )) at Ll3a fli'St
5t11dS' site 34'01'0 11Li:ropS:led
t(i the level necessary to detf: iill3'la= a dla4.'.,'lioSiS, Gross laSfofiS
were recorded and il~.~ ti~sStflk,s
}'t,eIe retained from [l3cs~~ [?1a5, At the secoI3C1 study s]tc, p1's dI<3:t
died prior to Dal 49 ('os.

45. 23, Y8, 35), pigs found dead on Day 49 prior to euthanasia (Nos. 2, 43,),
and piA;~s
eutl:arai:rt;ct on Da~~ 49 svc~-c mcropsicd. Any ~rc~s4 l.csions wcre
ra~.~teci ancl. the percentages of
2:? Itirag4vidi l4sioas 4vcro rcc~.-~rci.:ci ora the sr4c:i-opsy RepcYst Form.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
F:roni each of ttic 103, pil;, acec:rop,ied at the sc:coilc1 study site, a
i.is,r7e saanp:l~:. of

torYsil, lYnig, heart, li~er, misonteric; lvrYiph node, kitlnoy and inguinal
Ivii1p1L iiode ti.ris placid
ii:qca a siragic contaiaer witli bAtffered Ãtf% forniali:n. while a otfaer
tismsc sarnfale rr-rarn the
saitie aforementioned orr.~-tati;: avas Plac.ed iiaÃo a Wliirl~pa1: (M-Tech
Diagnostics Ltd.,

> TliclNk~.tll. Ir.K:} ai-A ,;acla Wb:irl-pak wws placed cm ice. Eac1i
cotitaitier Nk~.ts prc~pcrly labeled.
Samp:le coIlec.ti.ralls N~~fzrc I,;c~.~rclecl ora the Nccr~.~p.y Repoi-t
Frarni. Allerwards, f'6rntalin-1= cd
tr;:sue samples and a I?iar.iostic 1~~:~~t.~t~ t .~c~?rs~~ is~~.r~.
aisl~fl~~itt<tl f~:?r 11-1.~:' t:est:i'- IIIC' l~:>:tifl~g
was conducted in accordance wiÃ1i stanclarcl 1SU .lab~.~rmcarv> pt-caccd res
for rcceie, ir~g satiiples,
sanifale as I slide preparation.. a:~id staining tLcliniqFaes. Fresli Iissues
in Why.rl-pa.ks ~N-ere

lt~ shippetl witli ice packs to the Study :'Ivf.otiitor fcsr,tora;;G (-70' W
10' C) atid pcsssible firturL
aa,e. l~=O.M7alia}-fiNesi tisstw, were emminesi by apa:tlio.ls>ggst fo:r
detection of PCV2 by I.HC;
as)tl scoretl Ia,in;; tiLe f61loaving sccsriyg;; sisteyti: 0 -No~ic; 1-Sca.rrt
pxssytis,e ,tainiygg. few
sites_ 2 = .k.frsde:rate: positive ,ta.inin<F. xiigaltiplc ~ites; and 3 =
AbunÃi.ant positive staini-tig>
clrffu.sc t11roFl-Oyotct ffi,: tissue l:?ire to tl;e fact tlyaÃ the patholo-
,ist cotilsi iiot positi3+:.ly

1i diffi.:reritiate mginzral .l.N f:rorn .1ncsc.literiU .t,NN, results -~br
tlic,c tiõu" werc gimp.ly hibelcc! a_s
Lymph Node aaici tlie score given t:lic highest,core for w.ucii of'the m'o
tissties per aaiiziial.
Itesults

IR.esult, tor tliis eNairiple are given bclm~-. It is noted that ozic
pigÃ'rom Group 9 sire cf
htt before I3aN~ 0, aXtel _> niore pigs cliod po:.t-Va.c.cinatioac (1 pa,:
1'rc~~~i Group 4: 1 pig l:rnail Grntip
ta: 2 pigs ti-ort~ Gr~.~ril)S: and I pig, from .~'sroti.p 9l. ~~~Ã ~Yrt~r
tcri~ s:vtriiiiiatiori indicated all six
tlied dzflc to rtndcrlyi-ag, infections tli<3:t so-ere riot nssi.~cimetl witla
vsrrc;isintic.yir or T'MWS.
AelcliÃxt?nalh~. zio a&erse e~,erats or a:a~#cctaoac site react.inns ai:ere
noted ai:ith aily A;~roups,

Atcrat;e daily Nkcight gain (ADWG) i-estklts are farewrrtecl I=_aelc~~,,- in
'Cabi,; 6. Group t>,
2i the strict ricgative ocisitrol t;roa.p, liaci tl:ta; hi~licst A0"'(3- (1.06
0.17 lWda;-).:t'ollcmed b;-

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Group 5 004-=- 0.212 lbs/day), 3s-EaiGh received on~-. dose ol'8Ãzg of s-4-)RF-
2. (aror7p 3, wiaiGh
received oll,; dose of 4 ttg Lif l'ORF'2, I3i1d thE lowest ADWG (0.49 0.211
lbs'dF31'.)), fi)llmNed

by Gr.~.~cip 7(0.50- O.:15 lbs/day), N~~fii.ch reccivecl '2 closes oiÃ'killed
vacci_ e-

? 'f'able+6< Summary of Group Averit.ge Ditily WÃ:ight C-aiai (ADWG)

Group Treat~~ietit N :1DWO - lbs'c#aN, (I.~~~~ 24 to Drai 4')) or
acijust~.-:d I~br pigs dead before l-?rai -?'?
------------------- -----------------------------------------------------------
-------------------------------------------------------------------------------
--------------------------------------------------
1. x-f_)R.l'2 - 16 lig (:l doge) 12 1;t.87 + 0.29 .lbs/ciav
------------------- -----------------------------------------------------------
------------------------ = --------- = ----------------------------------------
---------------------------------------------------
h \,ORF? --- 8 p-tg (:l dose) 12 0.700.321 lbs/day

0.49 ~0.21 lbsr'd~v
3 vO:&t-F? --- 4 gtc, (1- tlc-?s,:)

4 rORF2 - 16 (1 dose) 11 0.84 0.30 1bs:'day
~ rt:~~_F~ 8 ktg (I ctc~4c) 1.~ t~.~~4 ~ (~.'? lbs/day
------------------- -----------------------------------------------------------
------------------------ = ---------- = ---------------------------------------
----------------------------------------------------
ti rt?.Iti'J '- 4}ig (.l dtast) 1.1
0.72 -+ 0.25 1b5/dw:
7 KV f'' ci~.~ses) Ã". Et. 54) ~ Et. I3 lbs/day
8 C;hallcngC Controls 1t3 0.76 0.19 1bs:'dxy
9 St:ricÃ Nig<3tiv4 Co-atri"ls ] l 1.06 -~ 0.17 lbs/day

vE?R1 -2. isolated 'i_r;z:Ã ()kl'2; r0Ã;Ã : teciaarl,itaaztt
Ã?;ai:xElovit2i:..xÃxrCs. r:.d t)tmu I; ki.llicl sa.he?li ~-:::ÃI
fFldS '= I'CV2 Y'Fri1S gF-fP\4TF 1F3 '-tf31ctblC t~!c-ll i:.LflLE3F-i'.

}'~~V21 scrolog4 rewl.ts atc prescntecl belosv in Table 7. A1.1 nine gi-oxap4
4N-cre
5eronegptiw foi' PCV2 otr Day -3. Osi. Day 14. Gi-ottps receiving Yt;1R.F'"I
vaccines had t:lle
highest tgte.rc. which zartgeel :from 1.87 ; to 529.2. Ri<Fs receiving killed
v.im1 vaccine had tJie
ne\i highest tiiGrs. Iollkiti~ed by tiyc groups reeeivii~~~ KAF2 vac,eisrcs.
Grot)ps 8and 9
46

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
rcniained sc:rc~~~~ gativG zit this iince, On Day. ?24 and Dzie 3 1, Pigs
r~.c.~:.:i~~i~lA e i~~! ~~~cci.~ac ~
c.oni:~lu..cl t~.~ d~.1t10aYmme ii Si~ong, serol~.~gical re;spoiase, followed
closely by the s4roup that
reccivccl two clo4cs c;t' zi. Iill,;ci vir.zil vacc.:in.e. Pigs receie, int;
rOR.F'' vaccines were slowe:r tca

roat.n-miCt scrolovacal1:y and ~'ii'ottpa 8 and 9 conlinxsed to n;nniin
s<e'mwl;ativc. (11 Day 49, pig's,
> rc:=vn:qg- vORF2 vaccirse. :? ~~scs of ilac Iill,d viral vaccine and thc
lowest clost; of r.~.'I~t.F2
clcrncansiraitecl the strormcsÃ .cro:lotgical vcsporase~. 1?i~-~4 receivirst
1.6 fLg arac~ 8 pg of rORF2
vaci:itaes 11ad slightly higher iF'_.r'! titers t:liasi chaltetav< ca-)ntrols,
Cirot~p 9 on Day 49
clcrncanstraitecl a strorst;~ scrolcag-ical reslao sc.

Table 7. SFiÃximsa~-y of GroFila PCV2 IFA Titcrs;
AVERAGE f.F.:-N':l'1':l'Is-12

Group Troalna<flat Day -_t Day 14 Dtas 24 Da~;v '_3 1" Dtas 49x,..
1 vO.Rl?'k " 1 ri tig (1 dose) 50.0 529.2 4400.t;1 786t5, 7 11054.5
-------- - ------- --- - ------
' NORI ? 8 pg (1 dose) 50.0 i0tij# 3466,7 6800:0 1t#181.8
3 vt)R1=2 4 ag (1 dose) 50.0 1S7.5 1 13.3 5 733 3 93 3 3.3
4 rORi,'2 - 16 [i,:f1 dnw) 40.0 95.5 15Y(1m 3, i-'?d1.9 wtlom
5 :rE):&t.F? _ 8 ~<F (1 dose) 50.0 75(l 887.5 2266:7 74 16.7

Ã.l_Ã.l 50.0 5idl.dl 3118:2 10-570.0
6 rORFw 4w) (i dose) i

7 KV (2 doses) 50.0 204.2- 3 087.5 4620.8 868[1.[1
8 Challenge [.'.c?litrc.ils 50.0 55.0 5E1.E1 50.0 5433.3
9 Stt'ictNegabt'c Cc3rsErols :?f}..f} 5i3.1 54.5 Ãi1.aÃiA
v(}'I l..'~;; t.;>l.r.ti:c ~ t
t 3a"11 t.?.t~l ~~x ~I.~'? - r~x~,ttah3~~z3aaE hz3,_ifl~>~~3r~i= wxpav, c~k
s.ili.k 2; killed zOwlc. w.wll
47

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
viriF = ?Ct2,,:i~ i~ ~roENll nl s?lita9.,lc ~~]1 culttire
*For- calculation pu:rpc.~scs, a<It1t) T.FA t:itcr ,~Aas cicsigliated as a
tittcr c?f-''5f#"; a.:''64ÃIE1 T.FA
titor %vas siesigmtw.cl as a titer o.f"12.800"

"Day of t;l)al.te.il+je
~"*-'DaS' d?f.Nt;01'Clpsy

T'lle results from ÃI1c 1~4~St c1~i311e~1~4= clinical obsel'vatio1'ls are
priseslticf b41cm- il'1Tzlble.
8. This s~~nunary of results inc.:lnclcs observations for Abnonuat I3o1~a-
vior. Abnormal
Ikesrsiration, Cough tt1Ye1 13i<3rrlle<3. Table 9 itlclYtele:s the reslslts
t'roril the SumnYarly of Group
Overall ilit;itletlce i.~t Cliilict3l S;y-nlpt:clnls and Tzable. 10 Hlrludes
resti.lts frc.~ill ÃIlc Szi-a~~xla~ of

1.(l Groxsp Mortality Ratcs :llost-c(lalleuge_ ':l'tle niost cnnulcn:al
cli.zl:icat spuptclni noted in this
study was abnormal b411avior, N-Oiicil wa.s sri.~re.d <3.s l:llild to severe
l4=tllzaryyy. Pigs receiving
the 2 losv.:t- cÃ~.~ses ~.~f' vOR.1~'2, pigs rec.civi:ng :lti Ãig of rOR:l~2
and pigs reLcivi:ng 2 cioses, of
KV va:ccmle had iiwid<fllc~; raus of => '? r.;:3~ro. Pigs roc:ei.ving 8 1q, of
3-ORF2 ailc.i 11w alris;:t
r~egativc coll:tzol gro fa ]::act ia~.~ aIlnon:n.tl bc11.tvior Ncalie of Ã11e
pigs :in. tiai.4 study
tl<mc?nstrat.ed any aianornlal n silisation. C'oifl"'lling was 11
(ltecl frequently isl all gi-oiips t0 to
25t''i}3, ils " tas diarrhea (0-20%). NaOne of the clinical symptoms noted wen
Iaat:Ilogploflllic: for
}?k1w S.

Ttle csvGrall iygcaclesice of clinical symptoms -,'a.rierÃ Iletivee.n g!l-
otlps. Groups receiving
any o.Ã'tlic oO.t2F"2 vaccines, ttle group receiving 1.61ig o#'z(3R.F?.. ffie
<Fre~l.cp avceivi.tlg 2 doses
N of .h V o accinc, a:ncl t11e challenge control ;rol.ip 11ad tlic
la:i<Ftlc.st incidence o1 c-lvcrall cliliical

gati s L control groFap, tlic group receia iyg 8 gg of' rOR1 2.
synLptoms (:' 3t> =f%}. The strict n,

and the gyroup receiving 4 jig c?f r0Ri;2 lzacl o1eral1 i~le=idezlce= rzltes
o.t'c;liaiical 'symptc3ms of
f 1'j er, e i..i % ;3.t1C1 9.1 ~~'fu, reS17i;Ot1.vi;lS'.

Overall mortality :ratcs txMecn groups varied as well. The grotrp receiving 2
c!c?:scs
24~ o:t' KV v<lcciaie llucl the il.igliest mc3rtzllity ratw. {]6.7N(,):
~NJiile gg1=oups that received 4 lag of
48

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
vORF?, 16 tug al .rO:ltili?, or 8 p.tg of'rORF? ziatd tEae strict ncgfaiivc
cnntro] group fall had W,~~
~~i~rl~litb rtitcs.

Takilc: 8. Su~~~s-nary. of Group Obsc rvations 1'or AkmornnaÃ Bc.havior,
Abnorma1
h Respiraii43n, C~~igh, iiraci Diarrhea
------------------- -----------------------------------------------------------
----- ----------- -------- ----- ----------------------------- ----------------
--------- -------------------------
Ca:rout> Treat~~ictit N Abnormal Abnormal Cough Diarrhc;~:.a4
13eEa~t~ in:r Bchaviora

(1 dose) 12 2r'12 {Ill:'. +:12 2 :12
1. Y(3RF2 - 1.6 ltg

(167 % (0%) (23%) (1 6 7%}
"""""""""'"""""""""""""""""""""""""""""""""""""'õ"""""""""""""""""""""""""""'-
"""""""""""" """"""""""""'
2 k.Ol:F2 _8 ~tg (l dc"se} t' 4/12 12 1/12 1:/l2

(s..~:~t~
3 vORF2 ~ 4 l1g 0 dose) J,?
811,12 ft I2 ~f ).2 ).i S.2

. . . ............................: .........................
.........................
...................
...............................................................----------- ----
-------------------------
4 r0RF2 - 16 [i'.: (i clow) 11 'ii 1 Ã.}ii 1 0'11 (W'0 2:11
(27.W,;~f~ ) (iA<;~~) )l~ (1 1?27;~:'.
'~)

? r0R.F2 -8 la~ d 1 tl~~~~ 1.-) 0/12 0112 1/12 0:1210%#
------------------- -----------------------------------------------------------
--- --------------------- --------------------------------------------- -------
------------------ ------------------------
fa rC}R.l '~ 4 lw (l i-lc.~se) 1 i lr 11 t<} 1",<,) f1/ 11 0/11 ({}"<~) 4#:'
12 (t)%)

7 KV (2 doses) fal2. o.~, 12 0 12 C11x~~4T1 14_21

0 8.J} (8.3%)
49

11 '\ 3~:' 'ltjil? - {} ~ [~ (~i)
~t~~lf~J ~ ~~j~.A:#1 ~, S:_[.~;'tY)

9 '4taictNLg ata~eC.~t~t~caJ~ I1 1.1 t~:111 t3,t1 t#)'.'.~} (3r1.1 fd~y;r,3

0:'Ll!5F r1 i1/l
) ~2fif>J

a,ix]xaesi virzfl #:)]k ÃI; t()Rl -:: i~ i a~e~tt iii ir3E I>aLIz.tiWii-E3s c
rpre.ti,e.d OIZ]: 2,kil(edivtto(e ce11.
virus PCV2 vxnt: ~;rnwn iiA

''.l'otal zlumber of pigs, asY 0-ac1~ grotip that demonstrated any absYoranal
behavior.t'or at least oi1w.
~ clay

"Total ~~~~iiilser of pigs in each group that demonstrated any a1xlory:na1
respiration for at least
c~iic~ clav

'1'otal auumber of pigs a:za i;acli group that c#emanst:rat~..cÃ a cough:l'cvr
at least wle day
"Towl iluiialie:r ot'pags iac each grntip that dwaionstratc:d diarrboa for at
tefast one day

'i'ablt 9. Summary of Gi=ouls Owf=atl Incidence of Clinical Symptoms

Group 't'reatmem l.uciclezice ofpi.;s Nvith Isi6cleaic;e
Cl izi i cal "Swul pÃouls' Rate
-----------------------------
1 v4:3RF2 - 16 gg # l dose) I.? ? 4I.. 7t'r,
--------- --------- --------- --------- --------- --- ---- --------- ------ ---
------ --------- -- - --------- -----
2 vORt?a 8 ag (1 dose) 12 5 41 711:,,
- --------- --------- --------- --------- --------- ---- ----- ---------~ -----
--- --------- --------- ---t-- --------- ----=
3 Y-E'}RF'l 4~.rT (l doso # 12 8 66.7"'i,

4 K).Itt~=2 - 16 ug {1 tit-aSe) 1.1 4 36.4E'fr
> rORF? - 8 ~w d.i dose) 12 1 50

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
6 r0RF2 -4 lE.b (t dt?sc) l i 1

7 KV (2 closc,j 1.2 7 5 8,3"f~
8 chx.tlcsige ['c?lltr~ls 14# 4 4E1"~t
- --------- --------- --------- --------- --------- --- ----- ---------- ------
-- --------- --------- ---t-- --------- ----~
9 StE 9C.:t NegaEi.vti; CkZ3ac5ls l 1 $} 0%
is~>l,~t~:.l v3rsr1 C~t~} ; ~t 16N = Tsxeatttbiru3m 1,311eit ..tltolf--~ G~cll
vzrifl:-; - t'{ ,. ,' z:iEYE 6110V;R azt SEaiWN: cell C1,11i-e.rr::

7'otal numlae:r ot' pigs in cac:h group #.Eant clenionst{=a#ed "my ciia}.ical
somptoz11 l'(i{= at least One
(by

Table 10. Stumnxtr~y of Group Mort<aIita~ Rates, PEast-ehall~"git

tix~~irp '.l'a~:at{a~ea~t T:3ea~1 Post- N~.t~~rt~~tita R~te
challeng~

.........................
..........................................................................
...............................................................................
...........................
k vOl\i'2 - 16 go (1 dose) i-)
1 8.3%
2 t'ORFs 8 pg 0 cloCc} I-s 1 cVi..Stiit
------------------------' -----------------------------------------------------
-------------------- ------------------------~---------------------------------
------' -----------------------------------------
~ vORF7 H 4 ug t.l dosO '17

4 rORF2 - 16 ~atg (1 cios4- 11 fl 0%
5 rORF2 - 8 },Eg (.l dose) 12 El 0%
6 flt?RF' - 4 u{:l cl:osci 1.1 1 9..1%
, KV ( 2 dctst:.s ) 12 51

pC-'V2 a}asa:l shedding results arc pavs,:nt:ed below in Table 1.1. Fo.Ile~wl-
ag cIAall,::ag
,,v
c?ii Day 24, 1 pig m Group 7 1?cgan shei-ldirlg PCV2 oji Day 27. ;to:ac of
tlle c?tlier groups

wxl~erieixcd sheddi:n;,,t tmtil Day a+. '1'lie bul.lv of nasal sliw.clding was
zioted fi=oni Day +i to
Day 45. Groups aemvizi;.; :3ny of t=lze tlia=w.e Yi:.?RFM rac~cisies and
groups remvMg either 4 or
8}rg of'r0RF2 had the Ic.~~Ncqt i.rac:idmce c.if anassxl s.hedcling of'l'C;V2
(_ t)..t"õ). 'T'lie challenge
c:c?aitrc?l group (Group 8) liacl tli~:. liighcsiÃ sbedcfisi- r.3te (80%),
.Fc?llcawed by tlie strict negative
l.tl control :,'roap (Grorip 9). wliiclr had aar i-rcicÃ~..ace rate c?f
63.1i%'r.

i'r~fslc 11 ;suinmriry W'+l.:xmup Incidence 4rf ;tiasa1 Stre(lF#ing of PCV2

Cxrt?tip Treaiz~x~a~t N No. Ã3.t'pigs tllat 4ici-1 1srUli-lealce .IZate
for at least m1c day

1 vORF2 - 16 gt4; { l. closQ} 1"? 1 5.-1 %
2 b.d)hT?? 8 lag (i dose) 12 1 83%
3 Y ORF2 - 4 ~ A 0 clc?se3 12 1

4 3'C)~'tF2 - 16 (1 dose) 1t 2 18.2%
5 rOR) ? ii !Ag a 1 t1o5c 3 t? l 8.3%
6 r0R.l~'2 4 ia~ 4l t1oq1.1 1 ~,~.1:'~~t,
52

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
--------------------- ---------------------------------------------------------
-- ...................
=.......................................................... -------------------
--------------------
r KV (2dcrses) 121 Y 41 . 7%~
8 Cl)al.fvnoe: Cozrtr=ol.s 1.t3 8 801:i,
9 Sta=ict.N-Chatave C'crarttc?Js 11 7 fia.(r
--------- -------
vt3RIP-) is~Aateci vrea3:f ()R 1-:, a:t 3RF? T t4c.iaF)tl?rtrai:at
t?iNcrfIOVrtti:= CXtrrV.>S~.d c:)Rl ?:. krÃleil WT2e=1e ;:.~:fl
\ EFIFs:" P( V2 vFS'i35 gF'tFcViI 4F3 St_i11: able i'd'.l1 CtEI1=E1F'f;

':l'1)e Sirr)ia~iary c)1' Circrup incidor)Ge of loter-us. Group tawidc:z)c~:.
of Gastric U:lcers,
Gr'cyrrp ;Gleza-) I rtr)i
g L.esiot) $cor4s. and [aroup lt)cideric;e or Lung L.esiot)s are ~.,l)mv-t)
below it)
Tdif)lcl" Six pigs diecl at t:lru lir-4t test site cttr:rir).g the past
s>aecir).atim lah,-ise of t:lrc study
(Cr-oiip 4. N:::1: Cir-airp 6, M-1; Group 8> N --'; Group 9, N--2~. Fotitr-
(Yirt of six pig>: had
fibrinous lesiorrs i:rl cMIC 0r,111crre body cav:ities. crrr:c pig tCrc~~p 6)
lrzrd l.esi.01:rs cr.~r)sisteat Nk:itll
s;.losmA,ittl disease, ar)cÃ osre pi.g (Ge'octp 9) had no gr(iss lesions. Nom,
of the piY.~-> that died
1.() tlxaring tlre pt)st-vXte~6mitioar p:lrasccf (.71' (lie study l)xtd
lesions consistent witl) t'ZlWS.

Pigs that died p~.~st-clralleage m~:cl pigs cra.tlY,-inirecl or) Day 49 were
nec:rotasi.ed. At
aree.r'opsy , icteras aaicl g-isffie: aleem iz.ere aiot pre..ser)t in my,
grcrup. Witlr regard to mean"i,
faattg :fvsiazrs.. Cirortts 9 t)ad, lotv+:,t mvarr % l1mg lesions ff%~)..
totlots>+ d by Group .1 ts=itli 0.40
? 0.50% zirAti C:ir=ow 5 ts=itli 0.68 :~= ].. (-i:r+.?tclx, 13. 7 "md 8 .h,,3d
tliv t)iglrecÃ mvarr "i, tr.ca)t;

l :? ~ S1C)I1S ~... :. , . a~. .:<]~ ) [?l t ]t;SG ~~(1T" ~;r't?(1~AS
C~!)ti)1!)~[ ~:[1G 1}B ~? ~t lt 1 ''<z ()Il~ eS1C)11S ..'.; ~ . ~~r ,.

which cke.we:d the results higher for tllese :cou:r groul)c. With the
exccptioai O:C Groul) 9 with
i~<'ro3 1tFr)t; lesioais aiotecl, the retami:rririg 8 gr-otips had --- t~%
1t.Fart; le..siotrs. Almost ill It:rngo;
l"icrriq )icrtcd~~~cre desc:rib<.d as redipurple a1)cl ctrnsolida-tccl.

20 Table 12. 'stÃmanary. of Grtantt iayc:ictenee tyf Iete.f=m. Ga~tmp
lnt;:.ft.tsbnce (ri' Gastric Oeers,
Group Mean % f:tr;ng Lesion Scores, and f,i ciut) .t-fic:lclc.aice ot".C-=Ã~ng
l,csions Noteci
53

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
------------------- ----------------------------------------------------- -----
-------------------------- .....................
=................................... ..................................
(~~-oc~p Treat:ancliÃ lc-tert7s GasÃric \ie:an % LimA;. Inc:ie(e;noc of
U1cers UsicMIS Ltttig .L.e~w.yils
NoÃed

1. 1ORF2 - 1fi [1. (3t1.~ (d)"4,) 4f12 0.40-t 47.50'3 1t};]?
tit., ;õ
Sej ((l : ea) {c~_i rr,}

------------------- ----------------------------------------------------- -----
-------------------------- ----------------------------------------------------
-----;
2 vO:ltiF? - 8 ltg (.l di?sc) 0 1 2 tdN Ã}i ih 7,41 a 2Ã.}.?' v 10/72
~ 1{)kF." -4 tag d ldo{e3 4,12 (dl"'i,) #)i l 2 9.20 20,9",i; 1 t~/:l ?

{ 0(%)

------------------- ----------------------------------------------------- -----
------------------------- ---------------------- ---------------------
4 ~ 4~FÃI'? - 16 gt~ (1 t~' 1 l(C?",
i,) ~3f l t l,5~~-.74',41":L l
[l~~sG? (t~''<~'t (3 0'=i,)
R rORF2 8 tig 0 elocc) [1a 1.2 0i'1 ~ 0.68 -~- 1 1.5% 911, 1'
................... .....................................................
............................... .....................
....................................
..................................
6 rORF2 4 u g 0 dosc 3 t} t l (W'[~} 0; l 1 2,9 5 -~ 5, 12 u.iJ ] l

q.~3=Y .='i} / ~i lT
: ik 7 )

7 KV (2 doses) #.~ .t 2 (mi,) Or':12 7.27 '? 9",t) 9r 1?

{0".i1} (75%)
------------------- ----------------------------------------------------- -----
------------------------- ---------------------- F-----------------------------
---------------------------------------
S Challenge C'oactTols 0110 11:'10 9.58 29.2% 81'10

400'd?~

9 StriCÃ Ner5tat.#ve [k"1 1 (t)t"'t,) 0f 11 0f 11 #3/ l ~

co.~trots (cf;yil) (cf;y~il!
................ ......................................... ..... ...... ....
...... ..... ............
i t3Ã:} 2 i, Eatcd s ira3. O3::F2, rr.<:{aixahFmnii ba iElc>vir3.t,
cxpts.,ssxÃ ()IkF', KV or killed
54

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
LSI-to1o cell vIms = ['CV2varLEti ,TrG~4~'tt in sEi3t::1~14~ cell iii]ttaa~:~

The Sa:llnman c?fC,roupfl-1C;- Positive llic>rcteme Rw.stllts is stiow1i izi
Table 13. Group
1 (vORF2 - 16 pg) alitt Group _5 (t()1.2.Tj2 - 8}Ag) had tlgc lc?~-vesrmtc of
111t;- latisitar-c result:s
(167%). Cl'otlp 8 (t lta.tlclip ['oj~tzols) ai~.t~ Ci:~t?~113 9 (:~b-ict~
i~eVaF:ive ('c.~.lttrols) lxit1 tttc
liiglaest rflÃ:e of lI-1C positive l'e~szltts, 9M aiid W respet;tively ,

'i'able 1.3. Sumina.rN ot Grc-up I.H(' Pori#ivc ir.4c.idence Rate

Group 'T-re.ltmeut N tria, Of pigs that liacl at laeadezice
least C?S1C tissue positive
Ri3te
fc3r.NC'V2

I vORF2 - 16 ktg # l dose) 12 2 ! 6. 74''i,
-------------------------------------------------------------------------------
------------ ..................... --------------------------------------------
------------ ----------------------------
N t'(?Rt M8 la- (l ilcaw-} 1? : 25,0%

3 vORF2 - 4 pg (1 dosc) 12 8 66,7%
4 16At21'N 16 gg (l dose) l. l 4
+Ea.3 %
> rORli? - 8 ~1 g (t dose) 12 2 I tZ 7%
6 r[).t2F" 4 Izg
(l dosz ) 11 4 33 6.4 %
7 KV (2 doses) l.w 5 -I-l .7"<0
~ C laal.tc;1~~ C's~l~tl=c~lc l.tl ~? ~~i3.i3 ~=t,
9 Strict .4ehtltive C;ontrt?ls 1:t lf1 90.9%
----- ---- ---
vt?RI 21 i,ola3ted viral (.}I.F?; KJÃ:F2 - r-eLom1>lnatli Ãtl .tll.>sixsY,
c.y:l>rtsst~l C)i~}': KV or 1:.ille~il
~St3dlti'. cell t S.C3:1~ '~~~~~' 2 Y'4F7Eti t',fd1Si 32 in tiE33iiB1>t6'.
cell L:i3~:iF~C~'. .

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Post-cllaflenge. Group Y, whicli recc:iz:eel one dose of S~m of r()RI'2
aaci.ign,
outperformed tlie other 6 vacciiLe grotflps. Group Y htid the liigliest ~UMfG
(0.94 0.22
lbs/cla-,,.}, the l.Owcst :inciclc: cc of al.~ncanrml behavior Ã1i;; second
lmvest i_ c.ideticc o:f

cough (13 it'.r,). the 1om.,<sÃ incidence ol'overall s;.li41ica,l Syn1ptoma
ilic lowest snoe'[alitt>
> matc (0?%), tl::c lowest rzite oF: asal shedding oÃ'f?CV2 (8.3?%), the
second lowest rate f"or: xara

% lA#Ii4 lLs;iol1s M.68 1 .l.5%1 s'.E11:c1 the lt3w,.sk i11ciC1L'1:FO.C. rate
for positive tis.tEti;4 06.7%}..

~'zrcn.xps rec<iving, variorss levels of rORF2 atltigoia overall
oiflt:performec.i groip>. TOs;:CiVifl19
varioAts levels of a()RF2 and the woup i-eccivi_ g 2 cf:osc4 ca#'kill.cd
wIYoIc c.cil PCV2 ~~acci_ ,;
la<.rÃorrnetl the worst. 'l.ables :14 mLCI 15 corrt-iy.r~ summaraLs o1"gs
csaq) Ixsst-challeyg;,~e data,

l t~

Table 14, Somanatn, (ii' G:rOop PÃt4t-Challenge Data - Part 1.

~~+ra~,ll
cii'otitp 1 Troatnl<flrt A0W{s Abnormal Cough

{lbs/ cla4 } Behavi~.~r iracideticc c?l'
C: 1i11i.c.-.l

S s nifatoms
l 12 vORF2 " l6 ug {}.87.-s: 212 ~/:l2 41. 71%
(I dose) 0_2 9 (1 6.7",,~) (,?%)

2 12 3 O:&t.F2- 8 1ic, 0.70 _ 41' #? 41. 7': e,
( t El[?tiG') 0 ,_'ry ( 3 3,3 3'i, (8 yia

----------------------------- .............
...........................................
------------------------- ----------------------------- ---------------------
.........................................
..i 12 ~D$iT'2 - 4 0.49 ... 8 121 ~,' 12 tx(l.? )r+s
{141ose) 0:21 (66'' ,[~) (it,,'' :o
--------------------- ---------
4 11 r431~F'? - 16 kfg [f.84 ~ ~: f l f3:'11 +f~.4"~~

(I dl'?5e) 0.330 (2 7.:+E,ir~

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
~ 1-2 t0.ltiF2 -8 ~Lg 0.94 a f?/:l.? (0%) li 12 Sl %

(1 dose) 0,22 (8,3%)

6 11 K)YiF24 p g 1).7? 1;11 f{),1"iI tt; I 9.1l'ia
f tl 4:iwtic ! 0,25 7 12 KV

tF. 5() m Z,' ] 2 ('583) (3112 ,'_i"'~~

(t[? :~U9) ~). ~. ' ({~v'rr~

8 1o c11;lllcngc EF 76 1 t 10 (10%) "~:' ld} ÃEF'.''Jz
C'U[t~t'C71s d).l~-) (..#}:
~
9 11 t?6iioZ N 0 L1: 106.~. (VA I L'.f%) R??.1 S. 0%

C-~Iatt'i~15 0.17 o""~1

vE?RE-1. xaollziÃ:d 'i=im3. OIi.[-"; zC3Ã;Ã~2 - reG<.ilt3biaxiuat
bacxElc7i=zriEa c~qstcaseel t)t*'I~ KV c?3: killed
wF3t)le ci;lF t'S:f3:E" =Pl'V2 '4tuti 3.?f )St'it Fit tiE33iiE})le cE'11
i:13li8Lfr,.

~ 'Usblc 15. Swumarv cyt' Group Post-CÃusl[ragr DaUt - :F?'arl: 2

G-rozEp N Ttet3[-aicia m~.~rtt3lii} Nnw1 Memi ".i) 1ii~~idetac~, Rntc of itÃ:
Rf ai:c S(icddxn ,t l.,uiig lczist ozic tissltc Ix-1C;
Lesiojis positive for PCV2
------------------ -------------- ----------- ---------------------------- ----
--------------------- ------------------------------------------------- -------
-----------------------------------------
'T ~)R F~'~ . - 16 (}a~~)r) il5 ~ Y).4tF'y. .14~7, i 1~'U
~ ~v titA~ c } ez

(:l dose) 0 .5

~1.21 1'<1R P,, 8 9.3iri) 8.3% 7,41.

2 i-.';s,,~
~1 dose)

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
~ s,,.'
3 12 v{~I~i~? 4 ug 4?:~~ 8311 %201
~ .. ":
1 [ime3

4 11 {)R& y - 16 Ag Q"'i, l t 2"t, l.54t " ~ ~,:
~ ~,..~.~~,
4 . ; TAN,
~ l doqc)

12 rf.3I~F2 - 8 ~tg 0.68 --t 16.7~
(l dose1 l.

6 11 t4_fll P2 ~S- pg tl'. S. % 1). 1 t! Cl 2.95 A. 347.''t%

(.i Cio5e) 5 1 1"'~
i
7 12 KV 1{),7"% 4L7% %.27 I ti..7'~'~

~,..

8 10 a~,114~~.o~. t'~~~'''i' ~~,k~t3 '~t):t)t"'i,
Ch4 i[f,.~ R

{' y tiCl;'
\..onuoi1

9 11. St7-iCt Negative t}W",s 67 fa"a 0r'1.1 90YI',11

L'OR1~2 3Solat[:(l \'ir:El ORF~2:, E{?RF2 - Ie4t3337bZ[3fi3-EF b.tcitli?1',EIt-
Ls e'tiÃT3[.ss[:'d 0R'..f'2, KV ofkEl~~'d
tk,ht~)e cell <'fF"1Fi= },'C.V'. b'Fri1) gro:l'n ttP )1i'll,Nc: Ldlt
a=LEf1:1irE:

Rowlts of tlgs sÃtidy AWicMQ that all further vaccine e1Yorts slac.~zflld
roc,tis oii a rORF2
5 vaccinc. Overall. nasal shocldhig of PCV2 vms ti<tected po--st-cha11<fl~ge
anc.i vac:cinali~~~a with
a PCV2 vac=c.hc in a ra;ciuction. (.?t' shi:dding, of sdcctcd
l4'3]Fpi1C]i(t OSst1i.:s also sc~mi:Ci as a good p83[a#1lewr for 0acc11:Fi:
ti.l'l.3ci3Gt'. 1S'}344tcas .laT~,.':.'~
diBbrences hi .IDGVQ ctisica.l symptoms. and gross lesioiis wert not daccteei
l3<txxeeai
grou:Ps.. 77:i. 4iua~~, was c.cattaial:icatcci by Me .Ã'.tcÃ il:at extn.nccms,
PCV2 was irtmctwcci at

14) soj~te point timtg ttte stucty. as coitlenceci by nasal siicddiiig of
PCV2. PCV2 scrocono%ersion
58

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
and positive lHC tissu:es in Group 9, t81e strict 11egative control group.

Di sc ss:icm

Sey-<11 1't;'t'2 vtlcc:i~ies c;<1'e evaltitatec.i in this studv.whic:ll
inel.ucloel tllscc: c.1iffi;roslt
dose l,;Ms of vORF2 antigeri acli:n:inisÃcred once on Day 0, tll:r,;e
ctiffiercilt dosc lcx<cls o:f
rORF2 anÃigel:i acta:u_nist:.red ori~;~: o1:i 1=?av 0 an.ci clnc dosc l,.M
ofkilled whole M1. PCV2
vact:ine adnunistered on Day 0 atlcl 1?ay 14. Overall, Group 'i, cvllicll
1'et;cived l dose of
vacci_t1,; c~.~ntairling t; tsg ol' itlRF". .ltTei1. had the best results.
(_lrcitlll 5 had the ItigliesÃ
ADWQ. (lie loivesm incidence of abnormal tx.llaa ior, ttic lowest
islcide.aic:e of abnormal

1 tl respirati(ml, tlic semlri low~cst i1lcirierlce of cou;;tl, tlie towest
iilciclLnce csfm~c:rall clinical
syzllpto:aas. the 1.-owecÃ mortality xat,:, tilc #c-lwcst rate of nasal.-
Oleclcli_tl~ c~t' f?C;V2, the second
.lC)SiGqt rate fUr :[11caI1 '}~'ca t11.E1S-'_, 1GS1C?11S ;1BlCl thG ImZ-<'.St
incidence r;lte for positive IHC t1SClJGs.

7ntere,ti-tlgly, Group 4, i0ich r,:cei-ved a 13igller do,e: elt':rtAF?
ant:i<Fm tllali Gl-otip -5>
did not perf.o:rii1 as Ns=e:ll or bctte.:r than Group 5 Clrol:ip 4 had
asllgtltly loNs>e.:r A1:)WG, a
1i higttcs' ilicidcslce of a.bnomtal I.seha:vit?1-, a illgttu :illcide:Ttc< of
overall el:illical svittpFoitts> I

lii~l~w.r rzlte of nasal shedding of 1?CV2, a higiliw.r sliwusl % tml.;
lesions, zlilcl a lzigli~:.r r.lte .Fclr
lx)sitio.e Tl-TC tissite:s ttitiil Group 5. Sttiixstical analysis, which may
have i-tldic<lteci tlga.t tlge
i-li-tIezwtc<s t3cM eeal t-hcse two groups were llot sta:tistlci-Ãly
s1Vnit'icant, wag not colidtictecl t?1l
these clat<l, but t.lle:re was <lil observed trend tllat t;ircll:lp 4 did
lic3t perfonn as vv~e ll as Clrc?1:t1) 5.

htt k'ost-vaoc.inat:inn. Ã4 pigs died at ttlc .f'i.rsÃ study sitc. For7r of
th~::. six pigs w-cre from
Gr~.~Ysl) 8 or GrcaYsla 9, which receivcd iltl vat;cine. Ncank, of tlle six
p14ys clmtotlstra.ted lesioils
cc.~tlsisÃe-at with PMWS, ni.~ sldk.ersi~ events wer4. repc.~rted a#lcf
overall, <311 seven vacci-les
appeared to F?c sal:c ~Nlacn aclan:izlistered to pigs appromnlatch, I t clays
of al;e, During i1ic
lxasÃrvacvill.ttiml pl::asc of the st dv. pigs receiving citl::er of tllne
close lev,;ls of VOR.l~'2

2i vacc,isl.: cys killcd wllcalc cell vacc:is14 ll;id the highest IFAT
lce,els, while Group 5 had tj1.:
59

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
tnai.e;st Il ~'I' lee.els jr~st lsr:inr tc~ cEarallGac~e, c~l tl~e ~a:cca:a~e
~rc~~fl~s.

AltlioYtg1L rLot formally proven, t1Li predominant rot7te of transmission of
PCV2 to
v>catuig swir~c sliortly after We.n_iag is beli,;vcd to be by oron.asal
clircct ccm Ãac:t and zira
efficacious va:cQ.ine t11zit retlttc nasal shodc.iina of PCV2 in. a
prodttQtiosi. s<ltinr.~- would help

> con tro:l the spr,.ad of inf',:cti~.~n. GroAtps r.eccivin 6) otac ~.~ftlirec
vORF2 antigcn.lcecls and the
gi-otap i-eccivi: g. li gg of rORF2 l::acl ÃIrc lowest irac.idcticc rate o:F
ruasal Nli,;cictirag. ol' PCV2
(8.3t'4ii. Expectedly, ilic challenge cesiti-ol ~>e'otitl~ had t:l~~.
l~igl~:esi. incidence rate ~sf tiiis;~l
slvcldir~g tSt}%;..

Gross lc..sioris i~) Pyt;s Nvith PMWS seccsacias-Y to PCV2 i~ifection
typically consist of
1 t~ gencralirt.tl lymphadea~apathN, ir1 coytibiaiatioyg witli 0310 or
anitj.liiplc of tlle 161lowing: (1)
iat#ea'sti.tial prt, Famonin with intcrlolsla.la:r etiema. (:'') cFat:ancou,
Pa.llrDr or ict+ :riss.. (3) 13,10tl:l, cl
atraphic livL:rs. (4} gastric lflcc.rs> (3) yieplititis aari (6.)
rc.prcduci:ivc riisor&rs. e.g. alort:ionr
stillbil-ths, xiigaiTixiiies. etc. At raeca-opsy. ictea- s. bc.patitis,
ncpl3:ritgs, and gasi:ric. ulcers were
aioÃ noted in any ~~~oups aa}d lyanptyariea}opatlyy was not spccif-ical.ly
cxasninecl.t'or. I'.lle mean

1i % har1a lesion scores varicd lsetweeti gmups. The grotrp receiving 16 tag
of vORF2 aaiti~e:n
liacl tilc~ lowest measi % lung; le:sron scc?rw. (t?A0 follos-vecl hN: the
group that received
8 trg of .r~-).12T?'d0.68 - l., l. 5'%), As c?;lacc;tcel, t11L clmlleagtje
cc3iitrol group had tlic hitj.Ãicst

z z % z~~ear1 % .tu:Tig lesion score E..~.~8 - '' w.~,~~. .:a}. I.si all
ft~t2~~ ga=c~r~l~s, tl1~c s7i~ca1i ;<, lr~~ig Jesic?llsCONs

were clevatw.cl r3trc to orle pig irl cacli caf'tliesw. groups tiaat liacl
vca=s lzigli 1tisig lcsac?ai sWres.
htt :,\1ost of tlle lung 1Gsions wcre described as rodipr7:rplc: and
consnlidatecl. 'I'~picallNlung
Ie;siolYs associmstl tNii:h PN1-WS are deseribcd as t<3ii a#td nort-
colLqsil.~le tNith inwrl~.~bular
edema, The 1; irg l4skmis zrotQd in this stifldy wer4~ eitlic;r zrot assmiated
witla PCV2 infection
or a scc.oacd pulrtionard infectious ragem may bave been present. Withi.zl
tlie; comext of this
study, the % Uig lesion sc,or.es laro1õsably, cl.ca ricat rc:f7.ec.t a ti'sic
rncasAtrc o:F ilw amouat of lung
2i iti_f4c:tiori cixto to 1'C-V".1

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Otller- rese:arclaers have clemoust:rated zi direct correlation b,m:c:eu tlrc:
presenco. of

PCV2 antigen by IIIC tiiid lu5toptlLology. tiistopaÃhology oir select (:i5sms
w-as fliot
conclucÃcd with this stucly. Group 1 (11.6 p6) of v0RF2:) an.ci rt-carip '? {S
tt: of rl~R.l~''} ]::acl the
lo-we>:t incidence rate of lxia;: posit:ize fer I'CV:' tatrkiYT<n t83''-i,;,
"'Ilile t4'zrotitp 9 (tll< Sttict

> ncgw:ixe control group - 90:T%) and Cy.roxala 8 (the cl-mli,.r~ge c.oi:qrol
group - 90.0%i had tlle
l::igliest incidence rates Rm- pip positive #x PCV2 aaki),e: .. T4-ts,; to the
nora~suE~jeckiv,; natur,;
of t11is testr IHC n;sifllis are probably otic of'ilic best pae'ti~snotors to
juclgw vaes;.ine ef"f'it.aez on.

'l"hAts, in orw a.slaect: ~.~1'the larese Ã inve Ãion, the l!'iinin-mtrt
PcartccÃive T3os.igc (ND1=?)
of a I mlr'I dcsse rLcombiniygt larolrict witli extractLcl .l'C'V3 Ol7k2
(K)RF?) antyt;Ln in the
1 tl CDC.D lyig 3nodel in the face of aPC: t'2 cWleage N%,as rletcrmi:nLci, Of
ilic t:tirce groups tllat

avecivecl ~~~rlyint; le~~els ol' r0RF2 antggea}. Group 5 (8 gg of r(_}RF:~
antige.a}) c:lea:r:ly11ac1 tlic
highest level of protectiom Group 3 either 1~ad the best results or= was tied
1i)r the aiiost
favoralale results witli r,:ga:rc-1 tc-i all of the parameters esaiiiixiec-l.
When Group 5 tix-as
compared wÃtla the w:h,:r six vaccinc gtonps lost-clraJlerage.. Group .5 had
t:h,: highest AI:?WG

1i (0.94 i 0.2' llss'day), tiie lowest ilicirlcliec of at3r1c.~.mia1 khavIo:r
(0".<,).. the second lc~~~~cst
clezice of coii~l~ (8,<No), ilic 1c3Nvest asicicleaice of overall c.Iuzica1
syniptotn s (8 '<No). tlie
lowest mortality rate t0%3, the lciw<st rate of nasal shedding o~l' .PC;L'2
(8.3%), ilic sec('ald
lm.z-cst ra-tc li.~.r meas) % lung lcsioais (0.68 -. 1.15%) atirl ttic lowest
iiiciclcsicc :ratc fo:r positive
111C: usst3c:ci (16. htt In another aslx;c.t of ilic, proseilk i.zrvention,
tlic lL''ll'D crl'a 1nrt;l dnso com.011tYona:l

produel that is ptrtiatlv pYtriliid PCV2 ORF2 (vORi'D antigen in ilic CDCD pig
iiiocisl in ÃIic
face of a PCV2 rhalli~nt
p was determi-aed. Of tli4 ÃIirce grotips that reccik ed varying 14 v6s
of e~OR.Fh antYz cn. Croup :l (16 pag of vORl ?) Irfad tEac highest level of
protection. Group :l
oxatpuf:ormed Groups 2 arict t with reslaect to AMG, tucan. % icirag les.iu s,
and THC-.

2:? Grcf ps 1anci 2 (8 ug ~.~("vORF21 aitigc.ra) pa;s#ormcd 4FltkaIly svitlt
r4sp.:cÃ to overall isiciderYc.:
61

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
of cli.n:ical si"txlptc?txls, Croup 3 (4 ~.z;- of aORit 2 ant:igon) had tlle
lc~-'vest :a1lortal:ity :r-me, fulcl a1<l

throe igroups pirl'orinod Qqaall}~ As,-itli r..spet;t t~.~ nasal s1Lidt1iiig.
OveraII, vORF vacciiLis tli.d
ricat pci-(ortta as w01 as ttlRF vacci es.

In yet another aspect of the pr ctit invention. flic efficacy of a maxim.t~rn
dose or a
> ''mÃ;/:? close Conventional Ki:llcd PCV2 vaccinc in the CDCD pi,; ttaodcl
ir~ the i'acc oi'a 1'CV2
chalJct~gc ~vas dctcrmirtecl. Of the s,.vcn vacci:ncs cvalu.tt:.ci in this
sÃucty. the killcd whole
cell PCV2 vaccine potf~~i-i~aied thc worst, Piglets rc.c<iving, two doses of
l:ilk;d whole cell
.PCV2 vaccine had the lowest ADWG, the sccotici higImst r.tt:. (.-("abnorrnal
Wi.tl icx

sccoairf hig
,,,hcst overall incidence of climcal sA anptcsans (58.3'r ), tlic highest
morta.lyty ratc
the sccond higlicst i~icidcaice of aiasal shedding (4I. 7"ro3l, highest mLari
lting
lesi~ins (9.88 ~29.2~,t,).. a high incidence of tut7g lesions noted (75%) and
araoÃ3:c:ratc 1N:C'.
isicitlcrice ratc in tisstxcs Holvc-vcr, it as still cJfccti-ve at invol;ing
aal islgmune
tvslannsc'..

bi ,ti11 "motlr,::r aslseuÃ OC tlr,: prc.sent it7veaitiot7, masal shedding
o:Ã' 1'C-'V2 w as ass+:s,,c:Ã3.
1i a.s a1l cÃlicacz parallieter aiid the prcviou_s PCV2 effica.cy parameters
from previous studies
%v~e:rc rw.coWinne cI, Results from this snAy hiclicute that tzasal shedding
c?1' PCV2 occurs,
follc3wn1g intr-a nasal c1la.llcntgL a.r1ci tliat PCV2 vaccines reduce nasal
shLilciarltj of FC.'.V2 Iac'st-
ch~allejlac. k'urthemroaz, azsults t3-o:1n this staxcly. aaicl reports in tltc
literature indicate tllat TI-1-t;.
s1ic3tlicl cozitiizue to be e:vula:tated inÃ'ut:are PCV2 vaccizie triaN- as
4vcll.

htl Sortic: fadclataoxial conclusions arising .l'rozn this st~idil are that
lyatlplladollt?patlly is Ozic:
of tlie hallmarks of PMWS, Another orie of tlre hallmarks of l;'M-WS is
lymphoid deplction
and in tilEiir~scl4atetlf"~ it3nÃ hisdim~'tes. Additiont311y, iio s3da.ers4
e;e-ats or in1jeGtiori site
reactions wcrc noted for ani, of i1i~:. 71'C LF2 vacci.nc:s ancl a1l 7.l'C;V2
vaccines aptx;ared 1-0 be
saic, wkn admirwstcr,;ci to younta pi;s.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
k:XANIMP:l.,k: >

"I"liis c.satrplQ tests ilie efficac,g Lif ei.zyht PC V'? candidate vacc;incs
aiid rouxiJ'~anYic
}'fW21 cltalle: gc pir.anxtcr4 1'tc~~~.-~ c.trlicr challe: gc sÃtlclics
f0llcawilag. cxlxasm-c to ~i, virtalcat
~ strain of PCV21. Oflie hrtndrecl and fifty (150) w%se'can tlerivcc.i
colosmun d<priv<tl (CDCD)

lyiglcts, 6-16 days o:F age. 4x:erc blocked by wei:ht and ranclomly clie,idccl
iro 10 g+-oraps Of
,.c1Ata1 size- '1'ablc lÃi sets forth the General SÃt+cly I)c it.. for this
Fxamp:lc..

Tal31a.~ 1.6. f,e.f3c:ral Study .l;}c:vÃ
GrouI.~ N'c". Ot Treatment D<3i- of :KLII.It. FA Challenge PRJ~SVN4.cropw
Pigs =,'Tre.3tmem ouOa~ 22 witii mz ori O<r~
aiad Day 28 VirLilesit Day 46 50
PCV2 O:1l
Day ''i
1 1 h PVt:;" '4't3.ccim 1 C? & 14 + -
16 ug
[ORI:'? IMS 1 314'=,
2 Ã l~
? VC'' Vaccine ' f}~- 14 + +
16 1+42
v ORF2 -- Carhopol,
~ 1.5 PCV2 V'acc:ine 3 d) 14 + + ~
16 m
zORF2 - Carbopol

4 ) i PCV2 Vaccine 2 #} + '# , -,
Ã Fi lr~
lt).Ã:.Tj? Carb~tapc?lÃ
1 i PVC2 Vaccine i 0& 14 + + 4-
4 lrl;
rQI~I~ 2 -- Carbopol
6 15 1-'L'('' Vicci.rae ? f? ~ 14 + + , .
l lfg
rOR F' C'arJx., z
pol

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
7 1 i PVC2 Vacc ine 3 d1 ~.~: 14 +
ltc;
tOliF2 Cat-lacaPol

S 15 PVC"2 V'a.cci.tac 4 t) & 14 + + ,
> 8.4# log
KV --- +C arbcipo1
9 cIYalle:t~'go N.A,
Controls
,
--------------- .................. ----------------------------------------- --
-------------------- ------------------------------------------------- --------
------------ --------------------;
~- - =
1 tA 15 None - Strict N/A
N egative C'oait rc-~1
CGt-c.~ztl~
---
-- --- ---
i'41k~t ~.C. = 3,aC?l~ki~x{ .iY':Zl OR}. 'L t0k'l-2 ros[lY?1bE1Yiii1F
ITZL:i:343.'fYlF.a o\pit,a;i't:d ORF L KV orkF3.lod
v,hr,le 'A1 virus = 1 4,:ti 2 irtas y rr,ENll az-l szaitable i~Il citltttre

Thc v.tccitie fbtmulati~.~ns given t~.~ eaicli. gr.~.~tip were as f:Wlows.
PCV2
> Vacc:iitu No. 1, aa.clmin istet-ed at 1~2 ml dose to Grottp l, was ahigl-t
dose d 16 ug/2 rn l closu}
of inat:tiva:tocl res;.onll=<ainatlt ORF2 antigen adjIt.xvanioel witli .1MS
1':314 (16 v(-)RF:' --- lZ4'S,
1') 14}. PCV2 laacci:~ic N~.~. 2. .idtiiin istor.ecl at lx 2 ml cls~~so to
Group 2., was a lrigh dose {lti
lfg;" an1 (lose) of apartial.ly pturaiicci VIDO R-1 geticr-ite(i PC:V"? ()RE,
antigen adjuvanted
at:li [:aÃ=bopo.l ÃV, Eag vORF2 -- C'artxopol). P("V'2 Vaceiyge \o 3.
adtnin;st;::t-eri at 1 x 21 ml

l(l dose to Group 3, was a high dose (.16 aÃ;/2 nil tlose) of inactivated
recombinant [)Rl~=2aat#:i<Fejg
adtlfvaygtLd witti t.arbolol (:16 g rORF2 -- Cat-tx-spol). PCV2 Vciccitie No.
4~ adanitiistere.tl at
1x 1. :nil dose #:o Group 4wa, a la:i<Fty dose (16 at; f.l ml dose) ofa t)
artial.ly pti:rirt,:cl V.l.l)O R-
1:GtiGrated E'C:V? ORF2 antigen atfju.vanted tvitJi Carbopol (16 tig 0-
(.)17l~=' - C'.arbopol).
Vacciaic No. 5, idani.~tistcred it .l x 2:tnl dose tc.~ Cxrottp 5, was 1 4qpC
ml dose o.t' aii

15 mactiv:3ter3 rw.comhi:tlatu ORF2 atitigezi acljuvaizter3 Nvith C'arbopol (4
ug r()Ia.i'2 --- Carbopol).
PC'V2 Vaccine No. 6, adtiiiziiste:rcd at 1. x 2 ml dose to (_rr-c.~up fi, was
a 1 ug:"k ml dose o.t'an
izixctivatcd recombinant ORF2 atitige:a a.cljtay-wltcd i6tlx ('xrlsopol #.l ug
r(3R.1 2 - C:ar-bopc.~l).
.Nt'.V2 Vaccine No. 7.1 administered at :l x 2 tiii dose to C,roup 7, Nvas a
iou. dose {0.25 ug,2
64

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
ml dose) of i.nactivatcd rect?nrl'ii.nazrt t7RF2,mtxgezr a(ljm.~am-cd ai: ith
t:'a:rbnpol (0.2 Y~~g rORF2
Carbopol). PCV2 Vacc;ine 'fo. 8, tichrYiiiisEerid at 1x 2 ml dose to Group 8,
ti.as ti liiglr

clcase (larc-inactiv.iii(y titcr > 8.0 lot;.,21 n.l dosc)lnacti.vatecl
Cometitional Kil.lecl V1DO Rrl.
mnwrat+ el PC'V"I Strirvc antig+ n acljj nar-ated with CarEopol (-=8.0 log KV
Carl3opol). 011
> T3ay~ f}, Cgri-y las 1-8 4N:crc treated with their a4signed vacc.:iacs.
Groups 1-3 .uici 348 i-ec.civecl

boosters of their respccfiec v.tcc.itics again on Day 14. The c#'fectiveraess
of a s:in.t.),ic cl.case of'.
16 wTo l' vORF2 -- Carbopol was tested osi ~irortl~ 4 s~~lli.~lr did not
recoize a booster on. Day
14. Piglets N~~crc observed for adverse cvcrits and rtccticyn ,siÃe
reacticsns #."o:llcawi:[ig both
i-acciygaticsar-s- t.)ti 13ay 21 the piglets ricre moved to a secotirl study
site where Cirotips 1-9

1 t~ wLi-c grolfl> lioFasLci in oiic bui1cIiiig aygri Grorip lt) was licsaisGd
in aszclmratc brtilcliiig. A11
avccivecl k-eyl;o.lc, l.iiiil.?ot lAemocN.amftt emaa-lsfflicel witla
incomplete Frc:~i-ndYc ad~~~N.-am
(ILl,.I':t/TC'l;'A) osi Oai.s 22 a:tirl 28. 011 Day 2:5, Urou-l)s 1 t9 im-erG
challenged with
apla.roximately 4 logs of viru.letit .l'C'V 2 ,vir7.rs- Bz- :C3ay 46, very.
few c-lcatlis 13ad ocennerl i-ti
tlae c:ha.llea},
'e coa}tro.l grr,up. .in "m attcnif.?#: to Vttaimmos#:imtcla:t, t11c f.?igs
aa}cl increase tlte
1i virulence of the .E't"V2 c.hall<nhc :aiaterial.. all Groups were trcat<rl
'vz.tth I.NGr;T_.VAC.~:~
.NRIaSV NIl'_.V {Forc>rize Rclwoductive aricl.Respi:natory Vac;cMa:. Modified
Live Vrnts) casi Dz~~~
46.

Pre- a.r1d po5t--clla..lksige blood samples ~.z-cre collected .t'Oa E'C V2
scrolc~gy. Post-
c.lzallenge. lxAe w-eiglit data for determuzation o:t' average ctaily weight
g53izi tADW(i;) and
htf observations ot'clinaca.l signs avere collected. 011 Da~ '50, all
sarz.iving pitg's were xiecrt~psae:el,

gross lesioiis 'were recorded, Izflnt~~s wcr~, scorccl for 1mtlrolc~gy, and
se;lectc-cl tissties were
preserved in Rmnalin for exa#taiiis3tiota ba; (ItfC) for detectioji of
I'C'Vw f urtigen at zi later clate.

2.?

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
:,\1mc:rials aaid >~.letllmls

'I"lii~ A-~-as aPartially-blind 1easibilit-y' study conducted in t~DC'D
6 to 16 days of .igc on T3ay t}. To l.xe iiac:la.ci:;ci in Ã1i:; study> PC'V'
IFA ti.t~ts of sows
iscre ~, 1:100{3. Ac.itl:itaonal1:yr Ã11c sorologic sÃtat:iss of'aows wei-<
fi~oiai a known PRRS_nega:tive

> hcrcl.. Sime,;ti (16.) sows ~vcre tcstcd for PC V'Ll scrcalogical status and
all sixteell. (16) Itacl a
I'CV2 titer oÃ' < Jf)t}tl ar~d N~~crc transferred to the first sta:cly site..
One lauriclrecl (af.iv {150}
piY.~lots'u<e-e delivered by e~e>:tan;an S~;s;.tionsisq>eri anel 'c;><ee
available for t1iis studv oti Da1v
~.~. 011 C.3ay' r:t 150 f':C3C-i3 pigs at the first staciv sitc ckcrc
svciglied, idctiix(iwcl cvitla car tags,
blocked t3N wcit;ht a.~id ranclcsanly assiolneii to 1 of 10 ~,~:roaps. as set
Ã'orth abmc in table 1.6.

1 t~ Blood saiaiples were collected fs cssii '111 Pigs. l.f any test asliai1a1
meeting tlle inclusion cratcr=ia
was enrolled in the stoclya:nel was Ja#:er ,xcttctieti for aa}v mason. the
Inves#:i<Fator aa}tl Mc-~iiitoz
coaisuJted in (Yrtler to detersui:nL t:1iL uqe of data collected fs cssii the
aarisua.l in i.lic fiygal anali ~is
Tlic c-latc of which cii-ral-lcc-l piglets were ex;,luÃi.ed and the reasan
fear exclusion tvas
cloctcmvn#ed. Nea,eaNvs n}ectÃal-V the inclusÃon czit,:ria.. se:lvct+:cl .Ã'or
the st:~idy anÃ3. transported to-

1i the first study satc were exeltadecl. No piglets were c?;Ultided f'rorn the
study, and i1o tcst
asiimal:~ ~N'-e:r~ rw.moved li=oaii the stticÃs~ prior to tersiiaaiatic?ii.
Table 17 siescrilxs the trrm
fi~t~mes f<ar tlie key act:ivataes ol'tlus

Table 1?. Stxtrlv Activities
--------------------------- ------------------------------- -------------------
-------------------------------------------------------------------------------
-----------------------------------=
Stu& Dav Artual 13atcs SWtlv Artiy-itz~
-------- ----- ------ --- ----- ------ ---- --- ------ -
3 4-04-03 Weighed pigs, health c.x.ant 1111dt?rnared tc.i gs'taups. collected -
------- ----- ------
lalocsd~~~ia~p
------------------------------- - -------------------------
l.cs ---------------------------------------------------------------
3k =1-04_0;-{
0-21 4-07-03 to [)hs,:mecl .Ã'ir m-crall health and f-"or adverse events post-
5-27-t.}3 vacoan.ataon
El 4-07-03 t3kiiiiiliistcs'ed respective l.VN to Groups 1-8
4-07-03 to Observed pigq I:or ir.tlectioes site riactiolts
o-".' 4-14-03

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
--------------------------- ------------------------------- -------------------
-------------------------------------------------------------------------------
-----------------------------------
I4 4-21 -f33 Boostorocl Gratrps 1 .3. i-8 witli rc.>:[caivt; IVPs; blood
sarti31.ed all ):i gs
14-21 4-21-03 to Obscrvcti pios Ã'o
r atYjcciam xcactiOTAs
------ ------- ---- ----- ----- ------ ----- ----- ------- --------- ---------
---------
1 9 :' l 4-2603tc Treated all pigs with antibiotics 4-28-03
--------------------------- ----------------------------- ---------------------
-------------------------------------------------------------------------------
--------------------------------
2:l 4-28-03 Pigs traygsloried fs csrii Struve Labs. 131c, to 4Ltcrfnars
Rc::t?~~rccs, Ia-tG,NRi;t
22-50 4-28-03 to Observed pigs lbr climu1signs pcasÃ-c;hallcritgc
22 4T,.~?-t}_~ Treated C~rc~~t ~s 1-I0 wat1i KLI-UIC'1 A
?-i 5-021-03 Collected blood saniples l:ro:rn all pigs: weighed all Pig5,
challQrc~lfljcz 19 -,\ iiIi PC t"' challe m~c anateria1
------------------------ ................................................. k --
-----
~'t " l)~ t-_~ Tr~.ri~ci ~tc~a~ l 1It t~ }F13 }tiT H.lC1~A
--- ---- ----- ---- ----- -----
32 3=09 t}:> CoIlc toct 1õtlcaotl samfalcs r~-~>tllr.ll Pth4
--------- ------- --- ------ - ----
t~ all. t>rc~~t?s
46 5-23-03 :1(hiiinrsterecl 1NC3EfrVAC':i. PRRS MLV
CoIlc,eted blood sa.mpl<s, ~vctghcd aiid necropsied all pigs-,
>#3 ~: 7~t#_t gross lc.;:i~stis ~s;~re ~-o;.orc.iec.i; lungs z~~or;~
ove~It~Att:e~. for
l~ sinr~s; tra :Ii aiid fiomialari fixeki tissric, samples were saved:
lst -li (G l,t~~tse=" c~f tl~c .kt~ci~

F'ollowin;T completion of the in-li.i'< phase (il' the study, for=m.talin
('i3cc.1 t:isst.xcs wore
exaniincd Iay ira~t~~ttra~~l~istca~.l~~t~~istr4 (IT-l:ty') for dctcction.
of'}'CV2 antigcn. by apatholca~.;ist,
kil<r~~tl satrrplet sv<rc evaluated for PCV2 acrolc~&v> aiid average ctailv
4N,cigl-tt gasa (A0WG)
"-as clotormin<tl t't-oi-ri DaN= ?; t(i Day 50.

Anii:n.tls wer,; hoa.scd ca Ã1rc.Ãir4t sÃticlti ~itc ii-i individual cages iII
scVc:$I r0c3l:rrs fz(Y.11).
birth tcs appresxim atLlN,. 1.1 ria~''S Of a=0;c [' a1)l)rt?airiiate1y Dai~ 0
oi'the stutt~, #. Each roorii as
gder3tica.l in laYou:t aiid corasgstcci of stacked iyuiia-idfial stainless
steel cages wit:li heated aald
filtered air Supl.?J:iecl separ-atc13 to each isolatioai unit. Each rooai7
laad s,:pa:ratc licat aiid

t11c:teby Iarei-eait:irig cr=wss-Gontamination oi' air betvvccri resonis.
Arlfanals we:t-c
boa:tsw.cl izi tw-c3 di.t'Icrent bualcliaigs at tllc "ecc?ad study site. Group
10 (Tlzw. Strict acgative
c;oaitrc?1 grotip) Nk..t;; lic?it;,c.cl separately in a conve:rtecf nrrr;;er-y
bitilcliiih a-ticl Groups 1-~:~ u-c:rc
liottscki iii acc.~.rtverted.farrowim, bixilclmg, F'aUl~ group ,~was hou5cd .m
a scparate pc,:rt (14-15
pitg~s lxr peail and eac~li pw.rz provided approximately 2.3 sc.Iuure:fcct:
per pi& Groups M. 4 aiid
67

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
ct.' d4'eX'e pi:'~nilt:d in Ll3.rE:i?~ aCUlFIut3t pLI3S C33'l i?ne, S#dL i?l'
Ã11e allUl 34'tll' #lild GroE1}'SS 1... 3. Y, 6, 7,

aiid 9 were pcimcd in six aeljaconÃ peiis oil the other sidQ of tlie, allG~vvi-
<3y. 'Ih~.. Group
separation sva4 clue to conccrn 1>~: the Study Monitor Ã1iat to ~'~t-carips
21,
4, and 8 had si:oÃ bccsi fully inactivated. lvac:l~ pen. wzis oii att
clevtaÃed deck with plast:ic slatÃed

f'l~.~rs. A pit bclow the pens scre,ed as a holding tanl: for cxcnrncrq, and
wastc.. Each
building b.;td its own scparatc beaÃin~ a-tad ventilation syst:;nis, wiÃ1i
little :likelifasoc>cl of crci44-
c.ontaminaÃion of air tn::m~;~:~1 iaiflildinr.~->:.

At the f ir.sÃ sÃticlv site. ~~i~lcts {rcre fed a. specially for nulaÃcd 3nilk
ration fzoill 1>irtll t~.~
approximaÃLli 3 wecJ;q of age. All piglets ivere consunfinÃ; scsl:id, special
mixed ration by,
1 tl 13ay, ? 1(afaproximatel> 4 F.=; wcel~-s of age). At ÃliL seccsaicl stutty
site, all faiÃ lcts were feci a

cus#:om ~~on-aatedicatcel commercial anix ratioa} appropriate for tlicit' age
and ivelght. ad
,rhriazrra. \'a';tter at botli study sites vvis also available od tihizffm.

All test pi;s, uerc treated witl3 1.0 tilL of NAk'C E1 , 1k1_ i. altcrailÃ:iag
harns on
Da3s 19, 10.. and :'.#. In addition, f7i~ N0
. 11 (Group l) wns #:rea#:ed ivitii 0.5 a-tt.L of
:'~:k~:('1n1, ~ 1zM c.~si Daz lfl. Pig No. 13 (Group 10) wis ti-cated with
1s7iL ol'1'csi:icil.lizt and 1
ml'_.d' PR1=n:DEi k 2X oai Day 10, Pig No. 4{C3rori~ ~)) was trcatcci ~-v~itlj
i.O ml, of
\AXCEt,, IM on Day 1 l, t~iicf Pigs 1 (Group 1), 4 aticl 11 ~ve.n;- eacli
treatetl dv:iFh 1.0 a~.-iÃ, of
''~ AX['1==UX c?ji l~ay 1.4 fo:r various bcalÃ11 reasons.

While at botii study sitcs~ pi.;s were rinder ve:terasi.3ry care. Aaiiziial
health
htt csama:tlatxons ai:cre conducted oii Day -:i axid were reco:rdecl on tlic I-
iea.lili Examination
lke;cord FvrtiY. All <3ninrals w-crs in gmoci licalt:li and fliYtti'iÃY~.~iial
sumfls before vaccinfatim as
tleteniiitaed l.iy i.~~~.,ervt3:tioji ota I3<3i. 0. All Ã:esÃ s3nimzals wQr4~
c.~bscrc:ed ti.~ be iii gooii lies3ltli and
ntatritional statr7s prior to cEaallGugc_ Carcasses fui(l tisslses were
disposed ol'bi rendering.
Final disla~.~sitioti ~.~J'stradv~ anirn.ils was recorded or~ the Aninial
D:islositif-m Record.

2:? 011 Days 0 and 14, pigs assit;ra4cl tci Gsoups 1 -t and 5-8 received '.#)
rsiL. of assigiicd
68

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
PCV2 Vaccines 1-4, r-ospGcÃxvcly, l\M in tlre r-aA;ht a:ard left :areck
rc,:xon. resp,rci.ive;l~. lflsirig rr

sterile r.(1 iiYL Luer-lock stiil~sc aiici ti sterile 20g. s'}" m..tllc. Pigs
assigned to Gr-~.~Yrls 4
received l.t} rrt1, of }?CV21 Vacr.iric Nca. ?, IM. in the riglit rrccl:
region tmirrg a stcrilc :t.t} rrt1,
L.ire.r-los; l; syringe iirid a ;:teril< 20t; x ' ;" needle on Day 0 crnlz.

On Day 221 all test pigs r-ec.civccl 2.0 rrt1, of Ki:l~-1r'.lCFA, MIM in the
lcft r:rccl=; regiora
Atsi_ng a sÃcrilc 3.0 mT_. l.trcr-:lock syrir~:gc aricl a sÃcri:lc 20g xl"
ricecll.c. 011.Day ''S all tcst p:igs
ret;cii:"Ã 2.0 rir.L. of KL1=II1CF_.r'! in the e-ialit lanl region irsiflrg a
sterile 3.0 iarL. .lutwr=-lcrt:k
sa r ir:it e.uicl a sterile 20g x 1 ' r:rc,.::ci lc..

t;?rr Day 25, pigs assigned. to Groups 1-9 recLivc.?;l LO rriT-. of PCV2 1-
SUV13I,
1 t~ clrallcrg;;e material (.3.98 lcrgEj~ TC'7D=,,,:'rriT-.) lNl in ilrL
rrgllt rrecl, rLgioal t:rsiart; a -sterilL 3.0 aIrL
l-.tccr-locl: syringe and a ct,::r.i#e 20o x 1." needle. :3.r7 additional 1.0
mL ot't11e same zrr.atc.r-Ãal
was adrtrirristr?:rcd it to each pig (t}.5 rtrll: per nostril) r.Fsrtrg a
sterilc a?.47 m.T-. lar:rLr-lock syringe
ar1d, amsa.l rr.arur.la.

E)n Day 46.. all test pi_vs r~:c~io~c.Ã3. 2.0 a~71-. 1-~(~l.i,k~~.~C~. l~l~.RS
Nl.l~-.~~ . l'~Ã, in tir.c right
1i aicck regrc?ri using a sten.le 3.0 iTr.l: Lu<.r-4#lock sy:r.iaihc aritl a
stenle '?t)h x l" trecdle. 'T'lie
.NRIaSV ;Mln.V was m aai attcrupt to izicrca,se virulence of llzw PCV2
challenge
aiiaterial.

7.'Lst pigs wea-c observed kla:i1y for c?ycra.ll health aaid adverse events
c?ir. Day -'-i atrrl
f'rc?m Day 0 to Day M 1. Each c?ftlre: pigs were scored for zioazrr.a1 o.r
abrioa=rixal 1avic?r,
ht~ :resp:ir-ation, crr- cotrl;ll. Observations were recorded on the Clinical
Observation Record. All

test pigs -,vere oEasirved frcrrit Day 0 to Day 7, and ~'srotr:p 7 t~~-as
further observed frcarYr Day 14
to 21, for irxjectimi reac,tions. Aa.er=s3g4~ ds3ilv wei4rliÃ: gt3i-a was
deteritairied E.~~ w4it
ghing

orach pig on f a ctrlibratc:d. su ale crzi Day s -?i and 50. or on the, df ai,
that f a pig ~N f as Icrund dead
aficr c.lrallcrrge. Bcrd4 4Ncigltts tverc recorded cYri the Br.~d}- Wciglit
Forrta. .C.3ay, r3 l;aody,
2i weights ckcrc titilizcd to block pigs prior to rasrdasriintimr. Daa ?5
stricl I?ay 50 sv..iglrt data
69

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
~N:as wiJind to dcte:rmino the average dfailil weight L-Yfaixi (ADWG) for
eacll piA;: duri.n4~ these

thii.. pvitLts. For pigs that tlicd a-Rcr c;haIIcm~.~e aiid before Day 50,
tlic ADWG i.v. as adjiusted t~.~
r~~tcsom the NDWG :Ã:rorn .C.3ay' '25 to the day of cluala.

In order to determino PCV2 s<e-olol;y, venous whole blood was collected from
each
> piglet from the orbital evious sinus oii. Davs r t ancl. Ã 4. For cach.
piglci, blca~.~ei was collected
f'rcym. the orbital ve: oa.s sititis by inserting a sterile capillary ta:t~,:
:iat~.~ the rnecli.tl c..uithtis of
oiao of tll< ~;z os and draining approximately 3.0 n1L of w11o1o blood into a
4.0 i1iL Sentm
Separator Tube (SST). On Days '25, 32, aticl 50. aenoAts who:le blood f'tcat-
ia each pig was
collected from the aygterior a cyga ca:s~a. usiaigo; a steryle 341g x 1' a"
Vacuiainenk. srcedlL (;Bec:tori

'I I~ Dickinson aI1d Ct?!)gl?aIly. .FraI1ldF91 Iõ1keS, Nt;w Jt;T"sL~S'), a.
''acCl.Eta9l1e1,!~ Bl<'.edlG 11Ctit1t;T" and a

13 mls SS'I'. Blood colle.ctÃons at eac.li tinie point sxere recorded oii tiic
Sample Collection
Re.cord. Blood in e.acli SST was allcsived to clot, each SST was tlicyg spun
dmz>n a:ti(l t:tic
seniiii ban~,:,t,:cl. &Iar<,-csted scrum was transferred to aste.r.ile. sma:p
tube and stoavd at -704-:
1 0 C until tested at a latez clate 4enum samples ivez,: testecl .l'or the
presence of PCV2
1i arliil~aclics ls~ 1~1lrI-~~~ 13 I3c~ 5t~r1~~<1..

Pigs werw <ibsw.r~~ed once (taily li=oaii Da-v 22 to Day- 50 Ior c.luziu1
syznptoms aaisi
scored for m:ranal or al~iion-nal behavior, respirat:ion or cc?afgll. Clinical
obs.c;rva.tic3lls were
reUo:r~-led oji ttic Clinical [?bserva:tion Record.

Pigs Nos. 46 (Grre?a:tl) l) uticl 98 (C,roups 9) diecl at the first study
site. Bc3tli of'ttiesw.
htt deaths wGr~:. c.atcgorind fas 1?leecli.n4~ deaths and neornpsies wGr~:.
iiot cnndnoteel oil tlic:se mo
pigs. At the second studv sitc, pi~~s that died al~e.r-- c;J~<31lcitga~ and
pric~r i:c~ Day 50, ~~i1cl pi~,~s
euthanized ota I3<3~ ~,O, w-cre llecropsictf. AnN' grms le.siotis wer4~ sioÃed
aiid the. I.,crc.ciitagQs of
luacg lob;s ~Nli1l lesions ~Nc:rc recorded oac the Necropsy Report Iin:rm.

Frorn each oJ' the pigs rae,cropsicd ca the scc.cand study site, a tis4uc
sattalalc of tonsil,
2i lurag> b4strt, arad rtiesortteric Jvriapli riocla was placed isiÃo a
siiYt;~la; oositaincr with but.f4s.:ci :lM

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
.1'ormat.ixt Avllik ant?ther tissciiz sampte froxia ttic gum al:orc:mentionc:d
ort,:~aas Avzis placed into

w<3s pltrceel on
ic.c. Facl~ c:o~~t.i~~:~~ r. s~ as laro~s~ rt4 la~b l~ cl. Sa iple collections
were rcc,ordcd~.~n the Zlccr~.~psy
Rclror[ I oem. o>:tic R+ cltxcst I~?ts~~.

> 4N'Cre stIbt3littC4d fCa3' IHC tct't3I3g. lHC ÃCsÃi31g 4vs'ES ~ondE1ctcCi
#tl accordance w3tll Sts'#1l.(ia#'(1

labmatory Proccdums for r.eceiviag samples, san:~plc and slide prepatt.ttiora,
aticl staining
teduliqiscs. Fro-Qi lisst.xes in ~Vbie-l-paks k: were shi:~lat;~Ã with is;,~:.
packs to the Study Monitor
for stcaragw (-:; t)' -4- 100 C) ard possible ('uttin u4e.

Foranalin-lixLci tisstxes im-erc examined by a pathologist for tlLtecti(mi of
PCV2 by I.II:C
1 t~ as)tl scoretl 11sin;; tiLe 1611oaz-ing sccsriyg;; si steyti: 0 -No~ic;
1Sca.rrt lxssytis~e stainiygg. few
sites- 2 = N-.tode:mte: positive stainiat<F. ai7Fattiplc and 3 = AbtinÃ3.mt
~~siti3e staining,
tliftixse throughout t:tic tisstFc. F(yr analitical plfrpmLs. a score of 0 was
c(misidered
negatÃve.>, aairl a score ot gre.ati:r than t? was considered .posittre.,>

1 ~ I~csult5

Resutt:s Ãc?r this iNairiple: are giveai be Iow-. It is noted t:liat h~s No.
46 <riirt 98 died c?ii
days 14 ~~id 25 rLslaec;fiz<Iy. These deatbs were categoaized as bIeecling
clLtitlls. Pig No. :11
(GrOtrp 1) was 1~antiT~g'~I-ith rapid respiratior1 c?ji 1_~ay 1-5.
()them~isc.. all pigs were nomral.for
Whavior, respiration aticl couggh during this c~bwrvat:ion pea=iosi uticl zio
systw.izfic aclvea=se

htt events were noted with an~ grotflps. No U~jcction sito reactions were
ximecl fotlowanb
vaccination oii I?ad 0. FoIlow-ina vfacs:mation oit L14, seven (7) c?zfll ~.~1
foutesfli (14)
Group 1pigs (7~lafsd miellin~,~ N~~itli a sc.i.~r~: o1'..~ " c~ji Day l~,
Ft~tir {4) out ~~rfotme4~ii
(14) ~s'rncip 1(28.0,~) still Iiacl fa sivell:in,: cyt' "2" on Day 16. Nn:aie
of the other g:ror7ps
experie: ccd i_ jcc.tican sit:; reactions (ollowint; eit1::er vaccim;tticx .

2:? Averava: daily ckei~lit gain (ADWG) resxttts we lyseserYted b..1~.-~w irt
Table 18. Pig
71

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
Nos. 46 ziacd 98 that died t':roni btud:cnA;. Avere exctudc:d from groisp
resu]Ãs. Group 4, 3s-Eaich
received oii~-. dose of 16 cig vOIU''? -- Carbopol, hti(i the highest ADWG-
(1.16 + 0.26 lbs/clay.),
(ollsmvec.~ ba Groups 1, I. :-' ), 5, 6, ~i-tac.~l 10 ts-hicla had A1?WGs that
ranged. from 1..07 ()'")

lb,&tdt$y to l.ll ~ 0.26 lbs.''tl.at. Group 9 had tlic lowest ADW~'z {0.88 ~
0.29 lbsr'tlay),
> follsmvec.~ 1>~y Gr~.~cilas 8 atid '?. wliir.:li laacl AD"-'C~s of 0.9~3 )
A. tl. 3~33 3 lbs;'clay' and 0.99 - 0.44
lb&aday , msp,;cÃivel:y.

Ta:k3le 1X Su~~~nutry of Group Average Daily Weight Gains (AOWG)
Gr~isl~r 'TB'e~~tfl~t~;~~t: 1 AT~L~ Ci lli~das
(1?ac ?i to ti3av ?[3) or acljuawd for pip
deacl bLfo:rc Dwt, 50
t rORF2 - 16 ag --- IMS 114 2 doses 14 1.08 m 0.30 lbs/dnv
2 ~ vORF-2 --- 10, ug C'arborc)l 2 dt?scs l~ 1.1 I 0. 10, lbs~clav
3 a0, R k T2 16 t g Curbopc?l 2 doses 14~ 1,07 0,21 lbq/clav
4 ~l-).12F') 1 fi ug Carb cs~l :1 cl~s~ l~ 1.1 fi ~ 0.26 llis:'~~la~>

l,ti7 0,2 6 lb,, ,'d aY.
i K.)RHI 4 p:g Carbopol 1dose 1i
------------------- -----------------------------------------------------------
------------------------ ----------- ------------------------------------------
-----------------------------------------
fa K?.lil~=2 - I l.i<F --- C'arlopol 2 doses ]. ~ :l .:l ]. T 0.26 lbs"clav
------------------- -----------------------------------------------------------
------------------------ ----------- ------------------------------------------
-------------------------------------------------
7 r0Rl;'=2 -- 0.23 gg -- Carbopol 2 rloseq 15 0,99 W 0.44 1bsiday

~ KV t- S.tl log - C'arbo~-~l ". clcases 1.> 0,91 031 11.~4/ctav
9 cha1l<nl;e Cotllr(lis 14 #3M ~ 0.29 lbs/dav
1SEricE.Z1egafie,eC't~~~tro:ls 1.5 1,07021 11.~4/clav

Ni.x3::(:: = ktTE<fied viral ORF2; f{?R1?2 < rti.mii#aii3aaiE
l,rci:izlo'Jria:i ti.xf1mi:3e:1 [?}LÃ{y; KtJ or l:ilÃti.d
1~1 v~hr,le x11 virus W] 4,:t%2 irus grr,ENll inszaita9-,le wll citltttre

PVC2 serology restilts are pa=wse sitw.cl belm, isi '1'able 19. All teai (10)
grc3up; 4vea=w.
72

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
set-on,i,tatave for PCV2 on Day ---i, On Ozie: 14. PCV2 ti.ters remained
loi.~~ for all ten (10)

grottps (raiige of 50-11 i). 011 Day 25, Group 8, v0iic.h mc.iiv..tl Ã1i.. w-
holr- cell killG(i virus
l.icc.itie, had the lvigh,.st PCV2 titci- (4017), fo:llca{recl by Group I
which t-eceie,ed 16 ug
,v4:3RF2 C'arbopo1. Group 4, which recoia ed as single dose of 16 ug a0RF2 --
C'~irbolat?l, a~id

trrt-caup .~. received 16 ttg rORF2 -- C.tr-bcipol, ~vhic1Y had tit:;us
of"21'?t}"7, 19210 ~i-lad 150-,
r.e.pectix ely. On C.3ay, t2, (~.~ric 4s oclti post challet~gc). titers for Gi-
orap4 l-Fi ancl. Grottp 8-
e'titt~ged f'sotrl 2360 to 7619: sY=hilo Groups 7 t:0.25 ug r4:3RF2 --
Carl<aopoll. 9 {Ch.tallon~>~;
C'cyntt'cal}. and 1.0 (Strict rwgative control) laaci dkrs or .' 3,82, 1?t1
and 78 r,;4pccÃive1:y, ()tl T3ati
50 (clay of"ygec:t=opqy). all tLn 0 03 groups demonste=ited high PCV2 taters
{'- 12257).

l t~ Or1 l-3a~s s 25, 32, atid .50~ Crr=oFap 3, wbiclt received two doses of
16 lrg rORF2 ---
C-;at=t~~pol, :hacl lylghe:r antibody titers than Gkc?tcp l, ivliicli received
two doses ot' 16 ug zORF?
_ lMS 1314, tlyg 17avs, 25, 12 micl 34. Giroup ?~ which receileci t--sz>o
closeq oi' 1.6 tig z~t3R1;'2<
l3acf higher titers tl3aai Groaip 4, iv.hich received otilz- oti+: does of
i.hc , same vaccitie. Groups

5, 6, 7- which received siecreasim ; levels of z(3R-F.2 --- C'nbc~pol.. of
1.6, 4, 1. and (l.?R u~
1i 1zspect:iv0V, demonst:ratcd cc.~tmsponclinh.iy cfccreamng antibody titcrs
c?ir Dayq 25 and 32.
'T'ablt. :1'). Suanmm~v of Group PCV2 1FA 'fitt:ns

tTrolfp Tre:tialleait DaN, -3 DaN, 14'* T.3av '.õ~~" Ozie~~ -12 Day
------- ..................................................... --------------- -
---- -------------
-------- ---- --- - ------ ---------------------------=---------
~lily l(~ tl 3t~ 4 Ã~ 1C~ t.i2 6j 43 l4
l rORF2 g -
1\l S l.,z 1~i- 2 doses
2 i{).121 ? 1.~7 ~Ã 50 l lf1 ~?~5l?7' .?{>2'' 4f1f1~
Cafbopol 2 doses
td}ll ~' lFj lr~ 5tl 80 l5tla ~.l,~tl C>7?tl
- C'arbc~pol 2 tlt}s~ s !
-------- ------- -----
------ ------- ---- ------ ,
4 ~~Rl"' - lti l~~ 5t1 113 1920 3720 1'' ~7
Carbopol I doge

~ 1ORt .2 - -i' 4tY. -- .a[3 61 1867 3) 9,33 3 4533
Catl;t~.~pol Ã dos~:

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
.......................... .......................... ................... -----
- -------------
-------- ---- ........................................................ --------
----
6 rOR1 hõ 1 ltg 50 70 490 ?360 5740
Carbn ol 2 dcrses
7 af?.lil ~- d~.2? lt~ 5tl 73 ti:? :?8'k -8 1.~)
Carbopol 2 doses
8 I~ ~' => 8,[~ lc~~> C~~rE~~~~l 5tl ;)' 4-~zl ' ;'{'>1~~ 1f~8.17
2 dc.~scs
t3 ~'l:~~ll~.r~u~. ~'catl?tl 't~ l 2'~ 4?~~
~ ----- -------- -------- - -- ----- ------- r_- -
--- -- - =
~tric#: ~c ('r~~7tr~:l~ 50 it3 tiC1 78 1 11205
~13

iC?Rl;'1 i,cla3ted viral x:}R(??; xORt?2 reLom1>inatFi Ãta.iflcivixies
ey:}}re,sed C)RF2 KV or 1:.ille~il
l4'1'3.[~li:~ cell '~'ir3.l' = PCV2 [ d~'LEti ;,Tr[~4i'~T in tiEi3Z:kl~li:~
cell t:il]:ZFlr4:~ .

"For es3lc;zfllat-ii.~ir purl~i.~ses, n'=l 00 IFA titer N-vt3.s designated as
a titer of 50 '. fs s6400 1FA
~ ttÃu was dcshpmte:el as zi titer oF..11180f)".

'kI3<3y of Challenge
Da.N citIN, ccropsa,

'I"he re.tsits froni the laost-cl:mli,.~~ge c.:litti.cal observaÃic~~~~ at'c
prc.entecl bciow. Table
20 inclraelc--,~ observations for .1:t3normal Behavior. .'4.1'<anomlal
Respiration. Cough and
Diarrhea. Table ~? l includes tho re-sults frot1i llw Srtmitiat-v of Group
Overall hwid<flrc:c of
Cliruical Syrnpt~.~rns and Table 22. inclucles i-estkits f'rorai the Sum:snary
~.~f ~'it'catip Mor.Ãal:ity
Rates Poat-c11<tllevlgo. 't'11c incitleac~; of abnormal behavior, respiration
and cough laost-
c11a:llenge weav .1oix :ilA 1mp receiving 16 iag tOR1;'22---1.MS 1314 (Group
1:), 1.6 tcg xO.t2F2---

.15 C'nbol.?ol (Giroup 3), 1. aag r(-)R.l'2---C'nzlsapol (Cirotcp t,). W25 ag
xO.121~24'arbol.?ol (Group
7:#..
and i:ll ial tllL Challenge C:ositro1 Giroup {tIsroup 9). The isicitlcaice of
abnos-mil bcltavior,
x,,piratgon, and cough post c:hn.llea}ge wag nro in pip, rcceivÃng .16 ~~&
Y(3RF24-'a-r=laolol
(Urctaap ', a single closO of 16ug zO.121;2--C'arLopol (Giroup 4). 4 s~s-,
K)Kl;?2--C'ar~opot (Circtaip
5). --S log Kt'--Carhopol (Group 8), asici in pigs in the strict ne;;aÃivc
control ;;:rtiul~ (Group
l t?}.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
':l'lie; ovora.ll incidenc~:. of olinical symcptoms varied bemwen t,:roups.
Pigs reccavi.n4F 16

ug \Ohli?--Carbc.~pci1 (Group 2), a single dose of 16 ~g vOIU-m Ciarbop~.~1
(Gr~.~Ysls 4), and pign
ir~ the Strict. ticgative cotiErcil woup {? t'catip W.} had incidence i~ates
of Et%: ~igs receiving :lti
ut.~ rORF2 --t;:'zetnolaol. (Group 3), and I isg rC}RF?--Carbopol (C'iroup 6)
had iflic:ick-mc< rates of

> 671~d4; pigs rec,a1.ira~~., Ãti tag rOR.l~214\14S 133314 (Gr-raAtp :l) lia(i
.tti raverall incidence raite of
;.lt'JJ,: pi4s receiving 4 ug rORF'~--Carl;a~.~pcal (Gr-raAtp >), 0.215 ug,
ttlM---CarLx)p~.~l dCroap 73,
iiittf >8 la~~,T KV vaccine had inc:ick;nc< rates of l_t.t"4a; and piYTs in
t.lle Challenge Cc~titr(il
Grc~~~sp (Ci-i-raxap 9) had ar~ iriciclerare r.zite of 1. l. 3M

t_?1era1.l mortality rates betsz>een groups varied as iz>~ll. C"iroup 8.
wliicti recei1ed 2
1 t~ (loses of ht' vaccisic l~ad the liaglicst anortality r-ite csf 20 0%;
follo cd by Group 9. t:liL
c1lalleng~ Contrr,:l group. and C;rs?ti1.? 7, which rcceÃv,cl 0.25 i.cg
K)Rl~24'arbopol aa}cl had
mortalitv ratess of :lCa?",i~ and l'. ''3 r, respectavely. Urestx~) k ivhicb
rc.cLived oiic dose of 16 lfgo;
N-()RF?---C'arbopsil had a ti'i.'. ; mo:r~al.itr rate. All of the other
C_irogaps, 1. ', 3.. ';.. 6, axid 1.0,
had a

Table 211. Summary of C;i rtul) Olxsc.n-aticAa~s for AktrgcAt-ma1Bchavior=, A
t3no3r.m;1l
RÃ:spirati0~~, and C;Oul;h P05Ã:-Cl:wlleraV
Geoltp Tr+alm<n.t N .~baormal Abygonnal Cout;lt',
Bollavi.Or Behavior'
1 K-IRF? - 16 ~~- 14 0'14 0114 1 f14
E~,
f.~tS 1.314 2 cl~~scs t'iF. l.
' vC.3R.l=~2 ... 16 tqg ... C'.arlx~pol 0'15 tl;1.
x ({~"')
2 ~, Clo.~ +GS . tk
t~;: -
;:i,~
t~(a
i z(YR-F.2 - 16 ag - Cartxsl3o1 15 011,15 t 361 5 H1.5
_ <)
>~t'r'
~
--------- ---- ...............................................................
-----------~-------------............................................... ------
-------- ~----------
4 vORF-h - 16 la.4F Carbopol t-=15 01'15
~{ r~fr1;1~ t'i}!l ( i 1
.l ~Ã~.~?L L I ~1~if1! (tF~+'U.t
R K?.:\l' ~4li<F 111.1.= (l:'.la
'l~,sa.~'b'L~l)l~?S .l dose [~f 1.iJ~ {ta1;5'l?! tY~~~t1F

z'.1'otal num lser o.l' pips in ea.cii group that demonstrated any
at3r1c.~.ry:n a1 respiration for at least
c~iic~ clav

~ :..1'ot~'~.1 mmitm- tAÃ' Imp i.~t each group tlxlt demolisti-a:tetl acouh.Ãt
1%,~ra:t l<ast c~lle kk1s

Ta-x1e 21. Sr;umnary of CprOr;4 p 0veraEl lrtciclence of t"lirtic:al
Svrttptunts Post-
C.13allc:ngc:.
G a ~~~}s Tz, a# a}e ~xt N I fl~L:icI.~~Ycs of pigs s~~ i tli l~tc,icl.~r~c.s

Clinics3l 'Sa,mpt~.~ms Rate
14 7 Izzo3
1 rC,}Rrt 2-.l Ã4 ta g
tM S }3) 14 ? d~~s,~~ s
vc3R.F2 --- 16 }i<F - C'.arr.opo1 2 l h ~3 t:A (t%"
doscs
3 rORF2 16 lt.l; Carbopol 2 15 1 ta 7 %
doses
4 vf.3RF2 - 1.6 fi.g C ~~r.bc~~as ~1 1 1~ t D t t'j ~
dose
5 rORF2 4}tl; a'3<,
'_, C'tat~~~~,1 1 e}.............................................. ~ ----------
------------- ----------------------------- --------------------
----------------------- ............. 6 aOi~k~2 - 1 lig
L.
C'arbopol 2 doses

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
--------------- .............................................................
-------------- ---------------------------------------------------------- --- -

'{~
i F~~.t~h Ã~.w? 1a4~ --- ~'arbnl~c~l li ? 1; 3
? doses
8 K V . &0 log Carbopol 2 l' ? 1.3 ?" a
d.cFse,,-;,
14 14.3% t) challeng {'oiltrols

Strict \"-at.ire Controls
l ' Ãl (l l}'' '~
zOl:tFw = 3~solsftid viF:tl t'RY2; FOFtl:-'2 = ze..t,3ail?illant
la.tciac?viFus oxpra~;~ad t.&Ã~'.u; KV cst l;ill~.~
,wh{PlC ci'.ll 11C'V-7 Y FS'iIs gFYP\4TF 1IF suitable C-!c-ll i:.LfltE3F'i'.

'7'ot:tl ntFFnlaer oÃ' pigs in ,;acla group iluit clemonstumcd ~i-ta~. dinical
sti:mptom. for zit least o c
Tablc- 22. Stiniinarv OF Grcaup M0iulity Rates PosarChal.lc,~iggc-

Geoup Tr+alnl<n.t N .17ead Post- mo:rt,i-v Rat.e
chal lon~
1. t{?.RF2 - 16 ug - 1 1 t~ (l. (l' N)
M-.tS ] 3l4 2 c1o5co,
h vORF2 --- 16 llg C'ar$qvl 15 ~t t1.0".R,
tloSGS
g Carbopol li 0 i 1. tl%
rORF2 16
doscs
------------------------ ------------------- -------------------------------- -
-----
-----------~-- -- -- - -- --
4 r(3ta.F2 - 16 lt- C'arbopol I Ã? 1 6 7%
(1ose
------------~----------- -- ---------~------------------------------------- ~--
--------
---------------------------------------- ------- -- -- - - - ---------- --
.. K).l*.l''2 + 0 ti.0':,,
t'arbd3 c3l I dose
6 ToS'1.3"'2 - 3 ltg S. ~ t1 (1. 0%
l,'4~tn, at}l L doaes
2 1~ ~",~
7 a~)RFk 4#.?:i ltg Carbopol 2
d.case4
-------- --------- ---- ------
------ ----- ----- ------- -------- =
------- -- ---- -----
j 5 ?f343i'~t
8 KV > 8.0 log -(.arbopol
dCtiw5
<,
9 ~-'1~all~ r~~;L Controls l l 1 4 ,3 ~
k -------------
lt;l St~e~t C-'c~tit~=c~ls 1.1 (i
vORF2 = ztola.iad vizetl ORF2; FC?:U-21 = recozuNFZ7ttt l etc:r~lc?~'ixiF,
eN}vtvta~xl Cal:l=I. KV or Killed
>i'htTl+;- cell V);FIEC = FIt._'j' 2 v't4'LFS y?:CtTSi+32 F32 SEllmbl+;- cell
13wi6Tr?:.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
'I"1i.. S-umm~~~y cii Group Won Percentagc L,un;~ Lesioiis and 'T'e;matrt,e
Ditigiiosis is

given l;a0~.~~,,. in Table 23~s. Group 9. tl:c c.hallcr~ge craraCtol grratap,
had the 1~igfacst pcrce: Ãa~~,e
ham> losi(itls with a itrcasi (?r 1 t).81. ~ '?.??%, faollow-ed by Graiip 7,
which roc:ciN<tl 0.25 rt,>
tO~F2--C.ar.J:x)fa~.~l artd l:aacl aii:w.ui of 6.57 --,- 24..74~1,,.
Cr.~.~tifa 5, Nkfaicli. r.eccivetl. l g lORF'-

C'arl.~p~.~l and had a. irwan of 2.88 W S.88%, artd CTroxala 8, 4N,-hic1Y
r.eccived tflc KV vaccine artd
had a tr1can ol'?.ti1 4 4989%, The resna:initr;' six ((i} groups had loxsor
nrcan perconÃage ltitflig
lesions that rangccf ('rcat-il t}. l. IA-t} iSc' ,', ti) 0.90 tt. l;?%.

'T"entativc cliagaiosiq csf"pneamonia -,'a.ricd a:iiioaig the grolfpq. Group
3. which rcccm~ecl
1 tf t o doses of 16 g ~r~'JRF?-E;arbopo1, liad the lcsivcst tcntatilc
diagnosis of faygcmnania, N%'itli
13.3%. Grotcp 9.. tllc: c1la:lleng,: control groal.?, had 50% of the grs~~ip
tentative:lyclia mos,:cl
witli piictxsiioriia, f'ollowcd by Group 10, the strict siegative control
group and Grolfp'~, iz>iiicli
avcc.ivec-1 tNvo doses of 16 t~g v()RF24_'arbnpol.. witl3 46.aiic-1 40%
rc:sl?ccttv+:.lr. tentat:ivc:l~cliagnosecl wit11 pnC:w7io:aia.

(imups t.2> "f .5. 9, a1iki 10 liacl ff'j ~of' tl:ie group teaitatfvely
diagync?sed as PCV2
inFicted: while Group 8, which received two doses if KV vacciaie, liacl Yli~:.
bi4i iest groopr.3tc
of tentative cliatjrlc3sis c?f PCV2 m-t'ectiom, ~z-iih 20%. Group 7, vehich
recLiz;ed two dos<s of
0.25 t2g rOM-Carboptal., aiid Crtaup 4, which received one dose of 16 t~g
vOR_F'?--t~~arboptal
had tezitative ggroup dia~iioses of f='C'V2 nzfectic?n W 133<No aaisi 6.7";;
of eacli ga=oap,

Gastric ulcers wk,re vrilv dia.gn~.~sid in vne, laio in Cirot7~.~ 7 (671'w.);
wiffle tlic. otlic-r-. 9
or~.~ti:p~s retix<3itied rree of gastric ulcers.

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
'I'abEe 23. Summary of Group Meafi % Lung Lesioti atic1 '.i'c:ntalie e
UiagiBosir
--------- ---------- ------------------------- -- ---- ------- ------
....................................... Group Ir~.li~~ier~t N No. L?i'1a3gs
that sl~ea~ for l~tt,icl~.l~c:e R.i~:t~,

at least one elay
--------- ---t-- --------- --------- ~------ --~--
--------- --------- ,
-------- --------- -------- ----
1 L1 t~ ~'i,
1. td}l~l ~' - 1Ãi tt9-~
1M S 133. 14 '2 clo s t;s
-------- _---- -------~ ---~~-- ----- -------- ------- -------- ------- --
1 1 t> ~' ~ii
' t~~f~ l-'? - 16 u,
CarE~ ~~l ? cl~ss+~a
3 z(3R-l'.2 --- 16 1lt~ 1 ti + 20, 01', '~
Carbo ol 2 tÃos4 s
------------ ------------
4 ~~C3R.F? - 16 lfg
1? 2 Carbc3 pt?t I dose
rt:.tR.F? - l fl.g - 1 5 20 Ã}" 0'
C'at-bo s>l 1. dose
6 l0 l~l k 1 f!r 3 6 1tD.(tt''J,
Ca:rbn ?ol 2 doses
7 t~:)t~iff'? --- 0.25 7 #~1.7'j;~
C'arbo ol 2 doses

8 KV -"' 8.0 1og,- '"' Carbopol 2 dosCS

9 ~'lizil l~.:tit;c. ~'c~ll u~t? ls
1-l .l~ 100.0% -------- ------ ------- 91
a 10 Stric:! ~i~.~,zlt.tk e~:l~iit~-c~l~ 1~ l l ~':: d,
--- -- ...........................................................
................... ........................................... ---- ----;
iX ).}CF2 = isC?lfki~x{ iY:Zf OfZl 'L t0fil-2 3 s.[tiY?1bE1iiiilt
1TZt:1:34A.'fYtF, L\pit,;itd ORl . .: l~V of kF3.lL'd
v-'t3C7te C:Cll v?_ElE's - P{1!..M S lE71S 610i"3k E3k .~f37.!abte cell C1,11l-
t.'1li:
7
The. $ummt3:ry of Grol:tp II-It:_ I-'i.~siÃia.e hic.idenc;e Ri~szfllts i~,,
show-n below in 1'abli 24.
~'z!-ot-xp 1 (16 t~g vDRF: IMS 11M had tho ]owest guot-xp rate or11-I.C
positive results witl!
(t"/"i of the pigs pt.?sitive for I='CV2. :Ã'6llc7wed Uy C-ir(7tip 2 (16 t~g
v0l=:i.F'2 - Ca!=k)pol} aiid

i t caup 4 (si_tiglc cl.casc 16 ug vORF2 - t;:.arbcapol). which IYtlc.~
t.~rcaup ll-:lC l.ti:;4 o:F .tncl
13:3tN} ret:p<ctivelv, Group 9, tllo challengt; co!lt!'ol g!'oup. had the
highest II-1.C positive
int;icl:en:ce raite Nvitl! 100% o:F the pi:s pc3siiive for .l'C'V2. followed
1>y Grci!!p 10. tl::e sm-ict
11"ative eontrt>l gloup. anct Cirt-stip 8 (KV vactrine), with 93.3% antl
StlE'10 oI'tlye pigs pc-Asitive
79

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
for PCV2. rospGctavely.

TablÃ: 24. Summm~y of Group 1I1C Positive iaiciciÃ:nce Rate
------ ----------------- --------------------------------- -----
......................................................... ------- -_
Group it azatailcatt N No. Of pigs tha[ shed l(ai l.nc.idenc< Rate at least.
otac dati

1 rORF2 - 16 ~ag 15 ip 0'?:b,
l.M'S, 1314 L doa
1 ' l 6 r " ,
2 v~~.~~''k --- ~.t~r e
~_ar_txi~c~l 2 c~c~s~~ -----
----- -- -------- ------- -------- ------- --
l5 3 ?(D.f~'?~r
~ a~?l71~2 --- 16 _, CaH'boaol L doaes

4 i'{)'='? 16 l' w 1~._aU'~k
C-aB'bo lol I dose
? ?tD.t;1'.'.ea
t$_}RF2 - l ~tta 15
Cathn~c~l 1 ~lc~sc '
.........................................................
........................................ 6 ]C~).~i.F~ - I
~ = ~ -------------------------------- ------------------ =
IIf 1-5 f~ 4(1.#3'.a
Carl.ao ol ' dos4s
1 ~ 7 4C>. F "<~
7 E r~~l~.F"? f}.:~>
C'aflbc)poI ? doses
8 KV :~ 8,#3 log ~;;~rt~~pol ; 15 l~?
2 doses
9 .14 14 l ll{l.fl",,
challim~e Cc,
iitrols
-------- ........................................................... -------
..........................................................
........................................
,~ ,~ a ,10 SiriGt ~ÃGl;~~tiv~: C'c~iltrnts 1 t '}~. }':ro

t t3RI} 2 3scrltlted 4 3rtd #)]k ['2, xOÃ' Ã Y rri ~a3:i3}a~a3;~tti ta
~ciEla>4 ir3 es rr~>t~ti,c.cÃ t:)[tiF'2:. KV ixi l,illrti
ti~hc?1G c.dl vFras -1'CV2 vmt: grmi=iz iiz :t33t;rb1G ce.ll c:ultFUe

I)isCusSioS1

Sw.veai PCV2 v:3c;c>uzw.s 4vea=e evaluutedin this e:eumpiw.. which hieiudwcl a
hi;h dose (16
lag) of KYRF2 w1t:igen a4jub antecl 'v6th TN1S .1314 aclministerecl twi,,e, a
liiglx clos<. (l 6 lg6j) of
vÃ3.1t1?2' antigen idju~~antccl witli Orbopc-~l aclministcs'ctl oaiee to o:ttc
gn-oup taf-13igs attcl twice

to a secc?acl group c?fpigs, a higli dose (16 lqg~) of rt?RF2 antigen
atljtiratitesi vv~ith Carbopc31

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
adaniacisterecl tai:ic.e;, a 4 ltg dt,sc: of rORF2 antigen aclia:vante:el
ai:ith t;:;arlx?pol administcred

twice, a 1}ts~ dose of rOIU'm antigon atljavame;el tidth Carbopol administerod
mice, a lrt~~
dose (EJ. 2'? fi.g) of rORF2 am:it cti a~jtkaan:tecl {rith Carbopol .icl-
ministcrccl twim antl. a high
dose (> 8 log) of l:ill<d whole c+ll PCV2 Cxbopol. t;lverall, Group

1. wh_icl: rccciv,:ci two (lc~ses of 16 trg rt:.'tJ?t.F:? --- :ÃMS 1~3 ) 14,
pcrforttacci sligltiiv> MÃcr tliara
Grcm~~s 2 thrcaugla 7. whic.la i-eccivecl vacciraes, co Ãai iqu, e,ariou4
1evels ~.~f citlicr vORF:2 or
e-CR~:' antigcn ti~~#tx~ ~sfl~t~ el c;>itll C'a.rb(ipo1 aiac.i nliflt h b<tter
than Graisp 8, which received two
closcs raf'kill.cd wlio:lc c0l 1'ti':N' vacc.:in.c. Grcitip l. :liaci the
tJ:irc.~ ]::igltcst AM"Ci- (1.80 EJ3 )t3
lbs: cJm l, t:helm-est. i:ncidc..nc:e ofabncsrmal befiaz ior (()'.'-z,), the
lowest iygcicJesicc of ahygornial

1 t~ resspirat~on (4%). a]oIz~ incidence of cough a]ow incirience of csvcrall
clanical
symptoms (7. ]."10, was tied Nvitli t11rc, otttct' grotil.?s to:r tl;e lc-
~lvest ansinality:rate ([1".~I), tlic
secoaici loxvcst ratc for mean % 1suig 1c..sic~ris [0.1.5 -- 0,. -l%#< t:tic
sLcosi(t lowcst. rate (csr
pricimionaa. (2l 4"4) and the .lowc.at ialcicctice ratc: f'or positive IHC
tis~t~cc (0%). Greaup 1.
was. lAowe3 e:r. tJic only gronp in Ns=liic.li iqjcction site zeactions were
iiotcel, Ns=liic.li inuluÃ3:c:Ã3.

1i 5011; of the vaccima:tcs I day a.fter t.hc s.cUo:ad va.ccinatiom 'T'11c
otl~cr YacUizieS akiiriiiiist:cs'ed to
C,roups 2 thrc3ugh 7 perÃ'onnecl be ttca= than the killed raccitic atici
izwurh- as we11;3s thc racc.isic
a.clministercd ic? Group 1.

Group 8t which received Mo dc.~ses of killed PCV2 v~aUciaic atljriv~a-nted
witlx
Carbopc31, liucl tliw. worst set c?l'resaits fW any vucc;ine group. Group 8
had the 1c3~~~ ~t ADWG
htl f0_93 -+ 033 lbs dad;t. ttic seco:aid higbcst rzitc of abnnnnal bchaz:ior
tlic higbost rzitc of

abnonYra1 respiration J67~--t,l, tied wiili tlire;k~ ottisr groups for tlie;
liiglie;sl overall
ilici(letici rnte of clinical symptcmtas (13.3".<)). had Ãlic laighest:
iiiorJality rate of all groups
t;200. and had the highest po5it:iz.c I.kiC.' rate t;S(l .vt of any vaccine
grotflp. There was
concern th.it ilw kil.lecl ccll PCV2 vac.ci e tuivy' not have bccn fikliv>
iraactivmcd pt-i~.~t- to

2i aclra:inisÃrstt_ion t~.-~ Group 8, xvMcli ma1 .:xplstira this tgroa:p's
poor i-cstklts. Ltn(arturYatcly,
81

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
clel'=i.nitivo (lata. ~N as acot av-failable to conl.ima this ooncem.
Ã?vcratt, in tlie contom of tEais
.,xampiG, a Conventional Killed PCV2 vacc:ine clid mt aid in tlic redri ctioiY
of 1ICV2
associated discasc.

As Previot.xsly mentioned. iio adverse event>. 4~~ca-e a;:sociated with the
test vatcisles
witli exceptioil. of tlic Vac.cine actjtavarqcd witli IkfS Ã3 14. lr~jection
sitc reactions wen noted
in '?f}.t}% ~.~I'tfae pig4 l c.~aa al'ter thc .ecoaci v.iccinati~.~n witli the
vacciac fsor nulatec.~ witli IM:S
13 l-f aiad in 28.6%6 oftlic: pigs 2 clays after th< second atircc:ination. No
roaction.s wore iiatocl
in .ny pigs receiving Carbcapol aclj varqcd vaiccirics. Ativ> ffirtlter st
clics that inOucic Pit;"-;,
vaceiygated iz>itfi IN1S 1.3:14 a4jui-amed s=accisies sliotild e:oyitisiFac to
closely momtor pigs for
F!) jt;ct1C)11 tille l't;;1C:tBCtBls

:3.lt. I.?igs were se.ro-a}ega#:ive: I'or PC;V.2 m.l-3ay -3 a:ncl oait3 Group
2 tiasi a tite:i- above
100 oti Day 14. 011 Day 2:5 (day oI' clialleyg;,~e). Ciresail) 8 l~ad ttic
higliest PCV2 antibody titer
(46:19).. folloi.vect by C_irogala 2Ã25 07i. Wit17 the exceptiean of Greaup,
7, 9 aiict :ltl.: all clemons#:ra:ted a strom n:atibodv revon,e bO, I:?av 31
f3N~- Da.3- 50, all groFaps ia}cluding Groupc

1i 7. 9 a:ltcl 10 demonsti-a:ted a st:ronh antibt?rÃz~ svspoatse.

dXzw. of the liallmarks of hkÃe stage PCV2 izif:eeÃam mzd sabsw.clticiiÃ
f?NIWS
dc.z;<I<apmLm is ga=ou-th rLta.rciation in ovea:tiecf pig;;, a.r1d in severe
cases, vveiglgt ic?ss is iiotecl.
Average daily weiglxt Vai.~a of groups is aÃfi~a.rltitati~.e :ai<~t.hoct of'
cleaii~ajisttratilig growth
ret:3rrtaÃaoal or %ve:iglit loss. In ÃIzis example, there was sic?t a lurtge
dilfea=w.ize.e in AI3WC3

ht~ MNveen groups. ~~-otip 8 lifad tlae ImNest AI3WG of d058 + 0.29 lbs/day.
while Cirol7p 4 had
ttis hit~facst ADWG of l.lta -- 0.26 ib'day-. Witliiri tlie coritsxt of this
stt7tiv Efaere w-as iioÃ a
s ffic:ietit ditf4rciic,e beween grotips to base rtit re k.amine ei1tcac:y ota
AgWG,

In a.clditioil to ~N:cigbÃ toss -- clyspt~ea, l~ t~art;i. pallor of tlle skixl
fulcl soxlaci.i.zu~:s
icte: ts are clin.acal svttalatcattas a44ociateci with f'MWS. In this
exarnfale, at~i.-m-mal befiavior.
2i a#ul .ibnocmal respiratiort aaicl c:cf ~li wora; ticaÃcd isif'rocla.csit1y
for .:acfi grcmp. As et idcnc,a;cl in
82

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
tbis stta.dy, i1ias clrtalleacge zrcnclet and cllttltonge stt-aiac do ilot
result in c:linit;al
syirlplomS and tliis is 110i ;I str~.~iig N3rameier oii whicli to base vaccinC
..fficacy.

Ovct'al:l, klicytialii:y rates svct'c not high in this eazwttplc atic.~ the
lack- of a high mor.tal:ity,
t:artt; i.tl ÃIl< clrtallongt; cotitr(ii -t'otitp 1imii.s this paranl<tet' otr
'~vltich to 1=<aa.se vaccine Off.ic:at:4'.
> }'t-it.~t- to Day 46. Gri-ytsps Ã and 7eacl:: laaci ortc i-ytsÃ of iiflcort
pigs die. Crt.~ttp ') ltad two out Of

fiottrÃeora pigs die and Grt.~ttp ' 8 It.;td tltre,; out of li('tecri pigs
clie. Dtke to the fiict that Group 9,
tlit; c:hallenr.~-e +~c~titr~i
l gi-oiflp w tas tiot ciemotr trarting, PCV2 clinical st>mptosn and 031l c two
cleat1Ys had t.~ce.tat-red in this group by Day, 46. Porcine Respiratory and
R:.procl:uctiVC
Syndrome Virtxs (PRRSV:# MlN -vaccine as acintinistere.rl to all pigs oii Wy
46. Earlier

1 t~ sttrclies had utilized 7.NG.111-.V.A,i' KPR.RS.Ml,V as aai
iytuttlfygostimu1ant to e speratePCV'~-
assoc:intcel .1'.NIMS cliscn,e: aa}cl ztAozmlitl, rates Ns>+:te higher in
tllcse: earlier stiaclics. Two
deaths occurred shortly after administering the.l'.RRS vicci.rte oii Day 46 --
Group 4 tiacl ~:tte
death oti Da-v 46 and Group 7 had oaie death oii Day 47 -- tvhic.lt ive:re
probably iiot associated
with tlye: "Iclmia}:ist:mtiOU ot'tl;e .E'12R:'4 vaccine. .13v Day 50 ,
(_iroFap 8, which received tnvo doses

1i of killed vxccinc. had tl1c i~ight=;st mortality m-tc (20",;), .tollmx.cc!
by 6:rortp t) (clxalle:~ge
coaitrre?l) atzsi C.iroup 7(#3.?5 u.; rORFa -- C'arbopoi.), watli mortality
rates of 14.3<No zttid :13.3%
r<spectiv~ely. Overall, adan-inistration o:1'thL PRRS vttcc:iae to the
challenge ilgoclel late M tlge
post chalJeng observation phase of tii:is emanplt did atcit si~t~ific~rli.t~
i.rac:re~_st 1--nort:ality
rztte:~.

htJ Gross lesions i1.1 pigs dvitlr .l"NÃ-WS secondary i:o PCV2 infecÃxon
typicttffi . consist of
gmeralind hmplittclm~.~patliy in combination wtli c?iYk, or iYiore of the
foIlow-ing: (1i
inEerstitial ptic-zi-ait.~tiis3 -witli Hiterlol.ittls3r e.detix<3, (2)
czflumet~tis pallor or ietms, (3) mi.~tÃ:lt',tÃ
atrophic fivers. (4) gastri~. a.tlcors, (5) zrel)Earitas and (6)
mprveJta:cÃxvc: clasor(lGrs. c.g, alorÃxt?n,
stilibirtl::s, mut:ttit~im etc. Nt nec:rctp4v> (Day' 50). ictems, bepati.ti.4.
attd nephritis 4N:cre t:tot

2i rtota cl i11 atia t soups ~gastric ttlc.:r was ticited iti arYo Grcfisp
7pi& btkt l4 mplYarÃoraop:iil~y
83

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
v~:as not speci:lioa:lly e:xamaned for. Based on the prc;setic.c of lesions
that 3!~-cre cn:ns:istczrt with

I'C Vm ir&-e;ction tlirie g-roaps had tit lcast oiie pig tiirtatiV.;lb
diaonosi;d w-ith PCV2 (PM-WS).
t;'rt-caap 8, Nklai.ch received two doses of l;i.llcd v.tcc.itie, :liaci
20'a:i, Ãctitati:v,.1y diagnosc~ ~vith
PC'V', while Gi-otitp 7 and Cii-otitp 4 had 13.;:3~ro at1d rc.slx:ctivoly.
tenÃtativel;y diagnosed

> wiÃli PCV2. The i.cara % ltirag ]csi.011 SCcMC4 Varied 1>ctwccn groups at
r~ccrolasti . Gtoups 1.

4. 6 and Ã t} 13.1d low 'a'tz lilr3t), lesio11. scores that [.ir3gecl frc33]F
0.. 11 ~3..?S'.'. ea tE,~ (3.t}() l.>%..

As exlrwterl, Cs-ottp 9, t11e chtall+nge cotlteo1 gi-oiip,ha.cl t1w hir.~ie>:t
~~ieasi '.N} ltitflil; losi(iil swre
(1 tl.8l. In ibur gr~.~ulas, tl::c, rncan % lring lesion scoi-es ~vcrc
elevated clxac to catic t~.~
three pigs is) each o1"il~esse groups ha~~~~g -',Ory high lting
lcsior1 scorLs. 'T'lle lusit lesions wcrc.
1 t~ recl:'plfrple and consolidated. Typica.lly , lFnn;; lesioygs associated
witli 1'NMWS are dc.scs-ibcd as
tas7.. ns?s7-colla:psibl+:, aa}cl with Vat.c:rlobu:lar eÃ3.cma.. 'I'.he hing
:lcslo:as noted la} this study were
citlies- rZot asscsc;fatcrÃ with Pt:'V? in:t-ection os- a secosicl
pFalsnoria.ry irlfcc.tious agent snay~ baze
been pavsetit. \N':ii.hi:11 tlic contex-t of this sturlv. the ".~I tiiaig
lesion sco:rc:s probably c-Io aio
x, :t7.cct a tm.cc mc:asFarc of tlte amount of lung inl'c:ction dtle to t'CV?.
Likewise. tcwati~~e

1i dia6mos:is of la~~cuallc.~slla may have bcL~ii ovez-utili.z.cki as A~iv
pigs witli lrr-ttg lcsit?jis,
some as srixall as 0. 10% wcre listed "i111 a teniatae cdaagnosis of
Pizw.umosiia. .111 this e xusuple.
t11Lrc was tic3 suCfic;ieait dilfereygcc between groups u-iih re:spect: tc?
tj:rt?ss l<si<arls <rjgd % liiaig
lesions oi1 NOlich to base YacUizle clfilcacy. ,

Il1C' restilts slzovv~cr3 t:lic 1.3rgcsÃ diMrcuc.es betwew.iz groups. C.;roup
1 {16 1tg rt3Ia.F2 ---
htt INlS 1314) had the lovi-cst po:.itive II-IC rosrfllts for k'f'V2 antigen
{f)".~~); w-bile Groups 9 and
Irfacl llis liigliest lacasiÃive 11iC raszfllts with iticidsflis.e rates of
100 ?4, <tiYd 933'"z; r~,sp~cliz el~ .
Groups 3, 5, 6 and 7, -which rec.cik. ed 16, 4, 1 or 0.275 1tg c.~ r rORF2 za-
a ti gem rcspec ti vela, ,
acituvante:d ivatli Carbopol. lia(Ã I.F-IC.' positive i-zitos of 21l'?<~,
20";o. 40% axid 46.7%.
reslxec.tivOy. C{i-orap 2, which received hk~ca doses of 16 ug l(}~~2
adjuvanted witli Carbopol

2i had an 1HC positive rate of 6.7N,,, wliilc Cqcaup 4 M-ac:li received onlti
cisic dose cil' the same
84

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
vacci.zre, had an !f-!C po5it:iz:o ratc: of l:'.:%. Da.ic to the oLtoc.tave
riature of this test alxle( t(re

fact thtit 1i1C rG-Rrslts correlat,;cf ~N:iÃh c\pemd resulÃs. lliC tesÃ~srg,
is probably oiie of Ãhe best
p.u-an:mer.s oll WIYich to bas~: vaccine efficacy.

T'lirts in om aspect (if'tll< lln;s<nt invention, tho Mininumi Protcct:iae
Dosage (NIP1_1}
of PCV2 t-C}RF2 muige: zid ) varqcd with Catb~.~pol in the CDCD pig model in
the f"acc of a
.I'CV2 c:hallenvc is dctermirwci. Chcaaps 3. :?. 6 a,:~d 7 each t-eceie,ed two
c.~oscs of t-ORF2
anti~T<a acijiflvanted with Carbopol, bist the ley-el of rORF2 anti~~ n varied
for each groiflp.
Grcn ps .' 3. :?. 6 aaci 7 eaich t-eceie,ed 16, 4, 1 ot- 0.25 trg of rtfRF"
antigen respt;ctzvely. In
;;encral, tte.crcasing tlre le~ ~ l csf" rOR.l~'2 asmge.n ttecreased PCV2
asitiht?ciy titers, and i.ricrLased
1tl the anonalatN rate. sireati lung
lcsions, a~id the iaicitter~~e ot'111C positiie tasslfes. Ot'ttic
folli- gl-s>ti1.?s re:ceivill-V varying levels of r0R.l'2 --- Carbopol, Groups
3 and '?, which receiv, cl
t o rioses of 16 or= =1 fa*g, csf rOR.l~2 asitigeri, resfcctis=Lh.. eacti liacl
ayr 1H.t:.positiz~L rate oi'orl.ly
20%. micf ea:cli had siniflar antibody titers. (h~, :rsll, based oji IHC
pos'it:ii~c results. the
minimuan l.?rote;,tive eloca<Fe of r43R.F.2 antigen administered twfce is
appro,",laaiately 4 tig.

1i I_11 aric?t.hc:r aspect of tilc present i~ive:ation, tllc antigenicity of
recorTibiraatit (:r[?.lZF2}
and VIDO Rr l (10I;.Fj2) NC'V? aiztigens were assessecl. (ia=oup 2 recw.ived
mo clcasc:s of !.a> pg
z;0Rl?'' aaicf Group 3 received two doses of 16 }rvj :r()l.t.F?. Both
vtrccirlLs were a4juz;amecf
~A ith ('xrlsolaol. Bc?t.h Vaecines were fbitaid to be qa.tc a1icl botll.llacl
0% :aiortallt-Y. rate. Cxrotip
2 iazrci uP(:-V? arztilxxly litea= of 2507 c?ii Day 25, while C.;roup 3 bar3
aPt;"IV'2 antibcx3y titer of

h~t 1503. ~s'rnup 3 had a :lmer mcan % l~sm- lcsion score than Grotip 2(0. l l
0-18% vs. (00_-:~
ff I5'"-i,), bYtl Gr~.~til) 2 lifad a lca-,i-er li-IC posiÃYvi incidence
rfat:e ilrfat: GrcaYsla ' f6.7" vs. wW'r~l.
Overall, bot1i vaccines had similar antige.riic.ita,, bzflÃ: vORI' -,vns
nssi.~c:intetl Nyitli sliglitlv
better I:tiC.' resulls.

T_ yet a otlaer aspect ~.~I' the present invention, the staiEabili.ty ~.~I'
two cfifI'ei-etrt
2i acijj vanÃs {C.ubopol zirad lNfS 1314) svas dct:ei-iiiirta>ci. Croups :l
and 3 both ra;cseiv.:ci two

CA 02635430 2008-06-26
WO 2007/094893 PCT/US2006/062662
doses of e.accine, Goma:in.ing 16 u,: of rOR1i2 antigeat, but Group 1 received
tlic antigeac
acltuvanted ~Ndth IMS 1314 ~vhilc: Group 3 r.;cei.vvd tlie a#itigGaY a(ijtZ
vamed with C<3rbopol.

Botli gr.~.~ulas:lia(i essc;mialiv> ilw sarnc.ADWG, esseraÃiatly, the sattae i
c.idence ~.~I"clirtical. sigras
laost-eltall<nl;c. 1110 %sfl~~~ 1.11ortality rate, at1d esaen:tiallt> the
same: mean % Iifln~,T lesions but
> tvrt'caup 1. had an IHC positie,e raÃe of 0% N~~hile Gr.~.~ti1a .) had .ui
lI-1C posItIve mt:; of' 20%.

HMN:cver, Group ' ), wlaic.:ti receiveci the vam c aci_ja.vanted Nvitfa
C.ut}opral, had l::iglter TFAT
PCV2 tilc.rs on D~ivy: i, 32, and 513 than Group 1, whic:h. reGoived t1w
vaccine adjjtitvan:tod
with IMS 1314. Ovemll., aIth:oAtgh the PCV2 vaccine adjuvanted Nkztl: TNIMS
131 14 did prravi(le
better T1-IC reqarlts, it did siot provide overvdielmingb, better protection
fio.n1 .1'C'V2 infection
a!)(l did 1I1dl3.ce Bl1J<'.C:t9CtBl site reacllo!). Wt)eret]S 1l1L PCV2 'l
aC0E1ge aL~jui=aI1ta;C1 with CarbS?I)(71
Ix.rÃ'01-mecl nearly as IN c.l.l as the 1MS 131 4 a.tl#lna:nted vaccine, 1Su:t
was not associated with
as)>' adverse es=Lnm

7:ti ,ti.ll ajiotlie:r aspect of i.he pre.,e:at iiive.titarsai, i.he
feasthiliA- of 1'C;V2 OR.F2 as a
I1A11. I dose p:rc-?duuÃ w-as cl,:tez~~lmed. Groups 2a:ncl 4 both receix-ed 16
1t<F of~-ORF2 vaccine
1~ acll~~~ ajitc,d witli C'arbopol on Dam ta, bitt Groul) 2:reee:ivcd a
sccotid dose oai Dwy 14. Group 4

liacl a sir.;htli. biglier ADWti z~iicf a lower mean % lum, lesions 11zm
C,rcarip 2~ but Grc3up2 laad
higher .IFA'T"Ã'{ V2 titers <ajg Day 25, 32 aaici 50, aaici a slightly lower
incidence rate of 1TiC'.
positive tissues. All otiicr result5 for ti1csc twci ~rclups were s:imilar.
Overall, one dose of
vORF2 acljravatzter3 evith t;'uncopol performed srmalur to two doses czl'11zw.
same vaccme.

hi1

?2635430 Summary - Canadian Patents Database (2024)

FAQs

How to search for a Canadian patent? ›

Search Options

Use the Patent Document Number Search to find a specific patent document by it's number. Use the Boolean Text Search to find patent documents with words or phrases in one, two or three text fields, using boolean connectors (AND or OR) to narrow or expand your search.

Discover More Details ›

Is a Canadian patent valid in the US? ›

A Canadian patent is effective only in Canada. A patent document can be either a granted patent, or an application open to public inspection.

How long do Canadian patents last? ›

Patent protection applies in the country or region that issues the patent. In Canada, a patent lasts for 20 years from the date that you file it. Patents can have a great deal of value. You can sell them, license them or use them as assets to attract funding from investors.

Explore More ›

What is the Canadian Patent Office record? ›

The Canadian Patent Office Record is published every Tuesday under the authority of the Commissioner of Patents. It contains new patents, Canadian applications open to public inspection, and important notices. As of June 22, 1999, the on-line PDF format of the Canadian Patent Office Record is the official version.

Keep Reading ›

What is the Canadian patents database? ›

Welcome to CIPO's Canadian Patent Database. This database lets you access 155 years of patent descriptions and images. You can search, retrieve and study more than 2,560,000 patent documents. You can now access a wider variety of patent-specific documents on the Canadian Patents Database page.

What is the Canadian Patent Office called? ›

The Canadian Intellectual Property Office (CIPO) is a special operating agency of Innovation, Science and Economic Development Canada.

See Details ›

What cannot be patented in Canada? ›

Some things that cannot be patented include:

"disembodied ideas, concepts or discoveries"
"scientific principles and abstract theorems"
"methods of medical treatment or surgery"
"higher life forms"
"forms of energy"
"features of solely intellectual or aesthetic significance"
"printed matter"

Get More Info ›

Does the US recognize Canadian trademarks? ›

Canada and the United States have separate legal systems. If you want the exclusive right to use a name in both countries, you have to obtain trademark registrations from both governments. This is something that one of our clients is learning the hard (and expensive) way.

Learn More ›

Can a patent be renewed after 20 years? ›

Why can't patents be renewed once they've lived out their 20 years? A patent becomes public domain (free for use by the public) upon its expiration, which is defined as 20 years from the patent's earliest non-provisional filing date. MPEP §201.04. The 20-year patent term applies to utility and plant patents.

Explore More ›

Can you sell a patent in Canada? ›

Patents can be very valuable. You can sell them, license them or use them as assets to attract funding from investors.

Find Out More ›

What are the different types of patents in Canada? ›

There are three types of patents:

utility patents.
design patents.
plant patents.

View Details ›

Is there a grace period for patents in Canada? ›

However, certain jurisdictions, such as Canada and the United States, have a one-year grace period to file a patent application if an inventor discloses their invention.

Read The Full Story ›

How to check if a patent exists? ›

Patents may be searched using the following resources:

Patent Public Search.
Global Dossier.
Patent Application Information Retrieval (PAIR)
Public Search Facility.
Patent and Trademark Resource Centers (PTRCs)
Patent Official Gazette.
Common Citation Document (CCD)
Search International Patent Offices.

More items...

Oct 18, 2018